Journal Article
. 2018 Jun; 378(24):2288-2301.
doi: 10.1056/NEJMoa1716948.

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Mark A Socinski 1 Robert M Jotte 1 Federico Cappuzzo 1 Francisco Orlandi 1 Daniil Stroyakovskiy 1 Naoyuki Nogami 1 Delvys Rodríguez-Abreu 1 Denis Moro-Sibilot 1 Christian A Thomas 1 Fabrice Barlesi 1 Gene Finley 1 Claudia Kelsch 1 Anthony Lee 1 Shelley Coleman 1 Yu Deng 1 Yijing Shen 1 Marcin Kowanetz 1 Ariel Lopez-Chavez 1 Alan Sandler 1 Martin Reck 1 IMpower150 Study Group  
Affiliations
  • PMID: 29863955
  •     1018 citations

Abstract

Background: The cancer-cell-killing property of atezolizumab may be enhanced by the blockade of vascular endothelial growth factor-mediated immunosuppression with bevacizumab. This open-label, phase 3 study evaluated atezolizumab plus bevacizumab plus chemotherapy in patients with metastatic nonsquamous non-small-cell lung cancer (NSCLC) who had not previously received chemotherapy.

Methods: We randomly assigned patients to receive atezolizumab plus carboplatin plus paclitaxel (ACP), bevacizumab plus carboplatin plus paclitaxel (BCP), or atezolizumab plus BCP (ABCP) every 3 weeks for four or six cycles, followed by maintenance therapy with atezolizumab, bevacizumab, or both. The two primary end points were investigator-assessed progression-free survival both among patients in the intention-to-treat population who had a wild-type genotype (WT population; patients with EGFR or ALK genetic alterations were excluded) and among patients in the WT population who had high expression of an effector T-cell (Teff) gene signature in the tumor (Teff-high WT population) and overall survival in the WT population. The ABCP group was compared with the BCP group before the ACP group was compared with the BCP group.

Results: In the WT population, 356 patients were assigned to the ABCP group, and 336 to the BCP group. The median progression-free survival was longer in the ABCP group than in the BCP group (8.3 months vs. 6.8 months; hazard ratio for disease progression or death, 0.62; 95% confidence interval [CI], 0.52 to 0.74; P<0.001); the corresponding values in the Teff-high WT population were 11.3 months and 6.8 months (hazard ratio, 0.51 [95% CI, 0.38 to 0.68]; P<0.001). Progression-free survival was also longer in the ABCP group than in the BCP group in the entire intention-to-treat population (including those with EGFR or ALK genetic alterations) and among patients with low or negative programmed death ligand 1 (PD-L1) expression, those with low Teff gene-signature expression, and those with liver metastases. Median overall survival among the patients in the WT population was longer in the ABCP group than in the BCP group (19.2 months vs. 14.7 months; hazard ratio for death, 0.78; 95% CI, 0.64 to 0.96; P=0.02). The safety profile of ABCP was consistent with previously reported safety risks of the individual medicines.

Conclusions: The addition of atezolizumab to bevacizumab plus chemotherapy significantly improved progression-free survival and overall survival among patients with metastatic nonsquamous NSCLC, regardless of PD-L1 expression and EGFR or ALK genetic alteration status. (Funded by F. Hoffmann-La Roche/Genentech; IMpower150 ClinicalTrials.gov number, NCT02366143 .).

Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer.
Yosuke Miura, Noriaki Sunaga.
Cancers (Basel), 2018 Aug 01; 10(8). PMID: 30060457    Free PMC article.
Review.
Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lung cancer?
Robert Pirker.
ESMO Open, 2018 Aug 18; 3(5). PMID: 30116594    Free PMC article.
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors.
Ming Yi, Dechao Jiao, +4 authors, Kongming Wu.
Mol Cancer, 2018 Aug 25; 17(1). PMID: 30139382    Free PMC article.
Highly Cited. Review.
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
Roberto Ferrara, Laura Mezquita, +25 authors, Caroline Caramella.
JAMA Oncol, 2018 Sep 08; 4(11). PMID: 30193240    Free PMC article.
Highly Cited.
[Molecular predictors in immune oncology].
W Weichert.
Pathologe, 2018 Sep 15; 39(6). PMID: 30215118
Review.
New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1.
Nicolas Villanueva, Lyudmila Bazhenova.
Ther Adv Respir Dis, 2018 Sep 15; 12. PMID: 30215300    Free PMC article.
Review.
Hedgehog Signaling in Lung Cancer: From Oncogenesis to Cancer Treatment Resistance.
Etienne Giroux-Leprieur, Adrien Costantini, Vivianne W Ding, Biao He.
Int J Mol Sci, 2018 Sep 22; 19(9). PMID: 30235830    Free PMC article.
Review.
Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives.
Francesco Facchinetti, Paola Bordi, +2 authors, Marcello Tiseo.
Drug Des Devel Ther, 2018 Sep 22; 12. PMID: 30237696    Free PMC article.
Review.
CXCR4 Based Therapeutics for Non-Small Cell Lung Cancer (NSCLC).
Ori Wald.
J Clin Med, 2018 Sep 28; 7(10). PMID: 30257500    Free PMC article.
Review.
Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer.
Herbert H Loong, Sui-Chun Sampson Kwan, Tony Shu-Kam Mok, Yat-Ming Lau.
Curr Treat Options Oncol, 2018 Sep 30; 19(11). PMID: 30267319
Review.
Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
Maria I Toki, Nikita Mani, +7 authors, David L Rimm.
J Thorac Oncol, 2018 Sep 30; 13(12). PMID: 30267840    Free PMC article.
Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients.
Akio Osa, Takeshi Uenami, +30 authors, Atsushi Kumanogoh.
JCI Insight, 2018 Oct 05; 3(19). PMID: 30282824    Free PMC article.
Durvalumab in NSCLC: latest evidence and clinical potential.
Nerea Muñoz-Unceta, Isabel Burgueño, Elizabeth Jiménez, Luis Paz-Ares.
Ther Adv Med Oncol, 2018 Oct 23; 10. PMID: 30344651    Free PMC article.
Review.
[Predictive value of PD-L1 diagnostics].
H-U Schildhaus.
Pathologe, 2018 Oct 28; 39(6). PMID: 30367225
Review.
Atezolizumab in non-squamous non-small cell lung cancer.
Takaki Akamine, Gouji Toyokawa, Tetsuzo Tagawa, Takashi Seto.
J Thorac Dis, 2018 Oct 30; 10(Suppl 26). PMID: 30370103    Free PMC article.
Atezolizumab for first-line treatment of metastatic nonsquamous non-small cell lung cancer: what makes the difference?
Melissa Bersanelli, Fausto Petrelli.
J Thorac Dis, 2018 Oct 30; 10(Suppl 26). PMID: 30370125    Free PMC article.
A case report of remarkable response to association of radiofrequency ablation with subsequent Atezolizumab in stage IV nonsmall cell lung cancer.
Jie Yin, Jingyin Dong, Wei Gao, Yina Wang.
Medicine (Baltimore), 2018 Nov 02; 97(44). PMID: 30383701    Free PMC article.
A new era of treating advanced lung cancer is upon us.
Glen J Weiss.
Transl Lung Cancer Res, 2018 Nov 06; 7(Suppl 3). PMID: 30393601    Free PMC article.
Identification of a novel therapeutic target in driver-negative non-small cell lung cancer.
Motonobu Saito, Koji Kono, Takashi Kohno.
Transl Lung Cancer Res, 2018 Nov 06; 7(Suppl 3). PMID: 30393606    Free PMC article.
Histology versus cytology: PD-L1 testing in non-small cell lung cancer.
Nagio Takigawa, Nobuaki Ochi, Hiromichi Yamane.
Transl Lung Cancer Res, 2018 Nov 06; 7(Suppl 3). PMID: 30393608    Free PMC article.
30-day mortality after the start of systemic anticancer therapy for lung cancer: is it really a useful performance indicator?
Jacobus Adrianus Burgers, Ronald Alphons Damhuis.
ERJ Open Res, 2018 Nov 09; 4(4). PMID: 30406123    Free PMC article.
The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis.
Min Peng, Xing Li, +3 authors, Qi Bin Song.
Onco Targets Ther, 2018 Nov 15; 11. PMID: 30425525    Free PMC article.
Review.
Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.
Shirish M Gadgeel, James P Stevenson, +12 authors, Vassiliki Papadimitrakopoulou.
Lung Cancer, 2018 Nov 16; 125. PMID: 30429032    Free PMC article.
Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC.
Niki Karachaliou, Manuel Fernandez-Bruno, Jillian Wilhelmina Paulina Bracht, Rafael Rosell.
Transl Lung Cancer Res, 2018 Dec 07; 7(6). PMID: 30505714    Free PMC article.
Review.
Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study.
Yasuhiro Tsutani, Yoshihiro Miyata, +8 authors, Morihito Okada.
BMC Cancer, 2018 Dec 12; 18(1). PMID: 30526545    Free PMC article.
Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics.
Sayuri Miyauchi, Sangwoo S Kim, +6 authors, Andrew B Sharabi.
Clin Cancer Res, 2019 Mar 01; 25(14). PMID: 30814108    Free PMC article.
Review.
From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer.
Deepa Rangachari, Daniel B Costa.
J Clin Oncol, 2019 Jun 04; 37(28). PMID: 31154918    Free PMC article.
Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Jingjing Liu, Shuang Li, +7 authors, Ying Cheng.
J Clin Lab Anal, 2019 Jul 10; 33(8). PMID: 31282096    Free PMC article.
Highly Cited.
Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy.
Heng-Huan Lee, Ying-Nai Wang, +15 authors, Mien-Chie Hung.
Cancer Cell, 2019 Jul 23; 36(2). PMID: 31327656    Free PMC article.
Highly Cited.
Practical Application of Real-World Evidence in Developing Cancer Therapies.
Marjorie G Zauderer.
JCO Clin Cancer Inform, 2019 Jul 25; 3. PMID: 31335165    Free PMC article.
PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study.
Niels Reinmuth, Maciej Bryl, +7 authors, Kazuo Kasahara.
BioDrugs, 2019 Jul 25; 33(5). PMID: 31338773    Free PMC article.
Inhaled Submicron Particle Paclitaxel (NanoPac) Induces Tumor Regression and Immune Cell Infiltration in an Orthotopic Athymic Nude Rat Model of Non-Small Cell Lung Cancer.
James Verco, William Johnston, +7 authors, Gere diZerega.
J Aerosol Med Pulm Drug Deliv, 2019 Jul 28; 32(5). PMID: 31347939    Free PMC article.
Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.
Yoshiya Matsumoto, Kenji Sawa, +12 authors, Tomoya Kawaguchi.
Cancer Sci, 2019 Aug 02; 110(10). PMID: 31368625    Free PMC article.
Novel Delivery Systems for Checkpoint Inhibitors.
Purushottam Lamichhane, Rahul Deshmukh, +8 authors, Narottam Lamichhane.
Medicines (Basel), 2019 Aug 03; 6(3). PMID: 31373327    Free PMC article.
Review.
Imaging of Precision Therapy for Lung Cancer: Current State of the Art.
Hyesun Park, Lynette M Sholl, +2 authors, Mizuki Nishino.
Radiology, 2019 Aug 07; 293(1). PMID: 31385753    Free PMC article.
Review.
Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?
Adrien Costantini, Paul Takam Kamga, +3 authors, Etienne Giroux Leprieur.
Cancers (Basel), 2019 Sep 01; 11(9). PMID: 31470546    Free PMC article.
Review.
High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.
Mari Tone, Takehiro Izumo, +8 authors, Hideo Kunitoh.
Thorac Cancer, 2019 Sep 05; 10(10). PMID: 31482678    Free PMC article.
The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer.
Ja Yoon Heo, Changhee Park, +8 authors, Dae Seog Heo.
Thorac Cancer, 2019 Sep 12; 10(11). PMID: 31509890    Free PMC article.
Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State.
Petros Grivas, Bradley J Monk, +6 authors, Markus Moehler.
Target Oncol, 2019 Sep 20; 14(5). PMID: 31535338
Review.
Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
Steven D Criss, Meghan J Mooradian, +3 authors, Chung Yin Kong.
JAMA Netw Open, 2019 Sep 26; 2(9). PMID: 31553470    Free PMC article.
Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities.
Antonio Santaniello, Fabiana Napolitano, +5 authors, Roberto Bianco.
Cancers (Basel), 2019 Sep 27; 11(10). PMID: 31554160    Free PMC article.
Review.
Combining immunotherapy and epidermal growth factor receptor kinase inhibitors: worth the risk?
Hira Latif, Stephen V Liu.
Ann Transl Med, 2019 Oct 03; 7(Suppl 3). PMID: 31576285    Free PMC article.
Pembrolizumab monotherapy for PD-L1 ≥50% non-small cell lung cancer, undisputed first choice?
Willemijn S M E Theelen, Paul Baas.
Ann Transl Med, 2019 Oct 03; 7(Suppl 3). PMID: 31576347    Free PMC article.
A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma.
Yong Tang, Zhu'an Ou, Zhifang Yao, Guibin Qiao.
Medicine (Baltimore), 2019 Oct 03; 98(40). PMID: 31577707    Free PMC article.
Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer.
Andrea Bianco, Fabio Perrotta, +3 authors, Raffaele De Palma.
Int J Mol Sci, 2019 Oct 09; 20(19). PMID: 31590386    Free PMC article.
Review.
The Kinetic Changes of Systemic Inflammatory Factors during Bevacizumab Treatment and Its Prognostic Role in Advanced Non-small Cell Lung Cancer Patients.
Butuo Li, Shijiang Wang, +5 authors, Linlin Wang.
J Cancer, 2019 Oct 12; 10(21). PMID: 31602260    Free PMC article.
Checkpoint inhibitors plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials.
Aung Myint Tun, Kyaw Zin Thein, Wai Lin Thein, Elizabeth Guevara.
Future Sci OA, 2019 Oct 15; 5(9). PMID: 31608159    Free PMC article.
Review.
Combined Antiangiogenic Therapy and Immunotherapy Is Effective for Pancreatic Cancer With Mismatch Repair Proficiency but High Tumor Mutation Burden: A Case Report.
Mengni Chen, Shengli Yang, +4 authors, Jianli Hu.
Pancreas, 2019 Oct 15; 48(9). PMID: 31609933    Free PMC article.
New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness.
Haitang Yang, Shun-Qing Liang, Ralph A Schmid, Ren-Wang Peng.
Front Oncol, 2019 Oct 16; 9. PMID: 31612108    Free PMC article.
Review.
Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer.
Hongge Liang, Mengzhao Wang.
Cancer Manag Res, 2019 Oct 17; 11. PMID: 31616186    Free PMC article.
Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer.
Mari Tone, Takehiro Izumo, +6 authors, Hideo Kunitoh.
Lung Cancer Manag, 2019 Oct 28; 4(6). PMID: 31645892    Free PMC article.
Clinicopathological correlation of immune response in human cancers.
Yuexin Liu.
Oncotarget, 2019 Oct 28; 10(56). PMID: 31645905    Free PMC article.
Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study.
David Lang, Florian Huemer, +9 authors, Bernd Lamprecht.
Target Oncol, 2019 Oct 28; 14(6). PMID: 31654203    Free PMC article.
Impact of clinicopathological features on the efficacy of immune checkpoint inhibitors plus conventional treatment in patients with advanced lung cancer.
Guanghui Gao, Meng Qiao, +8 authors, Caicun Zhou.
J Thorac Dis, 2019 Oct 28; 11(9). PMID: 31656652    Free PMC article.
A modified recursive partitioning analysis for predicting overall survival in patients with non-small cell lung cancer and central nervous system metastases.
Thiago Pimentel Muniz, Victor Hugo Fonseca de Jesus, +2 authors, Vladmir Cláudio Cordeiro de Lima.
J Thorac Dis, 2019 Oct 28; 11(9). PMID: 31656665    Free PMC article.
Five-year overall survival of pembrolizumab in advanced non-small cell lung cancer: another step from care to cure?
Paolo Bironzo, Francesco Passiglia, Silvia Novello.
Ann Transl Med, 2019 Oct 28; 7(Suppl 6). PMID: 31656791    Free PMC article.
Are we facing a cure in lung cancer?-KEYNOTE-001 insights.
Aharon Y Cohen, Waleed Kian, +3 authors, Yulia Dudnik.
Ann Transl Med, 2019 Oct 28; 7(Suppl 6). PMID: 31656794    Free PMC article.
Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma.
Lingdi Zhao, Yonghao Yang, +7 authors, Quanli Gao.
J Oncol, 2019 Oct 31; 2019. PMID: 31662753    Free PMC article.
Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review.
Ling Gao, Xi Yang, Cheng Yi, Hong Zhu.
Front Pharmacol, 2019 Nov 05; 10. PMID: 31680957    Free PMC article.
Systematic Review.
Engineered T Cell Therapy for Cancer in the Clinic.
Lijun Zhao, Yu J Cao.
Front Immunol, 2019 Nov 05; 10. PMID: 31681259    Free PMC article.
Review.
Recent advances and application of PD-1 blockade in sarcoma.
Wenli Zuo, Lingdi Zhao.
Onco Targets Ther, 2019 Nov 07; 12. PMID: 31692518    Free PMC article.
The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
Qing-Qing Chai, Jiang-Yang Du, Jun Zhu, Bin Wu.
Front Pharmacol, 2019 Nov 12; 10. PMID: 31708783    Free PMC article.
Systematic Review.
Immunogenicity of Del19 EGFR mutations in Chinese patients affected by lung adenocarcinoma.
Deng Pan, Dapeng Zhou, +4 authors, Yanyan Lou.
BMC Immunol, 2019 Nov 15; 20(1). PMID: 31722672    Free PMC article.
Clinicopathological values of PD-L1 expression in HER2-positive breast cancer.
Sasagu Kurozumi, Kenichi Inoue, +5 authors, Ken Shirabe.
Sci Rep, 2019 Nov 15; 9(1). PMID: 31723167    Free PMC article.
Immune checkpoint inhibitors in gastrointestinal malignancies: what can we learn from experience with other tumors?
Anand B Shah, Katelyn R Sommerer, Khaldoun Almhanna.
Transl Gastroenterol Hepatol, 2019 Nov 16; 4. PMID: 31728430    Free PMC article.
Review.
The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial.
Lili Wang, Zhen He, +21 authors, Qiming Wang.
Transl Lung Cancer Res, 2019 Nov 19; 8(5). PMID: 31737494    Free PMC article.
Immunotherapy in EGFR mutant non-small cell lung cancer: when, who and how?
Debora Bruno, Afshin Dowlati.
Transl Lung Cancer Res, 2019 Nov 19; 8(5). PMID: 31737508    Free PMC article.
KEYNOTE-042: is lowering the PD-L1 threshold for first-line pembrolizumab monotherapy a good idea?
Jose M Pacheco.
Transl Lung Cancer Res, 2019 Nov 19; 8(5). PMID: 31737510    Free PMC article.
The KEY to the end of the chemotherapy in advanced non-small cell lung cancer, or not yet?
Yiqing Huang, Robert J Walsh, Ross A Soo.
Transl Lung Cancer Res, 2019 Nov 19; 8(5). PMID: 31737512    Free PMC article.
Predictors of benefits from frontline chemoimmunotherapy in stage IV non-small-cell lung cancer: a meta-analysis.
Hazem E El-Osta, Frank E Mott, +2 authors, Anita L Sabichi.
Oncoimmunology, 2019 Nov 20; 8(12). PMID: 31741764    Free PMC article.
[The role of systemic therapy of lung metastases with lymph node involvement].
Y-D Ko.
Chirurg, 2019 Nov 21; 90(12). PMID: 31745581
Review.
Analysis of key clinical features for achieving complete remission in stage III and IV non-small cell lung cancer patients.
Takuya Aoki, Takeshi Akiba, +21 authors, Koichiro Asano.
Respir Res, 2019 Nov 23; 20(1). PMID: 31752884    Free PMC article.
The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance.
Albina Kibirova, Malcolm D Mattes, Matthew Smolkin, Patrick C Ma.
Case Rep Oncol, 2019 Nov 26; 12(3). PMID: 31762748    Free PMC article.
Immune-Checkpoint Inhibitors as the First Line Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
Yuqiao Chen, Yuan Zhou, +4 authors, Wei Zhuang.
J Cancer, 2019 Nov 28; 10(25). PMID: 31772659    Free PMC article.
Review.
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC.
Marika Cinausero, Noemi Laprovitera, +13 authors, Andrea Ardizzoni.
Ther Adv Med Oncol, 2019 Dec 05; 11. PMID: 31798692    Free PMC article.
Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients.
Bin-Chi Liao, Sebastian Griesing, James Chih-Hsin Yang.
Ther Adv Med Oncol, 2019 Dec 06; 11. PMID: 31803256    Free PMC article.
Review.
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer.
Lorenza Landi, Federica D'Incà, +18 authors, Federico Cappuzzo.
J Immunother Cancer, 2019 Nov 23; 7(1). PMID: 31752994    Free PMC article.
Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer.
Colby S Shemesh, Pascal Chanu, +10 authors, Sandhya Girish.
J Immunother Cancer, 2019 Nov 23; 7(1). PMID: 31753029    Free PMC article.
[A Single Center Analysis of Advanced Non-small Cell Lung Cancer Patients Treated with Immunotherapy in Real-world Practice].
Yanxia Liu, Tongmei Zhang, +7 authors, Baolan Li.
Zhongguo Fei Ai Za Zhi, 2019 Nov 28; 22(11). PMID: 31771737    Free PMC article.
Immune checkpoint inhibitors win the 2018 Nobel Prize.
Pei-Wei Huang, John Wen-Cheng Chang.
Biomed J, 2019 Dec 01; 42(5). PMID: 31783990    Free PMC article.
Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway.
Grace Wakabayashi, Yu-Ching Lee, +3 authors, Yun Yen.
J Biomed Sci, 2019 Dec 06; 26(1). PMID: 31801525    Free PMC article.
Review.
Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy.
Zuan-Fu Lim, Patrick C Ma.
J Hematol Oncol, 2019 Dec 10; 12(1). PMID: 31815659    Free PMC article.
Review.
Survival correlation of immune response in human cancers.
Yuexin Liu.
Oncotarget, 2019 Dec 17; 10(64). PMID: 31839882    Free PMC article.
Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer.
Jonathan W Goldman, David M Waterhouse, +7 authors, Karen Kelly.
Front Oncol, 2019 Dec 19; 9. PMID: 31850192    Free PMC article.
Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review.
Gilbert Lazarus, Jessica Audrey, Anthony William Brian Iskandar.
Oncol Rev, 2019 Dec 21; 13(2). PMID: 31857857    Free PMC article.
Theoretical and Practical Implications of Treating Cachexia in Advanced Lung Cancer Patients.
Philip Bonomi, Mary Jo Fidler, Palmi Shah, Jeffrey Borgia.
Cancers (Basel), 2019 Oct 28; 11(11). PMID: 31652685    Free PMC article.
Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis.
Jong Yeob Kim, Keum Hwa Lee, +12 authors, Gabriele Gamerith.
Cancers (Basel), 2019 Nov 07; 11(11). PMID: 31683809    Free PMC article.
Highly multiplexed immunofluorescence images and single-cell data of immune markers in tonsil and lung cancer.
Rumana Rashid, Giorgio Gaglia, +9 authors, Sandro Santagata.
Sci Data, 2019 Dec 19; 6(1). PMID: 31848351    Free PMC article.
FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management.
Isabelle Solassol, Frédéric Pinguet, Xavier Quantin.
Biomolecules, 2019 Nov 02; 9(11). PMID: 31671561    Free PMC article.
Review.
MicroRNAs in non-small cell lung cancer: Gene regulation, impact on cancer cellular processes, and therapeutic potential.
Hannah Petrek, Ai-Ming Yu.
Pharmacol Res Perspect, 2019 Dec 21; 7(6). PMID: 31859460    Free PMC article.
Review.
Clinical characteristics of colitis induced by taxane-based chemotherapy.
Ellie Chen, Hamzah Abu-Sbeih, +8 authors, Yinghong Wang.
Ann Gastroenterol, 2020 Jan 02; 33(1). PMID: 31892799    Free PMC article.
U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation.
Koji Haratani, Kimio Yonesaka, +15 authors, Kazuhiko Nakagawa.
J Clin Invest, 2019 Oct 30; 130(1). PMID: 31661465    Free PMC article.
Time to dissect the autoimmune etiology of cancer antibody immunotherapy.
Michael Dougan, Massimo Pietropaolo.
J Clin Invest, 2020 Jan 03; 130(1). PMID: 31895048    Free PMC article.
Review.
Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Kathrin Gennen, Lukas Käsmann, +9 authors, Farkhad Manapov.
Radiat Oncol, 2020 Jan 04; 15(1). PMID: 31898519    Free PMC article.
Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC.
Yoshiaki Amino, Satoru Kitazono, +8 authors, Makoto Nishio.
Int J Clin Oncol, 2019 Sep 12; 25(1). PMID: 31506751
[Progress of Steroids Effect on Efficacy of Immune Checkpoint Inhibitors].
Guoqiang Pan, Yun Fan.
Zhongguo Fei Ai Za Zhi, 2019 Dec 26; 22(12). PMID: 31874675    Free PMC article.
Incidence of Immune Checkpoint Inhibitor-Associated Diabetes: A Meta-Analysis of Randomized Controlled Studies.
Jingli Lu, Jing Yang, +3 authors, Xiaojian Zhang.
Front Pharmacol, 2020 Jan 11; 10. PMID: 31920646    Free PMC article.
Systematic Review.
Maximum Somatic Allele Frequency in Combination With Blood-Based Tumor Mutational Burden to Predict the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer: A Pooled Analysis of the Randomized POPLAR and OAK Studies.
Yu-Tong Chen, Sharvesh Raj Seeruttun, Xiang-Yuan Wu, Zi-Xian Wang.
Front Oncol, 2020 Jan 11; 9. PMID: 31921683    Free PMC article.
Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging.
Ziming Du, Jia-Ren Lin, +6 authors, Sandro Santagata.
Nat Protoc, 2019 Sep 20; 14(10). PMID: 31534232    Free PMC article.
Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy.
Abhishek S Kashyap, Martina Schmittnaegel, +18 authors, Alfred Zippelius.
Proc Natl Acad Sci U S A, 2020 Jan 01; 117(1). PMID: 31889004    Free PMC article.
Clinical Features of Liver Injury Induced by Immune Checkpoint Inhibitors in Japanese Patients.
Koji Imoto, Motoyuki Kohjima, +9 authors, Yoshihiro Ogawa.
Can J Gastroenterol Hepatol, 2020 Jan 14; 2019. PMID: 31929981    Free PMC article.
[Durvalumab after radiochemotherapy for locally advanced unresectable NSCLC-a breakthrough].
Matthias Guckenberger.
Strahlenther Onkol, 2019 Nov 20; 196(1). PMID: 31740982
Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.
Barbara Melosky, Rosalyn Juergens, +5 authors, Quincy Chu.
Oncologist, 2019 May 30; 25(1). PMID: 31138727    Free PMC article.
Current Status of Immunotherapy for Lung Cancer and Future Perspectives.
Ho Cheol Kim, Chang Min Choi.
Tuberc Respir Dis (Seoul), 2020 Jan 07; 83(1). PMID: 31905428    Free PMC article.
Review.
Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer.
Louise A Koopman, Mikkel G Terp, +12 authors, Henrik J Ditzel.
JCI Insight, 2019 Oct 11; 4(21). PMID: 31600169    Free PMC article.
The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis.
Xiaobo Li, Yong Li, +3 authors, Dongmei Zhang.
Cells, 2019 Dec 15; 8(12). PMID: 31835465    Free PMC article.
Review.
Odds ratio of programmed cell death-1 or ligand 1 inhibitor-related endocrine dysfunction in patients with lung cancer: A systematic review and meta-analysis.
Jian Xie, Zewen Zhang, +4 authors, Yuan Tian.
Medicine (Baltimore), 2019 Dec 20; 98(50). PMID: 31852114    Free PMC article.
Systematic Review.
Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors.
Nicholas Gravbrot, Kacy Gilbert-Gard, +4 authors, Srinath Sundararajan.
Antibodies (Basel), 2019 Oct 24; 8(4). PMID: 31640266    Free PMC article.
Review.
EPHB2 carried on small extracellular vesicles induces tumor angiogenesis via activation of ephrin reverse signaling.
Shinya Sato, Suhas Vasaikar, +5 authors, Alissa M Weaver.
JCI Insight, 2019 Oct 30; 4(23). PMID: 31661464    Free PMC article.
First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers.
Thierry Landre, Gaetan Des Guetz, +3 authors, Christos Chouaïd.
J Cancer Res Clin Oncol, 2019 Nov 07; 146(2). PMID: 31686247
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.
Hayato Kawachi, Motohiro Tamiya, +17 authors, Toru Kumagai.
Invest New Drugs, 2019 Dec 01; 38(1). PMID: 31784866
Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.
Hisao Imai, Satoshi Wasamoto, +15 authors, Kyoichi Kaira.
J Cancer Res Clin Oncol, 2019 Dec 20; 146(2). PMID: 31853661
Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.
Kohei Shigeta, Meenal Datta, +14 authors, Dan G Duda.
Hepatology, 2019 Aug 06; 71(4). PMID: 31378984    Free PMC article.
Highly Cited.
Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden.
Steven D Criss, Lauren Palazzo, +4 authors, Chung Yin Kong.
PLoS One, 2020 Jan 30; 15(1). PMID: 31995619    Free PMC article.
Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP).
Alejandro Ruiz-Patiño, Oscar Arrieta, +28 authors, CLICaP.
Thorac Cancer, 2019 Dec 13; 11(2). PMID: 31828967    Free PMC article.
Combined Atezolizumab and Chemotherapy for a Patient With Double Primary Cancers.
Shinichiro Okauchi, Yuika Sasatani, +2 authors, Hiroaki Satoh.
In Vivo, 2019 Dec 29; 34(1). PMID: 31882503    Free PMC article.
Analysis of the association between prior chemotherapy regimens and outcomes of subsequent anti-PD-(L)1 monotherapy in advanced non-small cell lung cancer.
Guanghui Gao, Keyi Jia, +7 authors, Caicun Zhou.
Transl Lung Cancer Res, 2020 Feb 06; 8(6). PMID: 32010570    Free PMC article.
Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018.
Zhengyang Hu, Ming Li, +3 authors, Qun Wang.
Transl Lung Cancer Res, 2020 Feb 06; 8(6). PMID: 32010587    Free PMC article.
Review.
The role of immune checkpoint inhibitors (ICI) in the treatment of metastatic non-small cell lung carcinoma in the elderly.
Johan Chan, Ravindran Kanesvaran.
Ann Transl Med, 2020 Feb 06; 7(Suppl 8). PMID: 32016101    Free PMC article.
Beyond PD-L1 Markers for Lung Cancer Immunotherapy.
Kamila Wojas-Krawczyk, Ewa Kalinka, +2 authors, Janusz Milanowski.
Int J Mol Sci, 2019 Apr 21; 20(8). PMID: 31003463    Free PMC article.
Review.
Research Progress Evaluating the Function and Mechanism of Anti-Tumor Peptides.
Xinxing Pan, Juan Xu, Xuemei Jia.
Cancer Manag Res, 2020 Feb 06; 12. PMID: 32021452    Free PMC article.
Review.
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
Nicolas Marcoux, Scott N Gettinger, +18 authors, Lecia V Sequist.
J Clin Oncol, 2018 Dec 15; 37(4). PMID: 30550363    Free PMC article.
Highly Cited.
Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508.
Suresh S Ramalingam, Suzanne E Dahlberg, +12 authors, Joan H Schiller.
J Clin Oncol, 2019 Jul 31; 37(26). PMID: 31361535    Free PMC article.
Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
Anne S Tsao, Jieling Miao, +11 authors, Karen Kelly.
J Clin Oncol, 2019 Aug 07; 37(28). PMID: 31386610    Free PMC article.
Is the game over for PD-1 inhibitors in EGFR mutant non-small cell lung cancer?
Maria A Velez, Timothy F Burns.
Transl Lung Cancer Res, 2020 Feb 11; 8(Suppl 4). PMID: 32038910    Free PMC article.
Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer.
Maria Jove, Noelia Vilariño, Ernest Nadal.
Transl Lung Cancer Res, 2020 Feb 11; 8(Suppl 4). PMID: 32038916    Free PMC article.
Combination immune checkpoint inhibitors with platinum-based chemotherapy in advanced non-small cell lung cancer: what's known and what's next.
Tao Jiang, Caicun Zhou, Jie Hu, Yuanlin Song.
Transl Lung Cancer Res, 2020 Feb 11; 8(Suppl 4). PMID: 32038935    Free PMC article.
TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity.
Myrofora Panagi, Chrysovalantis Voutouri, +13 authors, Triantafyllos Stylianopoulos.
Theranostics, 2020 Feb 12; 10(4). PMID: 32042344    Free PMC article.
Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis.
Leitao Sun, Leyin Zhang, +7 authors, Shengliang Qiu.
Sci Rep, 2020 Feb 09; 10(1). PMID: 32034198    Free PMC article.
Systematic Review.
Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis.
Xuewen Wang, Shijie Wu, +4 authors, Xiong Chen.
Front Pharmacol, 2020 Feb 23; 11. PMID: 32076409    Free PMC article.
Systematic Review.
Tumor-induced peripheral immunosuppression promotes brain metastasis in patients with non-small cell lung cancer.
Yuping D Li, Jonathan B Lamano, +6 authors, Orin Bloch.
Cancer Immunol Immunother, 2019 Sep 07; 68(9). PMID: 31489465    Free PMC article.
The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Chengdi Wang, Wenliang Qiao, +5 authors, Weimin Li.
J Cell Physiol, 2019 Nov 07; 235(5). PMID: 31693178    Free PMC article.
Systematic Review.
Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy.
Edward B Garon, Giorgio Vittorio Scagliotti, +17 authors, Maurice Pérol.
ESMO Open, 2020 Jan 21; 5(1). PMID: 31958290    Free PMC article.
Recent advances in the clinical development of immune checkpoint blockade therapy.
Atefeh Ghahremanloo, Arash Soltani, Seyed Mohamad Sadegh Modaresi, Seyed Isaac Hashemy.
Cell Oncol (Dordr), 2019 Jun 16; 42(5). PMID: 31201647
Review.
New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer.
Huiping Qiang, Qing Chang, +5 authors, Tianqing Chu.
J Cancer Res Clin Oncol, 2020 Feb 18; 146(3). PMID: 32065262
Review.
Immunotherapy for the Treatment of Breast Cancer: Emerging New Data.
Lida A Mina, Shannon Lim, Shakeela W Bahadur, Abdul T Firoz.
Breast Cancer (Dove Med Press), 2020 Feb 27; 11. PMID: 32099454    Free PMC article.
Review.
Combining microenvironment normalization strategies to improve cancer immunotherapy.
Fotios Mpekris, Chrysovalantis Voutouri, +4 authors, Rakesh K Jain.
Proc Natl Acad Sci U S A, 2020 Feb 06; 117(7). PMID: 32015113    Free PMC article.
Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus.
Misato Jono, Yuhei Kinehara, +10 authors, Isao Tachibana.
Intern Med, 2019 Nov 02; 59(4). PMID: 31666468    Free PMC article.
Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L).
Ryoji Kato, Hidetoshi Hayashi, +19 authors, Kazuhiko Nakagawa.
J Immunother Cancer, 2020 Feb 19; 8(1). PMID: 32066647    Free PMC article.
Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer.
Stephen J Bagley, Suzanna Talento, +4 authors, Anil Vachani.
J Natl Compr Canc Netw, 2019 May 16; 17(5). PMID: 31085759    Free PMC article.
Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial.
Sylvia Adams, Jennifer R Diamond, +9 authors, John Powderly.
JAMA Oncol, 2018 Oct 23; 5(3). PMID: 30347025    Free PMC article.
Highly Cited.
Should chemotherapy plus immune checkpoint inhibition be the standard front-line therapy for patients with metastatic non-small cell lung cancer?
Sarah B Goldberg, Roy S Herbst.
Cancer, 2018 Nov 02; 124(24). PMID: 30383887    Free PMC article.
Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients expressing EGFR (EXTRA study).
Yusuke Okuma, Kei Morikawa, +14 authors, Nobuhiko Seki.
Thorac Cancer, 2018 Dec 12; 10(2). PMID: 30536780    Free PMC article.
Desperately seeking…Models to find the right partner and the best use for checkpoint inhibitors.
Francesco Bertolini.
Br J Cancer, 2018 Dec 13; 120(2). PMID: 30538261    Free PMC article.
Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
Steven D Criss, Meghan J Mooradian, +5 authors, Chung Yin Kong.
JAMA Oncol, 2018 Dec 14; 5(3). PMID: 30543349    Free PMC article.
The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer.
Arutha Kulasinghe, Joanna Kapeleris, +6 authors, Chamindie Punyadeera.
Cancer Med, 2018 Dec 20; 7(12). PMID: 30565869    Free PMC article.
Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis.
Yixin Zhou, Chen Chen, +10 authors, Li Zhang.
J Immunother Cancer, 2018 Dec 24; 6(1). PMID: 30577837    Free PMC article.
Systematic Review.
Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Rui Chen, Xiaoming Hou, Liping Yang, Da Zhao.
Thorac Cancer, 2019 Feb 09; 10(4). PMID: 30734504    Free PMC article.
Systematic Review.
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Liliang Xia, Yuanyong Liu, Ying Wang.
Oncologist, 2019 Mar 02; 24(Suppl 1). PMID: 30819829    Free PMC article.
Review.
Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.
Deborah B Doroshow, Miguel F Sanmamed, +6 authors, Roy S Herbst.
Clin Cancer Res, 2019 Mar 03; 25(15). PMID: 30824587    Free PMC article.
Highly Cited. Review.
Genomic correlates of response to immune checkpoint blockade.
Tanya E Keenan, Kelly P Burke, Eliezer M Van Allen.
Nat Med, 2019 Mar 08; 25(3). PMID: 30842677    Free PMC article.
Highly Cited. Review.
VEGF in Signaling and Disease: Beyond Discovery and Development.
Rajendra S Apte, Daniel S Chen, Napoleone Ferrara.
Cell, 2019 Mar 09; 176(6). PMID: 30849371    Free PMC article.
Highly Cited. Review.
A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab.
Andrea Botticelli, Massimiliano Salati, +11 authors, Paolo Marchetti.
J Transl Med, 2019 Mar 29; 17(1). PMID: 30917841    Free PMC article.
Emerging therapies for non-small cell lung cancer.
Chao Zhang, Natasha B Leighl, Yi-Long Wu, Wen-Zhao Zhong.
J Hematol Oncol, 2019 Apr 27; 12(1). PMID: 31023335    Free PMC article.
Highly Cited. Review.
Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?
Xin Gao, David F McDermott, M Dror Michaelson.
Oncologist, 2019 May 01; 24(6). PMID: 31036769    Free PMC article.
Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice.
Wenwen Yue, Liang Chen, +10 authors, Yu Chen.
Nat Commun, 2019 May 03; 10(1). PMID: 31048681    Free PMC article.
Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis.
Fabio Conforti, Laura Pala, +9 authors, Aron Goldhirsch.
J Natl Cancer Inst, 2019 May 21; 111(8). PMID: 31106827    Free PMC article.
Systematic Review.
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.
Davide Bedognetti, Michele Ceccarelli, +53 authors, Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.
J Immunother Cancer, 2019 May 23; 7(1). PMID: 31113486    Free PMC article.
Review.
Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma.
Kazuki Takada, Mototsugu Shimokawa, +8 authors, Masaki Mori.
PLoS One, 2019 Jun 05; 14(6). PMID: 31163080    Free PMC article.
Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
Diego Signorelli, Patrizia Giannatempo, +11 authors, Immune-Oncology YOUNG Group.
Biomed Res Int, 2019 Jun 11; 2019. PMID: 31179334    Free PMC article.
Review.
A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer.
Mohammad Jafarnejad, Chang Gong, +6 authors, Aleksander S Popel.
AAPS J, 2019 Jun 27; 21(5). PMID: 31236847    Free PMC article.
Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer.
Yaru Tian, Xiaoyang Zhai, +2 authors, Jinming Yu.
J Hematol Oncol, 2019 Jun 30; 12(1). PMID: 31253167    Free PMC article.
Review.
Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front.
Maria Saigi, Juan J Alburquerque-Bejar, Montse Sanchez-Cespedes.
Oncogene, 2019 Jun 30; 38(31). PMID: 31253869
Review.
Comparisons between tumor burden and other prognostic factors that influence survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitors.
Yoshihiko Sakata, Kodai Kawamura, +9 authors, Takuro Sakagami.
Thorac Cancer, 2019 Nov 05; 10(12). PMID: 31679185    Free PMC article.
Clinical significance of the immune cell landscape in hepatocellular carcinoma patients with different degrees of fibrosis.
Xiaofeng Tang, Zheyue Shu, +4 authors, Shusen Zheng.
Ann Transl Med, 2019 Dec 07; 7(20). PMID: 31807510    Free PMC article.
Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges.
Kei Kunimasa, Taichiro Goto.
Int J Mol Sci, 2020 Jan 23; 21(2). PMID: 31963413    Free PMC article.
Review.
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Alberto Pavan, Lorenzo Calvetti, +7 authors, Laura Bonanno.
Oncologist, 2019 Apr 25; 24(8). PMID: 31015312    Free PMC article.
Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer.
Yusuke Chihara, Akihiro Yoshimura, +12 authors, Koichi Takayama.
Oncologist, 2019 May 02; 24(8). PMID: 31040252    Free PMC article.
Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer.
Shiqiang Wang, Chongling Hu, Fei Xie, Yanhui Liu.
Onco Targets Ther, 2020 Mar 12; 13. PMID: 32158220    Free PMC article.
Review.
Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives.
Sun Min Lim, Min Hee Hong, Hye Ryun Kim.
Immune Netw, 2020 Mar 12; 20(1). PMID: 32158598    Free PMC article.
Review.
Deep neural network classification based on somatic mutations potentially predicts clinical benefit of immune checkpoint blockade in lung adenocarcinoma.
Jie Peng, Dan Zou, +2 authors, Lijie Han.
Oncoimmunology, 2020 Mar 12; 9(1). PMID: 32158626    Free PMC article.
[Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)].
Caicun Zhou, Jie Wang, +13 authors, Shukui Qin.
Zhongguo Fei Ai Za Zhi, 2020 Feb 26; 23(2). PMID: 32093450    Free PMC article.
[Chinese Expert Consensus on Antiangiogenic Drugs for Advanced Non-small Cell Lung Cancer (2019 Edition)].
Chinese Society of Clinical Oncology, Expert Committee on Vessel Targeted Therapy, Expert Committee on Non-small Cell Lung Cancer, Expert Group on Antiangiogenic Drugs for Non-small Cell Lung Cancer.
Zhongguo Fei Ai Za Zhi, 2019 Jul 19; 22(7). PMID: 31315778    Free PMC article.
The Risk Ratio of Immune-Related Colitis, Hepatitis, and Pancreatitis in Patients With Solid Tumors Caused by PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis.
Yuan Tian, Zewen Zhang, +7 authors, Yi Zhao.
Front Oncol, 2020 Mar 18; 10. PMID: 32181158    Free PMC article.
Systematic Review.
Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy.
Leyre Zubiri, Ian M Allen, +16 authors, Kerry L Reynolds.
Oncologist, 2020 Mar 13; 25(3). PMID: 32162817    Free PMC article.
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics.
Akintunde Akinleye, Zoaib Rasool.
J Hematol Oncol, 2019 Sep 07; 12(1). PMID: 31488176    Free PMC article.
Highly Cited. Review.
Metabolic enzymes expressed by cancer cells impact the immune infiltrate.
Gautier Stoll, Margerie Kremer, +7 authors, Guido Kroemer.
Oncoimmunology, 2019 May 10; 8(6). PMID: 31069148    Free PMC article.
Addressing Recent Failures in Immuno-Oncology Trials to Guide Novel Immunotherapeutic Treatment Strategies.
Shazia K Nakhoda, Anthony J Olszanski.
Pharmaceut Med, 2020 Mar 12; 34(2). PMID: 32157638    Free PMC article.
Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer.
Peter T Harrison, Simon Vyse, Paul H Huang.
Semin Cancer Biol, 2019 Sep 29; 61. PMID: 31562956    Free PMC article.
Review.
Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab.
Tomoya Fukui, Shinji Hosotani, +13 authors, Katsuhiko Naoki.
Thorac Cancer, 2020 Feb 15; 11(4). PMID: 32057187    Free PMC article.
Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria.
Hongge Liang, Yan Xu, +3 authors, Jing Zhao.
Thorac Cancer, 2020 Mar 05; 11(4). PMID: 32129934    Free PMC article.
A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer.
Yasuhiro Kato, Yusuke Okuma, +4 authors, Tatsuru Okamura.
Cancer Chemother Pharmacol, 2019 Apr 18; 84(2). PMID: 30993397    Free PMC article.
Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?
Luigi Della Gravara, Ciro Battiloro, +4 authors, Danilo Rocco.
Lung Cancer Manag, 2020 Apr 08; 9(1). PMID: 32256708    Free PMC article.
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer.
B Ricciuti, M Brambilla, +9 authors, R Chiari.
Clin Transl Oncol, 2019 Jul 25; 22(5). PMID: 31332704
Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.
D Isla, J de Castro, +5 authors, J M Trigo.
Clin Transl Oncol, 2019 Aug 02; 22(5). PMID: 31368078
Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept.
Thierry Berghmans, Valérie Durieux, Lizza E L Hendriks, Anne-Marie Dingemans.
Front Med (Lausanne), 2020 Apr 09; 7. PMID: 32266275    Free PMC article.
Systematic Review.
Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?
Thaiz Rivera Vargas, Lionel Apetoh.
Front Immunol, 2019 Jun 14; 10. PMID: 31191545    Free PMC article.
Review.
Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma-Systematic review and meta-analysis.
Jaimin J Patel, Dylan A Levy, +2 authors, Terry A Day.
Head Neck, 2019 Nov 26; 42(4). PMID: 31762164    Free PMC article.
Systematic Review.
Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Fausto Petrelli, Diego Signorelli, +12 authors, Gianluca Tomasello.
Cancers (Basel), 2020 Mar 04; 12(3). PMID: 32120803    Free PMC article.
Review.
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents.
Paola Ciciola, Priscilla Cascetta, +2 authors, Roberto Bianco.
J Clin Med, 2020 Mar 07; 9(3). PMID: 32138216    Free PMC article.
Review.
Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer.
Takeshi Masuda, Kazunori Fujitaka, +19 authors, Noboru Hattori.
J Thorac Dis, 2020 Apr 11; 12(3). PMID: 32274176    Free PMC article.
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
Naiyer A Rizvi, Byoung Chul Cho, +28 authors, MYSTIC Investigators.
JAMA Oncol, 2020 Apr 10; 6(5). PMID: 32271377    Free PMC article.
An update on angiogenesis targeting in head and neck squamous cell carcinoma.
Ida Micaily, Jennifer Johnson, Athanassios Argiris.
Cancers Head Neck, 2020 Apr 14; 5. PMID: 32280512    Free PMC article.
Review.
Rational application of the first-line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta-analysis.
Rui Cao, Jie-Tao Ma, +6 authors, Cheng-Bo Han.
Cancer Med, 2019 Jul 13; 8(11). PMID: 31297962    Free PMC article.
A global immune gene expression signature for human cancers.
Yuexin Liu.
Oncotarget, 2019 Apr 09; 10(20). PMID: 30956779    Free PMC article.
Recent Findings in the Regulation of Programmed Death Ligand 1 Expression.
Xiangfeng Shen, Lihong Zhang, +3 authors, Zhi-Xiang Xu.
Front Immunol, 2019 Jul 02; 10. PMID: 31258527    Free PMC article.
Review.
Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis.
Jie Liu, Chengming Li, +2 authors, Xue Meng.
Oncoimmunology, 2020 Apr 22; 9(1). PMID: 32313723    Free PMC article.
Systematic Review.
Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial.
Jonas Kuon, Adriane Hommertgen, +8 authors, Michael Thomas.
Trials, 2020 Apr 24; 21(1). PMID: 32321565    Free PMC article.
Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions.
Masahiro Kagabu, Takayuki Nagasawa, +6 authors, Tsukasa Baba.
Int J Mol Sci, 2020 Apr 02; 21(7). PMID: 32230938    Free PMC article.
Review.
Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement.
Yuko Oya, Hiroaki Kuroda, +3 authors, Toyoaki Hida.
Int J Mol Sci, 2020 Apr 15; 21(7). PMID: 32283823    Free PMC article.
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Stefano Kim, Bruno Buecher, +21 authors, Christophe Borg.
BMC Cancer, 2020 Apr 27; 20(1). PMID: 32334548    Free PMC article.
Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer.
Dwight H Owen, Terence M Williams, +7 authors, Gregory A Otterson.
Lung Cancer, 2019 Jul 20; 134. PMID: 31319977    Free PMC article.
Current issues and perspectives in PD-1 blockade cancer immunotherapy.
Kenji Chamoto, Ryusuke Hatae, Tasuku Honjo.
Int J Clin Oncol, 2020 Jan 05; 25(5). PMID: 31900651    Free PMC article.
Review.
COVID-19: the use of immunotherapy in metastatic lung cancer.
Alexander P Davis, Michael Boyer, Jenny H Lee, Steven C Kao.
Immunotherapy, 2020 May 01; 12(8). PMID: 32349579    Free PMC article.
Immuno-oncology-the new paradigm of lung cancer treatment.
D E Dawe, C H Harlos, R A Juergens.
Curr Oncol, 2020 May 06; 27(Suppl 2). PMID: 32368177    Free PMC article.
Review.
The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab.
Taichi Matsubara, Shinkichi Takamori, +6 authors, Mitsuhiro Takenoyama.
J Thorac Dis, 2020 May 13; 12(4). PMID: 32395289    Free PMC article.
Neoadjuvant immunotherapy with resectable non-small cell lung cancer: recent advances and future challenges.
Sijia Ren, Chunguo Wang, Jianfei Shen, Chengchu Zhu.
J Thorac Dis, 2020 May 13; 12(4). PMID: 32395299    Free PMC article.
Keynote 42: Pembrolizumab, PD-L1, and where to draw the line.
James Isaacs, Jeffrey Clarke, Neal Ready.
Ann Transl Med, 2020 May 13; 8(7). PMID: 32395561    Free PMC article.
Exploiting immune-dependent effects of microtubule-targeting agents to improve efficacy and tolerability of cancer treatment.
Angela Flavia Serpico, Roberta Visconti, Domenico Grieco.
Cell Death Dis, 2020 May 14; 11(5). PMID: 32398657    Free PMC article.
Review.
Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition.
Madhawa de Silva, Malinda Itchins, Nick Pavlakis.
Ann Transl Med, 2020 May 16; 8(8). PMID: 32411778    Free PMC article.
Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia.
Ilaria Maggio, Lisa Manuzzi, +3 authors, Davide Campana.
Cancers (Basel), 2020 Apr 03; 12(4). PMID: 32235636    Free PMC article.
Review.
An advanced non-small cell lung cancer patient with epidermal growth factor receptor sensitizing mutation responded to toripalimab in combination with chemotherapy after resistance to osimertinib: a case report.
Juan Zhou, Fei Zhou, +3 authors, Chunxia Su.
Transl Lung Cancer Res, 2020 May 19; 9(2). PMID: 32420075    Free PMC article.
Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?
Camille Travert, Pascale Tomasini, Fabrice Barlesi.
Transl Lung Cancer Res, 2020 May 19; 9(2). PMID: 32420082    Free PMC article.
Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer.
Pengfei Cui, Di Huang, +9 authors, Yi Hu.
Ther Adv Med Oncol, 2020 May 20; 12. PMID: 32426052    Free PMC article.
Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC.
Alex Friedlaender, Giuseppe Banna, Sandip Patel, Alfredo Addeo.
Curr Treat Options Oncol, 2019 Sep 05; 20(10). PMID: 31482479
Review.
The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis.
Run-Cong Nie, Chong-Bang Zhao, +6 authors, Yuan-Fang Li.
Biomed Res Int, 2020 May 29; 2020. PMID: 32461994    Free PMC article.
Systematic Review.
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yunfang Yu, Dongqiang Zeng, +8 authors, Herui Yao.
JAMA Netw Open, 2019 Jul 11; 2(7). PMID: 31290993    Free PMC article.
Highly Cited.
Emerging therapeutic agents for advanced non-small cell lung cancer.
Ruqin Chen, Rami Manochakian, +6 authors, Yanyan Lou.
J Hematol Oncol, 2020 May 26; 13(1). PMID: 32448366    Free PMC article.
Review.
Canadian consensus: a new systemic treatment algorithm for advanced EGFR-mutated non-small-cell lung cancer.
B Melosky, S Banerji, +5 authors, P Cheema.
Curr Oncol, 2020 Jun 04; 27(2). PMID: 32489263    Free PMC article.
First Report of Severe Acute Graft-Versus-Host Disease After Allogeneic Stem Cell Transplant in a Patient With Myelodysplastic Syndrome Treated With Atezolizumab: Literature Review.
Mindy Hsiao, Sergei Tatishchev, +3 authors, George Yaghmour.
World J Oncol, 2020 Jun 05; 11(3). PMID: 32494318    Free PMC article.
Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
P Garrido, E Conde, +7 authors, F López-Ríos.
Clin Transl Oncol, 2019 Oct 11; 22(7). PMID: 31598903    Free PMC article.
LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial.
Claudio Vernieri, Monica Ganzinelli, +16 authors, Marina C Garassino.
ESMO Open, 2020 May 30; 5(3). PMID: 32467099    Free PMC article.
Infiltration of CD8+ FOXP3+ T cells, CD8+ T cells, and FOXP3+ T cells in non-small cell lung cancer microenvironment.
Jianqing Hao, Helin Wang, +5 authors, Jinghui Wang.
Int J Clin Exp Pathol, 2020 Jun 09; 13(5). PMID: 32509058    Free PMC article.
The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors.
Evangelos Koustas, Panagiotis Sarantis, Athanasios G Papavassiliou, Michalis V Karamouzis.
Biomolecules, 2020 Apr 30; 10(5). PMID: 32344837    Free PMC article.
Review.
Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma.
Olivier Bylicki, Florian Guisier, +8 authors, Christos Chouaid.
Medicine (Baltimore), 2020 Feb 06; 99(3). PMID: 32011450    Free PMC article.
Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells.
Tamio Okimoto, Hitoshi Kotani, +5 authors, Mamoru Harada.
Cancer Sci, 2020 Apr 02; 111(6). PMID: 32232903    Free PMC article.
Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer.
Shintaro Kanda, Yuichiro Ohe, +6 authors, Tomohide Tamura.
Cancer Sci, 2020 Apr 12; 111(6). PMID: 32277531    Free PMC article.
Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient.
Giovanni Rossi, Alessandro Russo, +13 authors, Carlo Genova.
Cancers (Basel), 2020 May 06; 12(5). PMID: 32365882    Free PMC article.
Review.
Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non-Small Cell Lung Cancer.
Michael S Leapman, Carolyn J Presley, +5 authors, Cary P Gross.
JAMA Netw Open, 2020 Jun 09; 3(6). PMID: 32511721    Free PMC article.
Identification of PD1-mediated regulation of antitumor antigen response in patients with NSCLC using the trans vivo DTH assay.
Diego A Lema, Ewa Jankowska-Gan, +2 authors, Ticiana Leal.
J Immunother Cancer, 2020 Jun 13; 8(1). PMID: 32527929    Free PMC article.
Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC.
Matthew D Hellmann, Barzin Y Nabet, +32 authors, Maximilian Diehn.
Clin Cancer Res, 2020 Feb 13; 26(12). PMID: 32046999    Free PMC article.
Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review.
Keisuke Onoi, Yusuke Chihara, +6 authors, Koichi Takayama.
J Clin Med, 2020 May 10; 9(5). PMID: 32384677    Free PMC article.
Review.
Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice.
Yu Chen, Yanqing Pei, +3 authors, Xiangjiao Meng.
Front Immunol, 2020 Jun 18; 11. PMID: 32547566    Free PMC article.
Review.
Immune microenvironment composition in non-small cell lung cancer and its association with survival.
Menno Tamminga, Thijo Jeroen N Hiltermann, +3 authors, Harry Jm Groen.
Clin Transl Immunology, 2020 Jun 18; 9(6). PMID: 32547744    Free PMC article.
Novel Nuclear Medicine Imaging Applications in Immuno-Oncology.
Stefano Frega, Alessandro Dal Maso, +4 authors, Laura Evangelista.
Cancers (Basel), 2020 May 28; 12(5). PMID: 32455666    Free PMC article.
Review.
Performance Status and Age as Predictors of Immunotherapy Outcomes in Advanced Non-Small-Cell Lung Cancer.
Tamjeed Ahmed, Thomas Lycan, +8 authors, W Jeffrey Petty.
Clin Lung Cancer, 2020 Feb 25; 21(4). PMID: 32089478    Free PMC article.
Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC.
Sohita Dhillon, Yahiya Y Syed.
Target Oncol, 2019 Nov 16; 14(6). PMID: 31728860
Review.
Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench.
Rui Jin, Jing Zhao, +4 authors, Yang Xia.
Ther Adv Med Oncol, 2020 Jun 23; 12. PMID: 32565926    Free PMC article.
Review.
Unique Genetic Characteristics and Clinical Prognosis of Female Patients with Lung Cancer Harboring RET Fusion Gene.
Zhixin Qiu, Bingwei Ye, +4 authors, Panwen Tian.
Sci Rep, 2020 Jun 27; 10(1). PMID: 32587276    Free PMC article.
Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients.
Lupeng Qiu, Xiao Zhao, +7 authors, Shunchang Jiao.
Medicine (Baltimore), 2020 Jun 17; 99(24). PMID: 32541476    Free PMC article.
Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression.
Etienne Giroux Leprieur, Zofia Hélias-Rodzewicz, +10 authors, Jean-François Emile.
J Immunother Cancer, 2020 Jun 26; 8(1). PMID: 32581058    Free PMC article.
Tumor Mutational Burden and PD-L1 Expression in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China.
Yuhui Ma, Quan Li, +10 authors, Yongchun Zhou.
Onco Targets Ther, 2020 Jul 02; 13. PMID: 32606739    Free PMC article.
Economic Evaluations of Immune Checkpoint Inhibitors for Patients with Non-Small Cell Lung Cancer: A Systematic Review.
Na Li, Huanrui Zheng, +3 authors, Maobai Liu.
Cancer Manag Res, 2020 Jul 02; 12. PMID: 32606944    Free PMC article.
Review.
Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Shingo Kitagawa, Taiki Hakozaki, Rui Kitadai, Yukio Hosomi.
Thorac Cancer, 2020 May 19; 11(7). PMID: 32421224    Free PMC article.
The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer.
Kirstin Perdrizet, Natasha B Leighl.
Curr Treat Options Oncol, 2019 Feb 20; 20(3). PMID: 30778772
Review.
The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis.
Ying-Nai Wang, Heng-Huan Lee, +2 authors, Mien-Chie Hung.
J Biomed Sci, 2020 Jul 06; 27(1). PMID: 32620165    Free PMC article.
Review.
Atezolizumab-associated encephalitis in metastatic lung adenocarcinoma: a case report.
Yoshitaka Yamaguchi, Hikaru Nagasawa, Yuji Katagiri, Manabu Wada.
J Med Case Rep, 2020 Jul 06; 14(1). PMID: 32620173    Free PMC article.
Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review).
Wenjie You, Bin Shang, +3 authors, Shujuan Jiang.
Oncol Rep, 2020 Jul 07; 44(2). PMID: 32627031    Free PMC article.
Review.
Imaging-Based Prediction of Molecular Therapy Targets in NSCLC by Radiogenomics and AI Approaches: A Systematic Review.
Gaia Ninatti, Margarita Kirienko, +2 authors, Arturo Chiti.
Diagnostics (Basel), 2020 Jun 04; 10(6). PMID: 32486314    Free PMC article.
Review.
Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors.
Justin A Chen, Jonathan W Riess.
J Thorac Dis, 2020 Jul 10; 12(5). PMID: 32642199    Free PMC article.
Review.
Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer.
Ana I Velazquez, Caroline E McCoach.
J Thorac Dis, 2020 Jul 10; 12(5). PMID: 32642202    Free PMC article.
Review.
Novel genetic variants of KIR3DL2 and PVR involved in immunoregulatory interactions are associated with non-small cell lung cancer survival.
Yufeng Wu, Sen Yang, +8 authors, Qingyi Wei.
Am J Cancer Res, 2020 Jul 10; 10(6). PMID: 32642289    Free PMC article.
A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses.
Wenjie Zhai, Xiuman Zhou, +6 authors, Yanfeng Gao.
Acta Pharm Sin B, 2020 Jul 10; 10(6). PMID: 32642411    Free PMC article.
Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle.
Max M Wattenberg, Gregory L Beatty.
Semin Cancer Biol, 2020 Jan 19; 65. PMID: 31954172    Free PMC article.
Review.
Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy.
Gaia Giannone, Eleonora Ghisoni, +4 authors, Giorgio Valabrega.
Int J Mol Sci, 2020 Jun 25; 21(12). PMID: 32575899    Free PMC article.
Review.
Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials.
Omid Kooshkaki, Afshin Derakhshani, +6 authors, Behzad Baradaran.
Int J Mol Sci, 2020 Jun 26; 21(12). PMID: 32580338    Free PMC article.
Review.
Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review.
Philippe Rochigneux, Alejandro J Garcia, +3 authors, Edward B Garon.
Front Immunol, 2020 Jul 17; 11. PMID: 32670271    Free PMC article.
Systematic Review.
Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy.
Fan Zhang, Di Huang, +14 authors, Yi Hu.
Ther Adv Med Oncol, 2020 Jul 17; 12. PMID: 32670420    Free PMC article.
Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies.
Robert J Walsh, Ross A Soo.
Ther Adv Med Oncol, 2020 Jul 17; 12. PMID: 32670423    Free PMC article.
Review.
The prospect of combination therapy with immune checkpoint inhibitors and chemotherapy for squamous cell carcinoma of the lung.
Yoshinobu Ichiki, Takashi Fukuyama, Kozo Nakanishi.
Transl Lung Cancer Res, 2020 Jul 18; 9(3). PMID: 32676343    Free PMC article.
First-line immune-chemotherapy combination for squamous NSCLC is already a reality.
Lizza E L Hendriks, Jessica Menis, Jordi Remon.
Transl Lung Cancer Res, 2020 Jul 18; 9(3). PMID: 32676345    Free PMC article.
Selected highlights of the 2019 Pulmonary Pathology Society Biennial Meeting: PD-L1 test harmonization studies.
Sylvie Lantuejoul, Francesca Damiola, Julien Adam.
Transl Lung Cancer Res, 2020 Jul 18; 9(3). PMID: 32676356    Free PMC article.
Review.
Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC).
J Nicholas Bodor, Yanis Boumber, Hossein Borghaei.
Cancer, 2019 Nov 07; 126(2). PMID: 31691957    Free PMC article.
Review.
Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study.
Muhammad A Khattak, Afaf Abed, +4 authors, Elin S Gray.
Front Oncol, 2020 Jul 23; 10. PMID: 32695680    Free PMC article.
A Novel Paradigm Between Leukocytosis, G-CSF Secretion, Neutrophil-to-Lymphocyte Ratio, Myeloid-Derived Suppressor Cells, and Prognosis in Non-small Cell Lung Cancer.
Montreh Tavakkoli, Cy R Wilkins, Jodi V Mones, Michael J Mauro.
Front Oncol, 2019 May 14; 9. PMID: 31080780    Free PMC article.
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
J Mazieres, A Drilon, +35 authors, O Gautschi.
Ann Oncol, 2019 May 28; 30(8). PMID: 31125062    Free PMC article.
Highly Cited.
Immunotherapy - new perspective in lung cancer.
Fillipe Dantas Pinheiro, Adriano Fernandes Teixeira, +3 authors, Fabrício Freire de Melo.
World J Clin Oncol, 2020 Jul 31; 11(5). PMID: 32728528    Free PMC article.
Review.
Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer.
Martin Reck, Thomas Wehler, +16 authors, Mark A Socinski.
J Clin Oncol, 2020 May 28; 38(22). PMID: 32459597    Free PMC article.
SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.
Yu Chen, Min Gao, +2 authors, Xiangjiao Meng.
J Hematol Oncol, 2020 Jul 30; 13(1). PMID: 32723363    Free PMC article.
Review.
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial).
Francesco Gelsomino, Giuseppe Lamberti, +15 authors, Andrea Ardizzoni.
Ther Adv Med Oncol, 2020 Aug 01; 12. PMID: 32733604    Free PMC article.
Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study.
David Chardin, Marie Paquet, +9 authors, Olivier Humbert.
J Immunother Cancer, 2020 Jul 28; 8(2). PMID: 32709713    Free PMC article.
Value of TTF-1 expression in non-squamous non-small-cell lung cancer for assessing docetaxel monotherapy after chemotherapy failure.
Akira Takeuchi, Tetsuya Oguri, +15 authors, Akio Niimi.
Mol Clin Oncol, 2020 Aug 06; 13(3). PMID: 32754323    Free PMC article.
Combination of Juzentaihoto and chemotherapy improves the prognosis of patients with postoperative recurrence of non-small cell lung cancer.
Hideki Kawai, Yoshitaro Saito.
Mol Clin Oncol, 2020 Aug 06; 13(3). PMID: 32754327    Free PMC article.
Successful continuous nivolumab therapy for metastatic non-small cell lung cancer after local treatment of oligometastatic lesions.
Satoshi Tobita, Yuhei Kinehara, +10 authors, Isao Tachibana.
Thorac Cancer, 2020 Jun 23; 11(8). PMID: 32567218    Free PMC article.
Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
Thomas E Stinchcombe, Pasi A Jänne, +12 authors, Everett E Vokes.
JAMA Oncol, 2019 Aug 09; 5(10). PMID: 31393548    Free PMC article.
Targeting Immunometabolism Mediated by CD73 Pathway in EGFR-Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance.
Anna Passarelli, Michele Aieta, Alessandro Sgambato, Cesare Gridelli.
Front Immunol, 2020 Aug 08; 11. PMID: 32760402    Free PMC article.
Review.
Organoid Models of Tumor Immunology.
Kanako Yuki, Ning Cheng, Michitaka Nakano, Calvin J Kuo.
Trends Immunol, 2020 Jul 14; 41(8). PMID: 32654925    Free PMC article.
Review.
Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context.
Sneha Gullapalli, Jordi Remon, Lizza E L Hendriks, Gilberto Lopes.
Onco Targets Ther, 2020 Aug 09; 13. PMID: 32764980    Free PMC article.
Review.
Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver.
So Yeon Kim, Balazs Halmos.
Lung Cancer Manag, 2020 Aug 11; 9(3). PMID: 32774467    Free PMC article.
Review.
Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis.
Tingting Liu, Bo Jin, +4 authors, Guang Li.
Ther Adv Med Oncol, 2020 Aug 11; 12. PMID: 32774474    Free PMC article.
The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China.
Yanhui Chen, Yating Wang, +5 authors, Henghui Zhang.
Exp Hematol Oncol, 2020 Aug 11; 9. PMID: 32775040    Free PMC article.
ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling.
Malinda Itchins, Brandon Lau, +16 authors, Nick Pavlakis.
Oncologist, 2020 Jun 20; 25(8). PMID: 32558067    Free PMC article.
PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis.
Jorge García-González, Juan Ruiz-Bañobre, +12 authors, Luis León-Mateos.
J Clin Med, 2020 Jul 09; 9(7). PMID: 32635291    Free PMC article.
Review.
[Progress of Bevacizumab in the Front-line Treatment of Advanced Non-small Cell Lung Cancer].
Bin Ai, Yifan Yang.
Zhongguo Fei Ai Za Zhi, 2020 Jul 25; 23(7). PMID: 32702797    Free PMC article.
Review.
Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors.
Magalie Dosset, Elodie Lauret-Marie Joseph, Thaiz Rivera Vargas, Lionel Apetoh.
Cells, 2020 Jul 28; 9(7). PMID: 32707692    Free PMC article.
Review.
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity.
Rong Tang, Jin Xu, +6 authors, Si Shi.
J Hematol Oncol, 2020 Aug 12; 13(1). PMID: 32778143    Free PMC article.
Review.
Current management of RET rearranged non-small cell lung cancer.
Thomas E Stinchcombe.
Ther Adv Med Oncol, 2020 Aug 13; 12. PMID: 32782485    Free PMC article.
Review.
Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm.
Giuseppe Luigi Banna, Ornella Cantale, +4 authors, Alfredo Addeo.
Oncol Rev, 2020 Aug 13; 14(2). PMID: 32782728    Free PMC article.
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status.
Joao V Alessi, Biagio Ricciuti, +12 authors, Mark Awad.
J Immunother Cancer, 2020 Aug 06; 8(2). PMID: 32753547    Free PMC article.
Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade.
Elisa Peranzoni, Vincenzo Ingangi, +2 authors, Ilaria Marigo.
Front Immunol, 2020 Aug 15; 11. PMID: 32793228    Free PMC article.
Review.
Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons.
Elisa Aquilanti, Priscilla K Brastianos.
Neurosurgery, 2020 Apr 18; 87(3). PMID: 32302389    Free PMC article.
Review.
Targeting PD-L1 in non-small cell lung cancer using CAR T cells.
Ming Liu, Xu Wang, +8 authors, Yong Li.
Oncogenesis, 2020 Aug 15; 9(8). PMID: 32792499    Free PMC article.
Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study.
Naoto Okada, Rie Matsuoka, +6 authors, Keisuke Ishizawa.
Sci Rep, 2020 Aug 15; 10(1). PMID: 32792640    Free PMC article.
Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
Tejas Patil, Rao Mushtaq, +10 authors, Robert C Doebele.
Clin Lung Cancer, 2019 Dec 21; 21(3). PMID: 31859066    Free PMC article.
Identification of a 4-lncRNA signature predicting prognosis of patients with non-small cell lung cancer: a multicenter study in China.
Rui-Qi Wang, Xiao-Ran Long, +11 authors, Hui-Yun Wang.
J Transl Med, 2020 Aug 21; 18(1). PMID: 32819367    Free PMC article.
Do Elderly Lung Cancer Patients Aged ≥75 Years Benefit from Immune Checkpoint Inhibitors?
Nagio Takigawa, Nobuaki Ochi, +7 authors, Hiromichi Yamane.
Cancers (Basel), 2020 Jul 28; 12(7). PMID: 32708291    Free PMC article.
Review.
Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer.
Akira Inoue.
Proc Jpn Acad Ser B Phys Biol Sci, 2020 Aug 14; 96(7). PMID: 32788550    Free PMC article.
Review.
Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis.
Shu-Ling Zhang, Cheng-Bo Han, +2 authors, Jie-Tao Ma.
Radiat Oncol, 2020 Aug 25; 15(1). PMID: 32831120    Free PMC article.
Scientifically based combination therapies with immuno-oncology checkpoint inhibitors.
Hui Yi Chew, Riccardo Dolcetti, Fiona Simpson.
Br J Clin Pharmacol, 2020 May 07; 86(9). PMID: 32372470    Free PMC article.
Review.
Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer.
Byung Woog Kang, Ian Chau.
ESMO Open, 2020 Aug 21; 5(4). PMID: 32817133    Free PMC article.
Review.
[Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer].
Di Zhang, Jiaqi Huang, +2 authors, Qisen Guo.
Zhongguo Fei Ai Za Zhi, 2019 Jun 15; 22(6). PMID: 31196371    Free PMC article.
Review.
[Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for Non-small Cell Lung Cancer].
Sixuan Wu, Chunhong Hu, +2 authors, Ping Liu.
Zhongguo Fei Ai Za Zhi, 2019 Jul 19; 22(7). PMID: 31315783    Free PMC article.
Review.
[Immunotherapy in Epidermal Growth Factor Receptor-mutant 
Non-small Cell Lung Cancer].
Xin Wang, Diansheng Zhong.
Zhongguo Fei Ai Za Zhi, 2019 Aug 28; 22(8). PMID: 31451147    Free PMC article.
Review.
Immunoradiotherapy as An Effective Therapeutic Strategy in Lung Cancer: From Palliative Care to Curative Intent.
Rodolfo Chicas-Sett, Juan Zafra-Martin, +5 authors, Felipe Couñago.
Cancers (Basel), 2020 Aug 09; 12(8). PMID: 32764371    Free PMC article.
Review.
PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy.
Ana Bocanegra, Ester Blanco, +7 authors, Grazyna Kochan.
Int J Mol Sci, 2020 Aug 23; 21(16). PMID: 32824655    Free PMC article.
Review.
Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
Angela Damato, Francesco Iachetta, +10 authors, Carmine Pinto.
BMC Cancer, 2020 Sep 02; 20(1). PMID: 32867715    Free PMC article.
Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer.
Wenjing Wang, Mengyue Zhao, +11 authors, Lihui Wang.
Mol Cancer, 2020 Sep 04; 19(1). PMID: 32878625    Free PMC article.
Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings.
R Donald Harvey, Val R Adams, Tyler Beardslee, Patrick Medina.
J Oncol Pharm Pract, 2020 Jun 23; 26(6). PMID: 32567494    Free PMC article.
Review.
Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers.
Wioletta Olejarz, Grażyna Kubiak-Tomaszewska, Alicja Chrzanowska, Tomasz Lorenc.
Int J Mol Sci, 2020 Aug 23; 21(16). PMID: 32823989    Free PMC article.
Review.
C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study.
Jakob M Riedl, Dominik A Barth, +16 authors, Florian Posch.
Cancers (Basel), 2020 Aug 23; 12(8). PMID: 32824580    Free PMC article.
Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV.
Wolfgang M Brueckl, Martin Reck, +10 authors, Eckart Laack.
Clin Med Insights Oncol, 2020 Sep 05; 14. PMID: 32884390    Free PMC article.
Cavitation and fatal hemoptysis after immunotherapy for advanced lung adenocarcinoma: A case report.
Ruijuan Wang, Kao Li, +2 authors, Minli Zhu.
Thorac Cancer, 2020 Jul 22; 11(9). PMID: 32691523    Free PMC article.
Next-Generation Sequencing at High Sequencing Depth as a Tool to Study the Evolution of Metastasis Driven by Genetic Change Events of Lung Squamous Cell Carcinoma.
Hicham Mansour, Abdelhak Ouhajjou, Vladimir B Bajic, Roberto Incitti.
Front Oncol, 2020 Sep 10; 10. PMID: 32903616    Free PMC article.
Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP).
Alejandro Ruiz-Patiño, Feliciano Barrón, +19 authors, CLICaP.
Thorac Cancer, 2020 Jul 25; 11(9). PMID: 32705787    Free PMC article.
Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis.
Xinru Chen, Zhonghan Zhang, +10 authors, Li Zhang.
J Immunother Cancer, 2020 Aug 31; 8(2). PMID: 32863271    Free PMC article.
Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review.
Haiying Ding, Wenxiu Xin, +4 authors, Yuefeng Rao.
PLoS One, 2020 Sep 03; 15(9). PMID: 32877435    Free PMC article.
Systematic Review.
Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
Gernot Wagner, Hannah Karolina Stollenwerk, +3 authors, Josef Singer.
Oncoimmunology, 2020 Sep 15; 9(1). PMID: 32923134    Free PMC article.
Systematic Review.
Biomarkers of immunotherapy in non-small cell lung cancer.
Lingling Wang, Yue Hu, +2 authors, Xiaochen Wang.
Oncol Lett, 2020 Sep 17; 20(5). PMID: 32934707    Free PMC article.
Review.
PD-1 Inhibitor Therapy in a Patient with Preexisting P-ANCA Vasculitis: A Case Report and Review of the Literature.
Amanda Ramos, Marcela Del Carmen, Oladapo Yeku.
Case Rep Oncol Med, 2020 Sep 17; 2020. PMID: 32934857    Free PMC article.
Supplementation of l-arginine boosts the therapeutic efficacy of anticancer chemoimmunotherapy.
Yusuke Satoh, Hitoshi Kotani, +3 authors, Mamoru Harada.
Cancer Sci, 2020 May 20; 111(7). PMID: 32426941    Free PMC article.
Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity.
Ilgen Mender, Anli Zhang, +8 authors, Yang-Xin Fu.
Cancer Cell, 2020 Jul 04; 38(3). PMID: 32619407    Free PMC article.
Suppressing neutrophil-dependent angiogenesis abrogates resistance to anti-VEGF antibody in a genetic model of colorectal cancer.
Yoshiro Itatani, Takamasa Yamamoto, +5 authors, Napoleone Ferrara.
Proc Natl Acad Sci U S A, 2020 Aug 21; 117(35). PMID: 32817421    Free PMC article.
Brain metastases: lessons and challenges in the targeted therapy and immunotherapy era.
Peter Kar Han Lau.
J Thorac Dis, 2020 Sep 19; 12(8). PMID: 32944368    Free PMC article.
The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients.
Xiaoyang Zhai, Jian Zhang, +4 authors, Hui Zhu.
Cancer Biol Med, 2020 Sep 19; 17(3). PMID: 32944393    Free PMC article.
Review.
Alternative splicing of HER2: a novel mediator of EGFR TKI resistance.
Zachary A Yochum, Liza C Villaruz.
Transl Lung Cancer Res, 2020 Sep 22; 9(4). PMID: 32953533    Free PMC article.
Development of Severe Heart Failure in a Patient with Squamous Non-small-cell Lung Cancer During Nivolumab Treatment.
Yumiko Samejima, Atsuhiko Iuchi, +11 authors, Tomonori Hirashima.
Intern Med, 2020 May 26; 59(16). PMID: 32448839    Free PMC article.
Tumor Endothelial Cells (TECs) as Potential Immune Directors of the Tumor Microenvironment - New Findings and Future Perspectives.
Laurenz Nagl, Lena Horvath, Andreas Pircher, Dominik Wolf.
Front Cell Dev Biol, 2020 Sep 26; 8. PMID: 32974337    Free PMC article.
Review.
ASCO 2018 NSCLC highlights-combination therapy is key.
Gabriele Gamerith, Florian Kocher, Jakob Rudzki, Andreas Pircher.
Memo, 2019 Jan 01; 11(4). PMID: 30595752    Free PMC article.
Review.
VEGF inhibitors in EGFR-mutated lung cancer: a never-ending story?
Mariam Alexander, Balazs Halmos.
Ann Transl Med, 2019 Jan 04; 6(23). PMID: 30603634    Free PMC article.
PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer.
Bairavi Shankar, Jarushka Naidoo.
J Thorac Dis, 2019 Jan 12; 10(Suppl 33). PMID: 30631548    Free PMC article.
Do toxicity patterns vary between programmed death-1 and programmed death ligand-1 inhibitors?
Dwight H Owen, Gregory A Otterson.
J Thorac Dis, 2019 Jan 12; 10(Suppl 33). PMID: 30631557    Free PMC article.
Immunotherapies in the management of epidermal growth factor receptor mutated non-small cell lung cancer: a role will be found?
Francesca Casaluce, Cesare Gridelli.
Transl Lung Cancer Res, 2019 Feb 02; 7(Suppl 4). PMID: 30705859    Free PMC article.
Immunotherapy in tyrosine kinase inhibitor-naïve advanced epidermal growth factor receptor-mutant non-small cell lung cancer-driving down a precarious road in driver-mutated lung cancer.
Rebecca Yin Tay, Christoph Jakob Ackermann, Raffaele Califano.
Transl Lung Cancer Res, 2019 Feb 02; 7(Suppl 4). PMID: 30705861    Free PMC article.
The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer.
Courèche Kaderbhaï, Zoé Tharin, François Ghiringhelli.
Cancers (Basel), 2019 Feb 13; 11(2). PMID: 30744168    Free PMC article.
Review.
Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis.
Kaikai Shen, Jinggang Cui, +8 authors, Dang Lin.
J Thorac Dis, 2019 Feb 13; 10(12). PMID: 30746209    Free PMC article.
Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update.
Hélène Blons, Simon Garinet, Pierre Laurent-Puig, Jean-Baptiste Oudart.
J Thorac Dis, 2019 Feb 19; 11(Suppl 1). PMID: 30775025    Free PMC article.
Review.
Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors.
Léa Berland, Simon Heeke, +11 authors, Marius Ilié.
J Thorac Dis, 2019 Feb 19; 11(Suppl 1). PMID: 30775030    Free PMC article.
Review.
The evolving role of immuno-oncology for the treatment of head and neck cancer.
Arianna L Strome, Xiaoyu Zhang, Scott E Strome.
Laryngoscope Investig Otolaryngol, 2019 Mar 05; 4(1). PMID: 30828620    Free PMC article.
Review.
Tumor Neovascularization and Developments in Therapeutics.
Yuki Katayama, Junji Uchino, +4 authors, Koichi Takayama.
Cancers (Basel), 2019 Mar 09; 11(3). PMID: 30845711    Free PMC article.
Review.
From Whole-Brain Radiotherapy to Immunotherapy: A Multidisciplinary Approach for Patients with Brain Metastases from NSCLC.
Maria Protopapa, Vassilis Kouloulias, +3 authors, Anna Zygogianni.
J Oncol, 2019 Mar 12; 2019. PMID: 30853981    Free PMC article.
Review.
Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials.
Jie Li, Qi He, +3 authors, Minjie Guan.
Cancer Manag Res, 2019 Mar 14; 11. PMID: 30863172    Free PMC article.
Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today?
Alex Friedlaender, Giuseppe Banna, +2 authors, Alfredo Addeo.
Front Oncol, 2019 Apr 04; 9. PMID: 30941314    Free PMC article.
Review.
Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer.
Chongkai Wang, Prakash Kulkarni, Ravi Salgia.
Mol Ther Oncolytics, 2019 Apr 13; 13. PMID: 30976658    Free PMC article.
Review.
A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer.
Jose M Pacheco, D Ross Camidge, Robert C Doebele, Erin Schenk.
Front Oncol, 2019 Apr 16; 9. PMID: 30984621    Free PMC article.
Highly Cited. Review.
Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review.
Vito Longo, Oronzo Brunetti, +4 authors, Nicola Silvestris.
Cancers (Basel), 2019 Apr 18; 11(4). PMID: 30991686    Free PMC article.
Review.
The ABCs of preventing hyperprogressive disease after immunotherapy: awareness, biomarkers, and combination.
Kenichi Suda.
J Thorac Dis, 2019 Apr 19; 11(Suppl 3). PMID: 30997217    Free PMC article.
KEYNOTE-024: goodbye to chemotherapy?
Rossana Berardi.
J Thorac Dis, 2019 Apr 19; 11(Suppl 3). PMID: 30997239    Free PMC article.
The role of osimertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer.
Chong-Kin Liam.
J Thorac Dis, 2019 Apr 19; 11(Suppl 3). PMID: 30997245    Free PMC article.
Systemic therapy of elderly patients with advanced non-small cell lung cancer-individualized treatment is key.
Robert Pirker.
Ann Transl Med, 2019 Apr 30; 7(Suppl 1). PMID: 31032327    Free PMC article.
Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis.
Alfredo Addeo, Giuseppe Luigi Banna, Giulio Metro, Massimo Di Maio.
Front Oncol, 2019 May 07; 9. PMID: 31058078    Free PMC article.
Highly Cited. Systematic Review.
Lack of clearly defined role for anti-programmed death-(ligand) 1 therapy in epidermal growth factor receptor mutated non-small cell lung cancer.
Aaron Lisberg, Edward B Garon.
Transl Lung Cancer Res, 2019 May 21; 8(2). PMID: 31106131    Free PMC article.
Incidence risk of PD-1/PD-L1 related diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis.
Caiqing Zhang, Shuisheng Zhang, +5 authors, Yuan Tian.
Cancer Manag Res, 2019 May 24; 11. PMID: 31118808    Free PMC article.
Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies.
Ryo Sato, Kosuke Imamura, +13 authors, Takuro Sakagami.
J Clin Med, 2019 May 31; 8(6). PMID: 31146442    Free PMC article.
Immunotherapy in breast cancer.
Soley Bayraktar, Sameer Batoo, Scott Okuno, Stefan Glück.
J Carcinog, 2019 Jun 05; 18. PMID: 31160888    Free PMC article.
Review.
Clinical associations and prognostic value of site-specific metastases in non-small cell lung cancer: A population-based study.
Zihan Xu, Qiao Yang, +6 authors, Jianguo Sun.
Oncol Lett, 2019 Jun 13; 17(6). PMID: 31186781    Free PMC article.
Uveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope?
Florian Castet, Sandra Garcia-Mulero, +4 authors, Josep Maria Piulats.
Cancers (Basel), 2019 Jun 20; 11(6). PMID: 31212986    Free PMC article.
Review.
Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date.
Jordi Remon, Laura Esteller, Álvaro Taus.
Cancer Manag Res, 2019 Jun 20; 11. PMID: 31213908    Free PMC article.
Review.
Highlights of thoracic oncology from the 2018 ERS International Congress.
Polyxeni Ntontsi, Clementine Bostantzoglou, Torsten Gerriet Blum.
ERJ Open Res, 2019 Jun 21; 5(2). PMID: 31218220    Free PMC article.
Review.
Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer.
Frank Weinberg, Shirish Gadgeel.
Lung Cancer (Auckl), 2019 Jun 27; 10. PMID: 31239797    Free PMC article.
Editorial on "The AvaALL Randomized Clinical Trial".
Laura Bonanno, Alberto Pavan, Giulia Pasello, Stefano Indraccolo.
J Thorac Dis, 2019 Jun 28; 11(Suppl 9). PMID: 31245096    Free PMC article.
Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade.
Florian Huemer, David Lang, +7 authors, Richard Greil.
J Clin Med, 2019 Jul 13; 8(7). PMID: 31295966    Free PMC article.
Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives.
Niki Karachaliou, Manuel Fernandez Bruno, Jillian Wilhelmina Paulina Bracht, Rafael Rosell.
Onco Targets Ther, 2019 Jul 30; 12. PMID: 31354290    Free PMC article.
Review.
Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice.
Sawsan Rashdan, David E Gerber.
Transl Lung Cancer Res, 2019 Aug 02; 8(3). PMID: 31367533    Free PMC article.
Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment.
Tianli Zhang, Bing Wan, +5 authors, Yong Song.
Transl Lung Cancer Res, 2019 Aug 02; 8(3). PMID: 31367543    Free PMC article.
Review.
Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies.
Oliver Butters, Kate Young, +2 authors, Naureen Starling.
Front Oncol, 2019 Aug 06; 9. PMID: 31380271    Free PMC article.
Review.
Clinical utility of ramucirumab in non-small-cell lung cancer.
Dipesh Uprety.
Biologics, 2019 Aug 16; 13. PMID: 31413541    Free PMC article.
Management of non-small cell lung cancer harboring epidermal growth factor receptor mutations in the era of first-line osimertinib.
Taiki Hakozaki, Yusuke Okuma.
J Thorac Dis, 2019 Aug 30; 11(7). PMID: 31463088    Free PMC article.
First-line immune checkpoint inhibitors for advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK): a systematic review and network meta-analysis.
Tingting Liu, Silu Ding, +3 authors, Guang Li.
J Thorac Dis, 2019 Aug 30; 11(7). PMID: 31463119    Free PMC article.
A Phase I, Randomized, Single-Dose Study Evaluating the Biosimilarity of TAB008 to Bevacizumab in Healthy Volunteers.
Jin Wang, Lu Qi, +10 authors, Xinghe Wang.
Front Pharmacol, 2019 Sep 03; 10. PMID: 31474863    Free PMC article.
The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer.
Jia Li Low, Robert J Walsh, +2 authors, Ross A Soo.
Ther Adv Med Oncol, 2019 Sep 10; 11. PMID: 31497071    Free PMC article.
Review.
Overexpression of B7-H3 as an opportunity for targeted therapy in head and neck cancers.
Juanjuan Hu, Caiying Jiang, +9 authors, Hui Yang.
Am J Transl Res, 2019 Sep 10; 11(8). PMID: 31497233    Free PMC article.
A multi-center, Phase II trial of nab-paclitaxel and gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
Motoko Tachihara, Tatsunori Kiriu, +8 authors, Yoshihiro Nishimura.
Cancer Manag Res, 2019 Sep 20; 11. PMID: 31534366    Free PMC article.
The Association Between the Incidence Risk of Peripheral Neuropathy and PD-1/PD-L1 Inhibitors in the Treatment for Solid Tumor Patients: A Systematic Review and Meta-Analysis.
Zhihua Si, Shuisheng Zhang, +9 authors, Yuan Tian.
Front Oncol, 2019 Sep 26; 9. PMID: 31552184    Free PMC article.
Systematic Review.
The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials.
Yangyang Xu, Bing Wan, +13 authors, written on behalf of AME Lung Cancer Collaborative Group.
Transl Lung Cancer Res, 2019 Sep 27; 8(4). PMID: 31555516    Free PMC article.
Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients.
Akihiro Yoshimura, Tadaaki Yamada, +16 authors, Koichi Takayama.
Transl Lung Cancer Res, 2019 Sep 27; 8(4). PMID: 31555518    Free PMC article.
Osimertinib in first line setting: for Asian patients.
Keisuke Onoi, Yoshiko Kaneko, Junji Uchino.
Transl Lung Cancer Res, 2019 Sep 27; 8(4). PMID: 31555530    Free PMC article.
Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings.
Tsutomu Nishida, Hideki Iijima, Shiro Adachi.
World J Gastrointest Pathophysiol, 2019 Sep 29; 10(2). PMID: 31559106    Free PMC article.
Review.
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas.
A J Schoenfeld, H Rizvi, +15 authors, M D Hellmann.
Ann Oncol, 2020 Mar 18; 31(5). PMID: 32178965    Free PMC article.
Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis.
Xiaodi Guo, Wendong Li, +2 authors, Qiang Su.
Eur J Clin Pharmacol, 2020 Jun 09; 76(10). PMID: 32507925    Free PMC article.
Systematic Review.
Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study.
Claire F Verschraegen, Guy Jerusalem, +15 authors, James L Gulley.
J Immunother Cancer, 2020 Sep 11; 8(2). PMID: 32907924    Free PMC article.
Landscape of immune checkpoint inhibitor-related adverse events in Chinese population.
Li Li, Gang Li, +8 authors, Yao-Zhong Wu.
Sci Rep, 2020 Sep 25; 10(1). PMID: 32968172    Free PMC article.
Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper.
Fabio Gomes, Melisa Wong, +4 authors, Andrea Luciani.
Br J Cancer, 2020 Jul 23; 123(6). PMID: 32694695    Free PMC article.
Review.
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer.
Rong Wang, Tadaaki Yamada, +24 authors, Seiji Yano.
Nat Commun, 2020 Sep 16; 11(1). PMID: 32929081    Free PMC article.
Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Xing Li, Lei Wang, +4 authors, Chunxia Su.
Thorac Cancer, 2020 Aug 12; 11(10). PMID: 32779372    Free PMC article.
MicroRNA-200b is a potential biomarker of the expression of PD-L1 in patients with lung cancer.
Seigo Katakura, Nobuaki Kobayashi, +13 authors, Takeshi Kaneko.
Thorac Cancer, 2020 Sep 08; 11(10). PMID: 32893980    Free PMC article.
ctDNA Concentration, MIKI67 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC.
Yao Chen, Xiaobin Li, +4 authors, Yina Wang.
Front Oncol, 2020 Oct 06; 10. PMID: 33014846    Free PMC article.
Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials.
Haiying Lu, Qiaodan Zhou, +4 authors, Jianyou Shi.
Signal Transduct Target Ther, 2020 Sep 25; 5(1). PMID: 32968059    Free PMC article.
Review.
Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50.
J F Gainor, H Rizvi, +25 authors, M D Hellmann.
Ann Oncol, 2020 Feb 19; 31(3). PMID: 32067682    Free PMC article.
Utility of immune checkpoint inhibitors in non-small-cell lung cancer patients with poor performance status.
Hirohisa Kano, Eiki Ichihara, +12 authors, Katsuyuki Kiura.
Cancer Sci, 2020 Jul 30; 111(10). PMID: 32726470    Free PMC article.
Are antiangiogenics a good 'partner' for immunotherapy in ovarian cancer?
Elena García-Martínez, Andres Redondo, +2 authors, Antonio Casado.
Angiogenesis, 2020 Jul 22; 23(4). PMID: 32691290    Free PMC article.
Review.
Targeting the immune milieu in gastrointestinal cancers.
Fiona Turkes, Justin Mencel, Naureen Starling.
J Gastroenterol, 2020 Aug 05; 55(10). PMID: 32748171    Free PMC article.
Review.
Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non-Small Cell Lung Cancer: A Phase 1 Trial.
Zhijie Wang, Jianming Ying, +13 authors, Jie Wang.
JAMA Netw Open, 2020 Oct 06; 3(10). PMID: 33017026    Free PMC article.
Severe delayed pulmonary toxicity following PD-L1-specific CAR-T cell therapy for non-small cell lung cancer.
Heping Liu, Yuxiang Ma, +16 authors, Jianchuan Xia.
Clin Transl Immunology, 2020 Oct 20; 9(10). PMID: 33072320    Free PMC article.
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.
Barzin Y Nabet, Mohammad S Esfahani, +29 authors, Maximilian Diehn.
Cell, 2020 Oct 03; 183(2). PMID: 33007267    Free PMC article.
HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial.
Yan Song, Ning Li, +12 authors, Jing Huang.
J Immunother Cancer, 2020 Oct 17; 8(2). PMID: 33060149    Free PMC article.
Management of Immune Checkpoint Inhibitor Toxicities.
Quentin Durrechou, Charlotte Domblides, +5 authors, Amaury Daste.
Cancer Manag Res, 2020 Oct 17; 12. PMID: 33061607    Free PMC article.
Review.
Understanding EGFR heterogeneity in lung cancer.
Antonio Passaro, Umberto Malapelle, +13 authors, Christian Rolfo.
ESMO Open, 2020 Oct 18; 5(5). PMID: 33067323    Free PMC article.
Review.
Impact of Age on the Efficacy of Immune Checkpoint Inhibitor-Based Combination Therapy for Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Xin Yan, Xuan Tian, Zhiqiang Wu, Weidong Han.
Front Oncol, 2020 Oct 20; 10. PMID: 33072551    Free PMC article.
Systematic Review.
Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer.
Chaoyue Su, Hui Wang, +7 authors, Jianye Zhang.
Front Oncol, 2020 Oct 20; 10. PMID: 33072580    Free PMC article.
Review.
The Potential of Immune Modulation in Therapeutic HIV-1 Vaccination.
Nabila Seddiki, Florence Picard, +2 authors, Véronique Godot.
Vaccines (Basel), 2020 Jul 31; 8(3). PMID: 32726934    Free PMC article.
Review.
Combined Methylome and Transcriptome Analyses Reveals Potential Therapeutic Targets for EGFR Wild Type Lung Cancers with Low PD-L1 Expression.
Weilei Hu, Guosheng Wang, Lonny B Yarmus, Yuan Wan.
Cancers (Basel), 2020 Sep 10; 12(9). PMID: 32899191    Free PMC article.
Radiotherapy Scheme Effect on PD-L1 Expression for Locally Advanced Rectal Cancer.
Jihane Boustani, Valentin Derangère, +5 authors, Céline Mirjolet.
Cells, 2020 Sep 16; 9(9). PMID: 32927784    Free PMC article.
Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Christian Borel, Alain C Jung, Mickaël Burgy.
Cancers (Basel), 2020 Sep 25; 12(9). PMID: 32967162    Free PMC article.
Review.
Harmonization of Molecular Testing for Non-Small Cell Lung Cancer: Emphasis on PD-L1.
Evgeny N Imyanitov, Alexandr O Ivantsov, Ilya V Tsimafeyeu.
Front Oncol, 2020 Oct 27; 10. PMID: 33102215    Free PMC article.
Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer.
Xiaoyang Zhai, Xuquan Jing, +4 authors, Hui Zhu.
Front Oncol, 2020 Oct 27; 10. PMID: 33102221    Free PMC article.
Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy.
Koji Nagaoka, Masataka Shirai, +8 authors, Kazuhiro Kakimi.
J Immunother Cancer, 2020 Oct 24; 8(2). PMID: 33093158    Free PMC article.
The Impact of EGFR Mutation Status and Brain Metastasis for Non-Small Cell Lung Cancer Treated with Ramucirumab plus Docetaxel.
Naoki Furuya, Kentaro Ito, +7 authors, Masamichi Mineshita.
Oncology, 2020 May 29; 98(9). PMID: 32464632    Free PMC article.
Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer.
Fang-Fei Qian, Bao-Hui Han.
Chin Med J (Engl), 2020 Sep 25; 133(20). PMID: 32969861    Free PMC article.
Review.
The relationship between pneumonitis and programmed cell death-1/programmed cell death ligand 1 inhibitors among cancer patients: A systematic review and meta-analysis.
Dongmei Xu, Hongmei Liu, +7 authors, Yuan Tian.
Medicine (Baltimore), 2020 Oct 09; 99(41). PMID: 33031304    Free PMC article.
Systematic Review.
The incidence risk of programmed cell death-1/programmed cell death ligand 1 inhibitor-related alopecia for cancer patients: A systematic review and meta-analysis.
Mingkai Li, Linlin Huang, +7 authors, Fuli Mi.
Medicine (Baltimore), 2020 Oct 22; 99(42). PMID: 33080690    Free PMC article.
Systematic Review.
Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD-1/PD-L1 Checkpoint Blockade.
Tomoko Aoki, Masatoshi Kudo, +8 authors, Naoshi Nishida.
Cancers (Basel), 2020 Oct 24; 12(10). PMID: 33092011    Free PMC article.
First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress.
Zhangfeng Huang, Wenhao Su, +6 authors, Wenjie Jiao.
Front Pharmacol, 2020 Oct 30; 11. PMID: 33117170    Free PMC article.
Review.
Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy.
Maitane Ocáriz-Díez, Mara Cruellas, +10 authors, Eva M Gálvez.
Front Oncol, 2020 Oct 30; 10. PMID: 33117698    Free PMC article.
Review.
Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial.
Ian Chau, Nicolas Penel, +14 authors, Charles S Fuchs.
Cancers (Basel), 2020 Oct 21; 12(10). PMID: 33076423    Free PMC article.
A case of simultaneous occurrence of hepatitis and pancreatitis during the combination immunochemotherapy for non-small cell lung carcinoma.
Satoshi Tanaka, Ryo Asakawa, +7 authors, Kiyonobu Ueno.
Respir Med Case Rep, 2020 Nov 03; 31. PMID: 33134073    Free PMC article.
Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).
Jyoti D Patel, Ju-Whei Lee, +12 authors, Joan H Schiller.
Clin Lung Cancer, 2020 Aug 19; 21(6). PMID: 32807654    Free PMC article.
Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors.
David Bomze, Nethanel Asher, +4 authors, Tomer Meirson.
JAMA Netw Open, 2020 Oct 24; 3(10). PMID: 33095247    Free PMC article.
Association of immune checkpoint inhibitor with survival in patients with cancers with protein tyrosine phosphatase receptor T mutation.
Zifan He, Anlin Li, +6 authors, Yunfang Yu.
Clin Transl Med, 2020 Nov 03; 10(6). PMID: 33135355    Free PMC article.
Biomarkers in immunotherapy: literature review and future directions.
Rebecca Pharaon, Maria A Koczywas, +2 authors, Erminia Massarelli.
J Thorac Dis, 2020 Nov 05; 12(9). PMID: 33145089    Free PMC article.
Review.
Future of immune checkpoint inhibitors: focus on tumor immune microenvironment.
Yunlong Jia, Lihua Liu, Baoen Shan.
Ann Transl Med, 2020 Nov 05; 8(17). PMID: 33145314    Free PMC article.
Review.
PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis.
Junwei Hou, Rongce Zhao, +20 authors, Mien-Chie Hung.
Nat Cell Biol, 2020 Sep 16; 22(10). PMID: 32929201    Free PMC article.
Update 2020: Management of Non-Small Cell Lung Cancer.
Mariam Alexander, So Yeon Kim, Haiying Cheng.
Lung, 2020 Nov 12; 198(6). PMID: 33175991    Free PMC article.
Review.
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial.
Miguel Quintela-Fandino, Esther Holgado, +19 authors, Santos Mañes.
Breast Cancer Res, 2020 Nov 13; 22(1). PMID: 33176887    Free PMC article.
A novel scoring method based on RNA-Seq immunograms describing individual cancer-immunity interactions.
Yukari Kobayashi, Yoshihiro Kushihara, +2 authors, Kazuhiro Kakimi.
Cancer Sci, 2020 Aug 19; 111(11). PMID: 32810311    Free PMC article.
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors.
Filippo G Dall'Olio, Francesca Abbati, +7 authors, Andrea Ardizzoni.
Ther Adv Med Oncol, 2020 Nov 17; 12. PMID: 33193825    Free PMC article.
Hypothesis generative head-to-head study comparing efficacy of afatinib and osimertinib based on immunological biomarkers in Japanese NSCLC patients with EGFR mutations (Heat on Beat study).
Kei Morikawa, Hisashi Tanaka, +9 authors, Nobuhiko Seki.
Ther Adv Med Oncol, 2020 Nov 17; 12. PMID: 33193830    Free PMC article.
Early palliative care of non-small cell lung cancer in the context of immunotherapy.
Małgorzata Pieniążek, Piotr Pawlak, Barbara Radecka.
Oncol Lett, 2020 Nov 17; 20(6). PMID: 33193856    Free PMC article.
Review.
The Resistance Mechanisms of Lung Cancer Immunotherapy.
Fen Wang, Shubin Wang, Qing Zhou.
Front Oncol, 2020 Nov 17; 10. PMID: 33194652    Free PMC article.
Review.
Systematic Assessment of Risk of Fever in Solid Tumor Patients Treated With PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis.
Hongmei Liu, Dongmei Xu, +4 authors, Yuan Tian.
Front Oncol, 2020 Nov 17; 10. PMID: 33194659    Free PMC article.
Systematic Review.
Therapy-Induced Modulation of the Tumor Microenvironment: New Opportunities for Cancer Therapies.
Sergi Benavente, Almudena Sánchez-García, +2 authors, Juan Lorente.
Front Oncol, 2020 Nov 17; 10. PMID: 33194719    Free PMC article.
Review.
PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC.
Chiao-En Wu, Ching-Fu Chang, +3 authors, Yu-Chi Chiu.
Anal Cell Pathol (Amst), 2020 Nov 19; 2020. PMID: 33204603    Free PMC article.
Immunotherapy for extensive stage small cell lung cancer.
Jose M Pacheco.
J Thorac Dis, 2020 Nov 20; 12(10). PMID: 33209460    Free PMC article.
Review.
A narrative review of synergistic drug administration in unresectable locally advanced non-small cell lung cancer: current landscape and future prospects in the era of immunotherapy.
Shuyan Li, Xiao Chu, +2 authors, Zhengfei Zhu.
Transl Lung Cancer Res, 2020 Nov 20; 9(5). PMID: 33209628    Free PMC article.
Review.
Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge-a narrative review.
Wu-Yan Xia, Wen Feng, +5 authors, Xiao-Long Fu.
Transl Lung Cancer Res, 2020 Nov 20; 9(5). PMID: 33209631    Free PMC article.
Review.
A pathological complete response to neoadjuvant chemotherapy and immunotherapy in a non-small cell lung cancer patient.
Pengqiang Gao, Hao Chen, +7 authors, Chun Chen.
Transl Lung Cancer Res, 2020 Nov 20; 9(5). PMID: 33209635    Free PMC article.
FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression.
Pamela Abdayem, David Planchard.
Transl Lung Cancer Res, 2020 Nov 20; 9(5). PMID: 33209637    Free PMC article.
Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer.
Arafat Tfayli, Majd Al Assaad, +19 authors, Fadlo Khuri.
Cancer Med, 2020 Sep 30; 9(22). PMID: 32991781    Free PMC article.
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).
Sara A Hurvitz, Jennifer L Caswell-Jin, +22 authors, Dennis J Slamon.
Nat Commun, 2020 Nov 19; 11(1). PMID: 33203854    Free PMC article.
Old Player-New Tricks: Non Angiogenic Effects of the VEGF/VEGFR Pathway in Cancer.
Panagiotis Ntellas, Leonidas Mavroeidis, +9 authors, George Pentheroudakis.
Cancers (Basel), 2020 Oct 31; 12(11). PMID: 33121034    Free PMC article.
Review.
Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells.
Iosune Baraibar, Marta Roman, +23 authors, Ignacio Gil-Bazo.
Cancers (Basel), 2020 Nov 01; 12(11). PMID: 33126649    Free PMC article.
Impact of PET/CT for Assessing Response to Immunotherapy-A Clinical Perspective.
David Lang, Gerald Wahl, +4 authors, Michael Gabriel.
J Clin Med, 2020 Nov 01; 9(11). PMID: 33126715    Free PMC article.
Review.
A Holistic Perspective: Exosomes Shuttle between Nerves and Immune Cells in the Tumor Microenvironment.
Mihnea P Dragomir, Vlad Moisoiu, +5 authors, George A Calin.
J Clin Med, 2020 Nov 05; 9(11). PMID: 33142779    Free PMC article.
Review.
New Target Therapies in Advanced Non-Small Cell Lung Cancer: A Review of the Literature and Future Perspectives.
Ramon Andrade de Mello, Nathália Moisés Neves, +3 authors, Victor André de Almeida Zia.
J Clin Med, 2020 Nov 07; 9(11). PMID: 33153004    Free PMC article.
Review.
First line Immunotherapy for Non-Small Cell Lung Cancer.
Nicola J Nasser, Miguel Gorenberg, Abed Agbarya.
Pharmaceuticals (Basel), 2020 Nov 12; 13(11). PMID: 33171686    Free PMC article.
Review.
The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy.
Linda Quatrini, Francesca Romana Mariotti, +3 authors, Lorenzo Moretta.
Cancers (Basel), 2020 Nov 12; 12(11). PMID: 33172030    Free PMC article.
Review.
Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
Stephen P Hack, Andrew X Zhu, Yulei Wang.
Front Immunol, 2020 Dec 01; 11. PMID: 33250900    Free PMC article.
Review.
RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients.
Anna Tessari, Kareesma Parbhoo, +21 authors, Vincenzo Coppola.
Oncogene, 2018 Aug 05; 37(50). PMID: 30076413    Free PMC article.
SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018).
M Majem, O Juan, +7 authors, M Provencio.
Clin Transl Oncol, 2018 Nov 18; 21(1). PMID: 30446985    Free PMC article.
A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2).
Ken Kato, Taroh Satoh, +28 authors, Narikazu Boku.
Gastric Cancer, 2018 Dec 07; 22(2). PMID: 30506519    Free PMC article.
Reversal of resistance to chemotherapy following anti-programmed cell death-1 immunotherapy in metastatic lung adenocarcinoma: A case report.
Xiaoli Liu, Huaimin Liu, Suxia Luo.
Medicine (Baltimore), 2018 Dec 14; 97(49). PMID: 30544423    Free PMC article.
Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer.
Elaine Reguera-Nuñez, Ping Xu, +3 authors, Robert S Kerbel.
J Exp Clin Cancer Res, 2019 Jan 13; 38(1). PMID: 30635009    Free PMC article.
Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer.
Ping Fan, Jingyuan Zhao, +4 authors, Xin Jin.
J Exp Clin Cancer Res, 2019 Feb 03; 38(1). PMID: 30709380    Free PMC article.
Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program.
J Corral, M Majem, +7 authors, M P López Criado.
Clin Transl Oncol, 2019 Feb 17; 21(9). PMID: 30771085
Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects.
Long Long, Chen Zhao, +3 authors, Honglei Chen.
Clin Drug Investig, 2019 Feb 20; 39(4). PMID: 30778885
Review.
Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy.
Robert Ali, Junaid Arshad, Sofia Palacio, Raja Mudad.
Drug Des Devel Ther, 2019 Feb 26; 13. PMID: 30804663    Free PMC article.
Review.
Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer.
Yuichi Ozawa, Yusuke Amano, +8 authors, Takafumi Suda.
Med Oncol, 2019 Mar 03; 36(4). PMID: 30825015
Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
Alessandro Russo, Tindara Franchina, +3 authors, Vincenzo Adamo.
Int J Mol Sci, 2019 Mar 25; 20(6). PMID: 30901844    Free PMC article.
Review.
The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma.
Chang-Ying Guo, Qian Zhu, +3 authors, Hao Hu.
BMC Cancer, 2019 Mar 31; 19(1). PMID: 30925904    Free PMC article.
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment.
Ming Yi, Dechao Jiao, +3 authors, Anping Li.
Mol Cancer, 2019 Mar 31; 18(1). PMID: 30925919    Free PMC article.
Highly Cited. Review.
LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer.
Laura Bonanno, Elisabetta Zulato, +4 authors, Stefano Indraccolo.
Int J Mol Sci, 2019 Apr 19; 20(8). PMID: 30995715    Free PMC article.
Review.
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV.
Hiroaki Akamatsu, Kiichiro Ninomiya, +30 authors, Nobuyuki Yamamoto.
Int J Clin Oncol, 2019 May 03; 24(7). PMID: 31049758    Free PMC article.
AVAiLABLE NIS - AVASTIN® in lung cancer treatment in routine oncology practice in Germany.
Mark-Oliver Zahn, Dominik Linck, +4 authors, Hans Werner Tessen.
BMC Cancer, 2019 May 12; 19(1). PMID: 31077164    Free PMC article.
Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies.
Meenal Datta, Lisa M Coussens, +2 authors, Rakesh K Jain.
Am Soc Clin Oncol Educ Book, 2019 May 18; 39. PMID: 31099649    Free PMC article.
Review.
Comparative safety analysis of immunotherapy combined with chemotherapy versus monotherapy in solid tumors: a meta-analysis of randomized clinical trials.
Alberto Carretero-González, David Lora, +4 authors, Guillermo de Velasco.
Oncotarget, 2019 May 31; 10(35). PMID: 31143375    Free PMC article.
New emerging targets in cancer immunotherapy: the role of TIM3.
Alex Friedlaender, Alfredo Addeo, Giuseppe Banna.
ESMO Open, 2019 Jul 06; 4(Suppl 3). PMID: 31275616    Free PMC article.
Review.
New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an "ESMO Open - Cancer Horizons" Series.
Matteo Lambertini, Matthias Preusser, Christoph C Zielinski.
ESMO Open, 2019 Jul 06; 4(Suppl 3). PMID: 31275617    Free PMC article.
Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion.
Anna S Berghoff, Beatriz Bellosillo, +8 authors, Christoph C Zielinski.
ESMO Open, 2019 Jul 13; 4(3). PMID: 31297240    Free PMC article.
Review.
The overall safety evaluation of programmed cell death/programmed cell death ligand 1 (PD-1/PD-L1) treatment for lung cancer patients: An updated systematic review and meta-analysis.
Heli Shang, Zewen Zhang, +7 authors, Yuan Tian.
Medicine (Baltimore), 2019 Jul 28; 98(30). PMID: 31348245    Free PMC article.
Systematic Review.
Correlation between the qualification for bevacizumab use and the survival of patients with non-small cell lung cancer harboring the epidermal growth factor receptor mutation: a retrospective analysis.
Taiki Hakozaki, Yusuke Okuma, Kana Hashimoto, Yukio Hosomi.
J Cancer Res Clin Oncol, 2019 Jul 28; 145(10). PMID: 31350622
Comparison of tumor cell numbers and 22C3 PD-L1 expression between cryobiopsy and transbronchial biopsy with endobronchial ultrasonography-guide sheath for lung cancer.
Ken Arimura, Mitsuko Kondo, +5 authors, Etsuko Tagaya.
Respir Res, 2019 Aug 20; 20(1). PMID: 31420048    Free PMC article.
How I treat ALK-positive non-small cell lung cancer.
Michael G McCusker, Alessandro Russo, +2 authors, Christian Rolfo.
ESMO Open, 2019 Aug 20; 4(Suppl 2). PMID: 31423342    Free PMC article.
Review.
New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment.
Shang-Hung Chen, Jang-Yang Chang.
Int J Mol Sci, 2019 Aug 28; 20(17). PMID: 31450627    Free PMC article.
Review.
Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinical Practice.
Laurie E Steffen McLouth, Thomas W Lycan, +7 authors, W Jeffrey Petty.
Clin Lung Cancer, 2020 Jan 10; 21(3). PMID: 31917067    Free PMC article.
Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancer.
Bassel Nazha, Subir Goyal, +9 authors, Taofeek Kunle Owonikoko.
Cancer, 2020 Sep 10; 126(23). PMID: 32902858    Free PMC article.
Superior efficacy of immunotherapy-based combinations over monotherapy for EGFR-mutant non-small cell lung cancer acquired resistance to EGFR-TKIs.
Lu Yang, Xuezhi Hao, +7 authors, Yan Wang.
Thorac Cancer, 2020 Oct 20; 11(12). PMID: 33075201    Free PMC article.
Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective.
Félicien Le Louedec, Fanny Leenhardt, +3 authors, Joseph Ciccolini.
Vaccines (Basel), 2020 Nov 05; 8(4). PMID: 33142728    Free PMC article.
Review.
Colonization with multi-drug-resistant organisms negatively impacts survival in patients with non-small cell lung cancer.
Jan A Stratmann, Raphael Lacko, +12 authors, Sebastian Koschade.
PLoS One, 2020 Nov 26; 15(11). PMID: 33237921    Free PMC article.
Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burden.
Colby S Shemesh, Phyllis Chan, +8 authors, René Bruno.
Pharmacol Res Perspect, 2020 Nov 27; 8(6). PMID: 33241650    Free PMC article.
Comprehensive Evaluation of Immune-Checkpoint DNA Cancer Vaccines in a Rat Cholangiocarcinoma Model.
Yi-Ru Pan, Chiao-En Wu, +4 authors, Chun-Nan Yeh.
Vaccines (Basel), 2020 Dec 02; 8(4). PMID: 33255375    Free PMC article.
CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer.
Man Zhang, Wei Yang, +10 authors, Bo Zhong.
Nat Commun, 2020 Dec 02; 11(1). PMID: 33257678    Free PMC article.
Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer.
Wentao Tian, Chenghui Cao, Long Shu, Fang Wu.
Onco Targets Ther, 2020 Dec 03; 13. PMID: 33262610    Free PMC article.
Review.
Vascular Heterogeneity With a Special Focus on the Hepatic Microenvironment.
Johannes Robert Fleischer, Chiara Angelina Jodszuweit, +2 authors, Lena-Christin Conradi.
Front Physiol, 2020 Dec 03; 11. PMID: 33262705    Free PMC article.
Review.
A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy.
Gizem Duru, Marjolein van Egmond, Niels Heemskerk.
Front Immunol, 2020 Dec 03; 11. PMID: 33262763    Free PMC article.
Review.
Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC).
Wolfgang M Brueckl, Joachim H Ficker, Gloria Zeitler.
BMC Cancer, 2020 Dec 05; 20(1). PMID: 33272262    Free PMC article.
Review.
A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer.
Xiaoyan Si, Jinwan Wang, +15 authors, Li Zhang.
Ther Adv Med Oncol, 2020 Dec 08; 12. PMID: 33281949    Free PMC article.
Changing paradigm in advanced and metastatic non-small cell lung cancer.
Dipesh Uprety, Kaushal Parikh, +2 authors, Konstantinos Leventakos.
J Thorac Dis, 2020 Dec 08; 12(11). PMID: 33282404    Free PMC article.
Review.
Radiation and immunotherapy: emerging mechanisms of synergy.
William G Breen, Konstantinos Leventakos, Haidong Dong, Kenneth W Merrell.
J Thorac Dis, 2020 Dec 08; 12(11). PMID: 33282406    Free PMC article.
Review.
PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma.
D Evrard, M Hourseau, +6 authors, S Faivre.
Oncoimmunology, 2020 Dec 11; 9(1). PMID: 33299655    Free PMC article.
Review.
Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges.
John D Martin, Horacio Cabral, Triantafyllos Stylianopoulos, Rakesh K Jain.
Nat Rev Clin Oncol, 2020 Feb 09; 17(4). PMID: 32034288    Free PMC article.
Review.
Immunotherapy Use in Patients With Lung Cancer and Comorbidities.
Mitchell S von Itzstein, Amrit S Gonugunta, +2 authors, David E Gerber.
Cancer J, 2020 Dec 11; 26(6). PMID: 33298724    Free PMC article.
Review.
Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy.
Lydia S Lamb, Hao-Wen Sim, Ann I McCormack.
Front Endocrinol (Lausanne), 2020 Dec 15; 11. PMID: 33312158    Free PMC article.
A narrative review of the role of fibroblasts in the growth and development of neurogenic tumors.
Cheng-Jiang Wei, Yi-Hui Gu, +8 authors, Zhi-Chao Wang.
Ann Transl Med, 2020 Dec 15; 8(21). PMID: 33313207    Free PMC article.
Review.
Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited).
Priyanka Patel, Doraid Alrifai, +2 authors, AstraZeneca UK Limited.
Br J Cancer, 2020 Dec 10; 123(Suppl 1). PMID: 33293672    Free PMC article.
Review.
Imperfect Predictors for Lung Cancer Immunotherapy-A Field for Further Research.
Kamila Wojas-Krawczyk, Tomasz Kubiatowski.
Front Oncol, 2020 Dec 18; 10. PMID: 33330041    Free PMC article.
Review.
Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer.
Yusuke Kagawa, Hiromi Furuta, +10 authors, Toyoaki Hida.
Cancer Sci, 2020 Aug 10; 111(12). PMID: 32770608    Free PMC article.
Tumor Vessel Normalization: A Window to Enhancing Cancer Immunotherapy.
Sai Li, Qi Zhang, Yupeng Hong.
Technol Cancer Res Treat, 2020 Dec 09; 19. PMID: 33287656    Free PMC article.
Review.
Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Bo Zhang, Ling Qi, +6 authors, Jing Huang.
Cancer Commun (Lond), 2020 Dec 15; 40(12). PMID: 33314747    Free PMC article.
Programmed cell death 1 (PD-1)/PD-ligand 1(PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer.
Yuxin Sun, Chi Shao, +6 authors, Zuojun Xu.
Asia Pac J Clin Oncol, 2020 Aug 07; 16(6). PMID: 32757454    Free PMC article.
Review.
The rediscovery of platinum-based cancer therapy.
Sven Rottenberg, Carmen Disler, Paola Perego.
Nat Rev Cancer, 2020 Nov 01; 21(1). PMID: 33128031
Review.
Immune Escape Mechanisms in Non Small Cell Lung Cancer.
Andrea Anichini, Valentina E Perotti, Francesco Sgambelluri, Roberta Mortarini.
Cancers (Basel), 2020 Dec 06; 12(12). PMID: 33276569    Free PMC article.
Review.
Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a 'Real-Life' Setting.
Marcus Skribek, Konstantinos Rounis, +5 authors, Georgios Tsakonas.
Cancers (Basel), 2020 Dec 17; 12(12). PMID: 33321730    Free PMC article.
Immune checkpoint blockade and biomarkers of clinical response in non-small cell lung cancer.
Andreas Hallqvist, Anna Rohlin, Sukanya Raghavan.
Scand J Immunol, 2020 Oct 06; 92(6). PMID: 33015859    Free PMC article.
Review.
4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39+ CD8 T cells from primary and metastatic sites of epithelial ovarian cancers.
Galam Leem, Junsik Park, +12 authors, Su-Hyung Park.
J Immunother Cancer, 2020 Dec 19; 8(2). PMID: 33335029    Free PMC article.
PD-1/PD-L1 Inhibitor Combined with Chemotherapy Can Improve the Survival of Non-Small Cell Lung Cancer Patients with Brain Metastases.
Chenglong Sun, Fei Zhou, +9 authors, Caicun Zhou.
Onco Targets Ther, 2020 Dec 29; 13. PMID: 33363383    Free PMC article.
Heterogeneous Tumor-Immune Microenvironments between Primary and Metastatic Tumors in a Patient with ALK Rearrangement-Positive Large Cell Neuroendocrine Carcinoma.
Takahiro Tashiro, Kosuke Imamura, +10 authors, Takuro Sakagami.
Int J Mol Sci, 2020 Dec 24; 21(24). PMID: 33352665    Free PMC article.
The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer.
Valerio Gristina, Maria La Mantia, +3 authors, Viviana Bazan.
Pharmaceuticals (Basel), 2020 Dec 24; 13(12). PMID: 33352844    Free PMC article.
Review.
Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study.
David Lang, Wolfgang Haslinger, +8 authors, Bernd Lamprecht.
Lung Cancer (Auckl), 2020 Dec 31; 11. PMID: 33376433    Free PMC article.
Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy.
Daniel R Principe, Matthew Narbutis, +12 authors, Ajay Rana.
Cancer Res, 2020 Apr 03; 80(15). PMID: 32238357    Free PMC article.
Immune-Related Neurological Toxicities of PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.
Yuan Tian, Aiqin Gao, +5 authors, Yuping Sun.
Front Immunol, 2021 Jan 05; 11. PMID: 33391266    Free PMC article.
Systematic Review.
Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors.
Leilei Wu, Linping Ke, +2 authors, Xue Meng.
Front Oncol, 2021 Jan 05; 10. PMID: 33392095    Free PMC article.
Review.
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy).
Paolo A Ascierto, Lisa H Butterfield, +17 authors, Igor Puzanov.
J Transl Med, 2021 Jan 08; 19(1). PMID: 33407605    Free PMC article.
Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis.
Han Li, Jinsheng Xu, +3 authors, Jingjing Jin.
Invest New Drugs, 2021 Jan 08; 39(3). PMID: 33409896    Free PMC article.
Systematic Review.
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors.
Lorenzo Galluzzi, Juliette Humeau, +2 authors, Guido Kroemer.
Nat Rev Clin Oncol, 2020 Aug 08; 17(12). PMID: 32760014
Review.
Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer.
J Gao, H-R Li, +2 authors, J-Y Ding.
Clin Transl Oncol, 2019 Mar 14; 21(10). PMID: 30864018
Highly Cited. Review.
Crizotinib-induced immunogenic cell death in non-small cell lung cancer.
Peng Liu, Liwei Zhao, +31 authors, Guido Kroemer.
Nat Commun, 2019 Apr 04; 10(1). PMID: 30940805    Free PMC article.
Highly Cited.
Predictors of survival among Japanese patients receiving first-line chemoimmunotherapy for advanced non-small cell lung cancer.
Yuri Ogura, Nobutaka Kataoka, +7 authors, Takayuki Takeda.
Thorac Cancer, 2020 Oct 31; 12(1). PMID: 33124197    Free PMC article.
ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models.
Dong-Hoon Yeom, Yo-Seob Lee, +9 authors, Weon-Kyoo You.
Int J Mol Sci, 2021 Jan 02; 22(1). PMID: 33383646    Free PMC article.
Plasma Biomarkers Screening by Multiplex ELISA Assay in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
Adrien Costantini, Paul Takam Kamga, +9 authors, Etienne Giroux Leprieur.
Cancers (Basel), 2021 Jan 06; 13(1). PMID: 33396187    Free PMC article.
Colon cancer and immunotherapy-can we go beyond microsatellite instability?
Rimini Breakstone.
Transl Gastroenterol Hepatol, 2021 Jan 08; 6. PMID: 33409406    Free PMC article.
Review.
Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer.
Kathryn Lurain, Ramya Ramaswami, Robert Yarchoan, Thomas S Uldrick.
Curr HIV/AIDS Rep, 2020 Aug 23; 17(5). PMID: 32827111    Free PMC article.
Review.
Effect of Treatment with the PD-1/PD-L1 Inhibitors on Key Health Outcomes of Cancer Patients.
Kyung-In Joung, Jong Hwa Song, +4 authors, Dong Churl Suh.
BioDrugs, 2020 Dec 18; 35(1). PMID: 33331991
Digital Monitoring and Management of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Treated With Cancer Immunotherapy and Its Impact on Quality of Clinical Care: Interview and Survey Study Among Health Care Professionals and Patients.
Oliver Schmalz, Christine Jacob, +6 authors, Razvan Andrei Popescu.
J Med Internet Res, 2020 Dec 22; 22(12). PMID: 33346738    Free PMC article.
Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity.
Masashi Arita, Satoshi Watanabe, +19 authors, Toshiaki Kikuchi.
Sci Rep, 2021 Jan 14; 11(1). PMID: 33437029    Free PMC article.
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
Marie Kostine, Axel Finckh, +20 authors, Thierry Schaeverbeke.
Ann Rheum Dis, 2020 Apr 25; 80(1). PMID: 32327425    Free PMC article.
Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis.
Qingyuan Huang, Yuzhen Zheng, +3 authors, Haiquan Chen.
J Cancer, 2021 Jan 15; 12(4). PMID: 33442411    Free PMC article.
RAS-targeted therapies: is the undruggable drugged?
Amanda R Moore, Scott C Rosenberg, Frank McCormick, Shiva Malek.
Nat Rev Drug Discov, 2020 Jun 13; 19(8). PMID: 32528145    Free PMC article.
Review.
Evolution of Lung Cancer in the Context of Immunotherapy.
Sheng Yu, Ruilin Wang, +10 authors, Yufeng Wu.
Clin Med Insights Oncol, 2021 Jan 16; 14. PMID: 33447125    Free PMC article.
Review.
Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial.
Jianming Xu, Nong Xu, +6 authors, Yiwei Dou.
Oncoimmunology, 2021 Jan 19; 10(1). PMID: 33457083    Free PMC article.
Antitumour immunity regulated by aberrant ERBB family signalling.
Shogo Kumagai, Shohei Koyama, Hiroyoshi Nishikawa.
Nat Rev Cancer, 2021 Jan 20; 21(3). PMID: 33462501
Review.
The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer - New Combinational Approaches and Strategies of Neovessel Inhibition.
Sophia Daum, Hannes Hagen, +2 authors, Andreas Pircher.
Front Cell Dev Biol, 2021 Jan 21; 8. PMID: 33469537    Free PMC article.
Review.
Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Taisuke Isono, Naho Kagiyama, +9 authors, Noboru Takayanagi.
Thorac Cancer, 2020 Nov 18; 12(2). PMID: 33201587    Free PMC article.
Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients.
S I Rothschild, R Nachbur, +2 authors, M Pless.
ESMO Open, 2021 Jan 11; 6(1). PMID: 33422767    Free PMC article.
Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapy.
Norikazu Matsuo, Koichi Azuma, +4 authors, Tomoaki Hoshino.
Invest New Drugs, 2021 Jan 24; 39(4). PMID: 33483882
Impact of Advantage in Tumor Response on the Correlation Between Progression-Free Survival and Overall Survival: Meta-Analysis of Clinical Trials in Patients with Advanced Non-Small Cell Lung Cancer.
Yosuke Yoshida, Masayuki Kaneko, Mamoru Narukawa.
Pharmaceut Med, 2021 Jan 24; 35(2). PMID: 33483892
Systematic Review.
Immunotherapy response modeling by ex-vivo organ culture for lung cancer.
Iris Kamer, Elizabeta Bab-Dinitz, +8 authors, Jair Bar.
Cancer Immunol Immunother, 2021 Jan 24; 70(8). PMID: 33484295
The Multiple Potential Biomarkers for Predicting Immunotherapy Response-Finding the Needle in the Haystack.
Tamiem Adam, Therese M Becker, +2 authors, Tara L Roberts.
Cancers (Basel), 2021 Jan 17; 13(2). PMID: 33451015    Free PMC article.
Review.
Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.
Hironori Uruga, Mari Mino-Kenudson.
Virchows Arch, 2021 Jan 25; 478(1). PMID: 33486574
Review.
Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
Ken Masuda, Hidehito Horinouchi, +9 authors, Yuichiro Ohe.
J Cancer Res Clin Oncol, 2020 Jul 25; 147(1). PMID: 32705363    Free PMC article.
Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice.
Paul Hofman.
Cells, 2021 Jan 21; 10(1). PMID: 33467720    Free PMC article.
Review.
The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis.
Xiao-Jiang Chen, Shu-Qiang Yuan, +4 authors, Yuan-Fang Li.
Dis Markers, 2021 Jan 26; 2020. PMID: 33488843    Free PMC article.
Systematic Review.
A narrative review of evolving roles of radiotherapy in advanced non-small cell lung cancer: from palliative care to active player.
Yue Zhou, Fan Yu, +9 authors, Jianjiao Ni.
Transl Lung Cancer Res, 2021 Jan 26; 9(6). PMID: 33489808    Free PMC article.
Review.
Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies.
Alessandro Russo, Andrés F Cardona, +4 authors, Christian Rolfo.
Transl Lung Cancer Res, 2021 Jan 26; 9(6). PMID: 33489820    Free PMC article.
Review.
Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review.
Ana Ortega-Franco, Virginia Calvo, +2 authors, Raffaele Califano.
Transl Lung Cancer Res, 2021 Jan 26; 9(6). PMID: 33489825    Free PMC article.
Review.
Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?-a literature review.
Gianmarco Leone, Francesco Passiglia, +2 authors, Silvia Novello.
Transl Lung Cancer Res, 2021 Jan 26; 9(6). PMID: 33489826    Free PMC article.
Review.
Combination of immunotherapy with chemotherapy in first line treatment of metastatic gastric cancer? Too much, too little or just right?
Matthew C H Ng, Su Pin Choo.
Ann Transl Med, 2021 Jan 26; 8(24). PMID: 33490204    Free PMC article.
Identification of an Immunologic Signature of Lung Adenocarcinomas Based on Genome-Wide Immune Expression Profiles.
Bo Ling, Guangbin Ye, +3 authors, Qianli Tang.
Front Mol Biosci, 2021 Jan 29; 7. PMID: 33505988    Free PMC article.
The cutting-edge progress of immune-checkpoint blockade in lung cancer.
Fei Zhou, Meng Qiao, Caicun Zhou.
Cell Mol Immunol, 2020 Nov 13; 18(2). PMID: 33177696    Free PMC article.
Review.
Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC.
Yaru Tian, Xiaoyang Zhai, +2 authors, Jinming Yu.
Cancer Med, 2020 Nov 25; 10(1). PMID: 33230935    Free PMC article.
Review.
Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades.
Jun-Yan Li, Yu-Pei Chen, +2 authors, Jun Ma.
Mol Cancer, 2021 Feb 06; 20(1). PMID: 33541368    Free PMC article.
Review.
EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma.
Zhiming Chen, Ji Chen, +5 authors, Haitao Ma.
Aging (Albany NY), 2020 Dec 09; 13(1). PMID: 33288738    Free PMC article.
Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study.
Eric Nadler, Bhakti Arondekar, +4 authors, Vivek Pawar.
J Cancer Res Clin Oncol, 2020 Dec 03; 147(3). PMID: 33263865    Free PMC article.
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Elizabeth Dudnik, Mor Moskovitz, +11 authors, Israel Lung Cancer Group.
Oncoimmunology, 2021 Feb 09; 10(1). PMID: 33552685    Free PMC article.
Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases.
Meng Qiao, Fei Zhou, +8 authors, Caicun Zhou.
Ann Transl Med, 2021 Feb 09; 9(1). PMID: 33553327    Free PMC article.
Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China.
Xiangyu Zhang, Liang Zeng, +11 authors, Nong Yang.
Cancer Immunol Immunother, 2021 Feb 11; 70(9). PMID: 33566148
C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients.
Namrata S Patil, Wei Zou, +5 authors, Priti S Hegde.
PLoS One, 2021 Feb 04; 16(2). PMID: 33534859    Free PMC article.
Smoking history and the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.
Da-Li Chen, Qing-Yuan Li, Qun-You Tan.
J Thorac Dis, 2021 Feb 12; 13(1). PMID: 33569202    Free PMC article.
Induction treatment in patients with stage III non-small cell lung cancer.
Ramón Palmero, Noelia Vilariño, Arturo Navarro-Martín, Ernest Nadal.
Transl Lung Cancer Res, 2021 Feb 12; 10(1). PMID: 33569335    Free PMC article.
Review.
Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer.
Caroline Huynh, Logan A Walsh, Jonathan D Spicer.
Transl Lung Cancer Res, 2021 Feb 12; 10(1). PMID: 33569337    Free PMC article.
Review.
Combinations using checkpoint blockade to overcome resistance.
Stefania Morganti, Giuseppe Curigliano.
Ecancermedicalscience, 2021 Feb 13; 14. PMID: 33574893    Free PMC article.
Review.
Tumor β-catenin expression is associated with immune evasion in non-small cell lung cancer with high tumor mutation burden.
Satoshi Muto, Yuki Ozaki, +18 authors, Hiroyuki Suzuki.
Oncol Lett, 2021 Feb 13; 21(3). PMID: 33574942    Free PMC article.
Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?
Francesco Passiglia, Maria Lucia Reale, Valeria Cetoretta, Silvia Novello.
Immunotargets Ther, 2021 Feb 13; 10. PMID: 33575224    Free PMC article.
Review.
PD-L1 as a biomarker of response to immune-checkpoint inhibitors.
Deborah Blythe Doroshow, Sheena Bhalla, +7 authors, Fred R Hirsch.
Nat Rev Clin Oncol, 2021 Feb 14; 18(6). PMID: 33580222
Review.
Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases.
Jianping Xu, Xiaoyan Liu, Sheng Yang, Yuankai Shi.
Oncol Res, 2019 Oct 16; 28(2). PMID: 31610827    Free PMC article.
First-Line Therapy for Metastatic Non-Small Cell Lung Cancer: State-of-the-Art Targeted Therapy and Immunotherapy Approaches.
Joshua Bauml, Christina Knepley.
J Adv Pract Oncol, 2021 Feb 19; 11(3). PMID: 33598322    Free PMC article.
To treat or not to treat: A rare case of response to pembrolizumab-based immunotherapy-chemotherapy in non-small cell lung cancer with acute liver failure due to multiple bile duct metastases.
Inna Shaforostova, Sebastian Huss, +2 authors, Annalen Bleckmann.
Thorac Cancer, 2020 Dec 29; 12(4). PMID: 33369224    Free PMC article.
Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors.
Yuan Wei, Xiao Xiao, +2 authors, Dong-Ming Kuang.
Cell Mol Life Sci, 2020 Sep 18; 78(3). PMID: 32940722
Review.
The clinicopathological significance and prognostic value of programmed death-ligand 1 in prostate cancer: a meta-analysis of 3133 patients.
Haixiang Shen, Jin Liu, +4 authors, Liping Xie.
Aging (Albany NY), 2020 Dec 16; 13(2). PMID: 33318295    Free PMC article.
A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study).
Ryota Shibaki, Hiroaki Akamatsu, +7 authors, Kazuhiko Nakagawa.
Ther Adv Med Oncol, 2021 Feb 23; 13. PMID: 33613698    Free PMC article.
Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
Shinkichi Takamori, Takefumi Komiya, Emily Powell.
Cancer Med, 2020 Dec 20; 10(3). PMID: 33340271    Free PMC article.
Therapeutic Sequencing in ALK+ NSCLC.
Mei Elsayed, Petros Christopoulos.
Pharmaceuticals (Basel), 2021 Jan 27; 14(2). PMID: 33494549    Free PMC article.
Review.
miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors.
Florian Huemer, Michael Leisch, +2 authors, Richard Greil.
Pharmaceuticals (Basel), 2021 Feb 04; 14(2). PMID: 33530393    Free PMC article.
Review.
The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer.
Jingjing Qu, Quanhui Mei, +4 authors, Jianying Zhou.
Ther Adv Med Oncol, 2021 Mar 02; 13. PMID: 33643442    Free PMC article.
Review.
nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+).
Daniel Morgensztern, Manuel Cobo Dols, +12 authors, Teng Jin Ong.
Front Oncol, 2021 Mar 02; 10. PMID: 33643895    Free PMC article.
Tumor Vasculatures: A New Target for Cancer Immunotherapy.
Zhigang Liu, Yifan Wang, +4 authors, Wen Jiang.
Trends Pharmacol Sci, 2019 Jul 25; 40(9). PMID: 31331639    Free PMC article.
Review.
Long-term efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients harboring MET exon 14 skipping mutations.
Yasuhiro Kato, Gou Yamamoto, +7 authors, Hiroshi Sakai.
Int J Clin Oncol, 2021 Mar 05; 26(6). PMID: 33660106
Multiorgan Signaling Mobilizes Tumor-Associated Erythroid Cells Expressing Immune Checkpoint Molecules.
Yasuyo Sano, Toshimi Yoshida, +4 authors, Jin Mo Park.
Mol Cancer Res, 2020 Nov 26; 19(3). PMID: 33234577    Free PMC article.
The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors.
I Araujo-Fernandez, J Delgado, +8 authors, F Pignatti.
ESMO Open, 2021 Jan 06; 6(1). PMID: 33399074    Free PMC article.
Review.
Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung.
Elizabeth Dudnik, Samuel Kareff, +11 authors, Israel Lung Cancer Group.
J Immunother Cancer, 2021 Feb 19; 9(2). PMID: 33597218    Free PMC article.
Fatal Adverse Events Associated With Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Xiaolin Yu, Xiaomei Zhang, +2 authors, Yanxia Zhang.
Front Med (Lausanne), 2021 Mar 05; 8. PMID: 33659263    Free PMC article.
Systematic Review.
Trends in Drug Costs and Overall Survival in Patients with Metastatic Non-small Cell Lung Cancer in The Netherlands Diagnosed from 2008 Through 2014.
Christine M Cramer-van der Welle, Bas J M Peters, +2 authors, Ewoudt M W van de Garde.
Pharmacoecon Open, 2020 Jun 14; 5(1). PMID: 32533521    Free PMC article.
A multidisciplinary consensus on the morphological and functional responses to immunotherapy treatment.
L Leon-Mateos, M J Garcia-Velloso, +6 authors, L Gorospe.
Clin Transl Oncol, 2020 Jul 06; 23(3). PMID: 32623581    Free PMC article.
Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody.
Naoki Furuya, Makoto Nishino, +6 authors, Kentaro Ito.
Thorac Cancer, 2021 Jan 16; 12(5). PMID: 33448648    Free PMC article.
Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years.
Andreas Koulouris, Christos Tsagkaris, Michail Nikolaou.
Toxins (Basel), 2021 Mar 07; 13(2). PMID: 33672017    Free PMC article.
Review.
Beyond immune checkpoint blockade: emerging immunological strategies.
Shawn P Kubli, Thorsten Berger, +2 authors, Tak W Mak.
Nat Rev Drug Discov, 2021 Mar 10; 20(12). PMID: 33686237
Review.
Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis.
Alberto Carretero-González, Irene Otero, +3 authors, Guillermo de Velasco.
Oncoimmunology, 2021 Mar 09; 10(1). PMID: 33680572    Free PMC article.
Systematic Review.
2020 Innovation-Based Optimism for Lung Cancer Outcomes.
Erin L Schenk, Tejas Patil, Jose Pacheco, Paul A Bunn.
Oncologist, 2020 Nov 13; 26(3). PMID: 33179378    Free PMC article.
Review.
Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer.
Hongxin Zhang, Pengfei Liu, +4 authors, Jianhui Cai.
FEBS Open Bio, 2021 Jan 18; 11(3). PMID: 33455075    Free PMC article.
Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma.
Minsu Kang, Changhee Park, +10 authors, Jong Seok Lee.
Transl Lung Cancer Res, 2021 Mar 16; 10(2). PMID: 33718015    Free PMC article.
Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer.
Shogo Nakamoto, Masahiko Ikeda, +3 authors, Akifumi Notsu.
Sci Rep, 2021 Mar 20; 11(1). PMID: 33737682    Free PMC article.
[Immunotherapy for Lung Cancer: Mechanisms of Resistance and Response Strategy].
Yaning Yang, Lu Yang, Yan Wang.
Zhongguo Fei Ai Za Zhi, 2021 Feb 26; 24(2). PMID: 33626853    Free PMC article.
Review.
Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment.
Peijie Wu, Wei Gao, +4 authors, Na Xie.
Front Cell Dev Biol, 2021 Mar 19; 9. PMID: 33732706    Free PMC article.
Review.
Efficacy and safety of immune checkpoint inhibitor monotherapy in elderly patients with non-small cell lung cancer.
Yasuhiro Chikaishi, Masaaki Inoue, +3 authors, Masao Tanaka.
Aging Med (Milton), 2021 Mar 20; 4(1). PMID: 33738379    Free PMC article.
Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China.
Xiaoling Chen, Jun Nie, +11 authors, Jian Fang.
Front Oncol, 2021 Mar 23; 11. PMID: 33747922    Free PMC article.
Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
Jun Shao, Chengdi Wang, +3 authors, Weimin Li.
Biosci Rep, 2020 Apr 22; 40(5). PMID: 32315071    Free PMC article.
Systematic Review.
Active and latent tuberculosis infections in patients treated with immune checkpoint inhibitors in a non-endemic tuberculosis area.
Gregory R Stroh, Tobias Peikert, Patricio Escalante.
Cancer Immunol Immunother, 2021 Mar 27; 70(11). PMID: 33770211    Free PMC article.
Identification of Proteins Deregulated by Platinum-Based Chemotherapy as Novel Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer.
Sarah-Louise Ryan, Keyur A Dave, +13 authors, Mark N Adams.
Front Oncol, 2021 Mar 30; 11. PMID: 33777753    Free PMC article.
Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC.
Sangtian Liu, Fengying Wu, +13 authors, Caicun Zhou.
Front Oncol, 2021 Mar 30; 11. PMID: 33777802    Free PMC article.
Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure-A Retrospective Study.
Peiliang Wang, Xiaozhuang Fang, +3 authors, Feifei Teng.
Front Oncol, 2021 Apr 02; 11. PMID: 33791214    Free PMC article.
Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis.
Angelo Borsarelli Carvalho Brito, Marcos Pedro Guedes Camandaroba, Vladmir Cláudio Cordeiro de Lima.
Thorac Cancer, 2021 Feb 16; 12(7). PMID: 33586297    Free PMC article.
Systematic Review.
A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung).
Daniel Heudobler, Christian Schulz, +15 authors, Albrecht Reichle.
Front Pharmacol, 2021 Apr 03; 12. PMID: 33796020    Free PMC article.
Immunotherapy as a treatment strategy in advanced stage and recurrent endometrial cancer: review of current phase III immunotherapy clinical trials.
Ramez N Eskander, Matthew A Powell.
Ther Adv Med Oncol, 2021 Apr 03; 13. PMID: 33796152    Free PMC article.
Review.
Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer.
Xue Wang, Xiaomin Niu, +2 authors, Zhiwei Chen.
Front Oncol, 2021 Apr 06; 11. PMID: 33816241    Free PMC article.
Peripheral Blood Autoantibodies Against to Tumor-Associated Antigen Predict Clinical Outcome to Immune Checkpoint Inhibitor-Based Treatment in Advanced Non-Small Cell Lung Cancer.
Juan Zhou, Jing Zhao, +7 authors, Chunxia Su.
Front Oncol, 2021 Apr 06; 11. PMID: 33816260    Free PMC article.
Association between 18F-FDG metabolic activity and programmed death ligand-1 (PD-L1) expression using 22C3 immunohistochemistry assays in non-small cell lung cancer (NSCLC) resection specimens.
Long Zhao, Jinjun Liu, Huoqiang Wang, Jingyun Shi.
Br J Radiol, 2021 Jan 26; 94(1119). PMID: 33492995    Free PMC article.
Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Koichi Ando, Ryo Manabe, +6 authors, Hironori Sagara.
Curr Oncol, 2021 Mar 07; 28(2). PMID: 33673470    Free PMC article.
Systematic Review.
Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma.
Kyoichi Kaira, Hisao Imai, Hiroshi Kagamu.
Cancers (Basel), 2021 Apr 04; 13(5). PMID: 33802298    Free PMC article.
Review.
Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial.
Ashley M Hopkins, Ganessan Kichenadasse, +3 authors, Michael J Sorich.
Cancers (Basel), 2021 Apr 04; 13(5). PMID: 33803256    Free PMC article.
Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives.
Sara Fancelli, Enrico Caliman, +5 authors, Lorenzo Antonuzzo.
Cancers (Basel), 2021 Apr 04; 13(5). PMID: 33806299    Free PMC article.
Review.
Immunotherapy for ALK-Rearranged Non-Small Cell Lung Cancer: Challenges Inform Promising Approaches.
Kamya Sankar, Sunitha Nagrath, Nithya Ramnath.
Cancers (Basel), 2021 Apr 04; 13(6). PMID: 33806977    Free PMC article.
Review.
Anti-Tumor Efficacy of PD-L1 Targeted Alpha-Particle Therapy in a Human Melanoma Xenograft Model.
Marisa Capitao, Justine Perrin, +10 authors, Joëlle Gaschet.
Cancers (Basel), 2021 Apr 04; 13(6). PMID: 33809167    Free PMC article.
If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer.
Jens Köhler, Pasi A Jänne.
Int J Mol Sci, 2021 Apr 04; 22(6). PMID: 33809660    Free PMC article.
Review.
IMpower132: Atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients.
Makoto Nishio, Haruhiro Saito, +7 authors, Tomohisa Kawakami.
Cancer Sci, 2021 Jan 20; 112(4). PMID: 33462883    Free PMC article.
Reconsidering Dexamethasone for Antiemesis when Combining Chemotherapy and Immunotherapy.
Tobias Janowitz, Sam Kleeman, Robert H Vonderheide.
Oncologist, 2021 Jan 20; 26(4). PMID: 33465258    Free PMC article.
Review.
Vascular reconstitution in the tumor for more effective tumor immunotherapy.
Nobuyuki Takakura.
Cancer Sci, 2021 Feb 16; 112(4). PMID: 33587826    Free PMC article.
Review.
Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes.
Zowi R Huinen, Elisabeth J M Huijbers, +2 authors, Arjan W Griffioen.
Nat Rev Clin Oncol, 2021 Apr 10; 18(8). PMID: 33833434
Review.
Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study.
Kenji Morimoto, Tadaaki Yamada, +12 authors, Koichi Takayama.
Front Oncol, 2021 Apr 10; 11. PMID: 33833990    Free PMC article.
Correlation of Clinical Parameters with Intracranial Outcome in Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Pd-1/Pd-L1 Inhibitors as Monotherapy.
Konstantinos Rounis, Marcus Skribek, +4 authors, Georgios Tsakonas.
Cancers (Basel), 2021 Apr 04; 13(7). PMID: 33805335    Free PMC article.
Immunotherapy in Advanced Biliary Tract Cancers.
Alice Boilève, Marc Hilmi, +3 authors, David Malka.
Cancers (Basel), 2021 Apr 04; 13(7). PMID: 33805461    Free PMC article.
Review.
PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis.
Margarita Majem, Manuel Cobo, +9 authors, Luis Paz-Ares.
J Clin Med, 2021 Apr 04; 10(7). PMID: 33810441    Free PMC article.
Review.
Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities.
Stergios Boussios, Matin Sheriff, +7 authors, Nicholas Pavlidis.
Ann Transl Med, 2021 Apr 13; 9(5). PMID: 33842644    Free PMC article.
Review.
Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy.
Elena María Brozos-Vázquez, Roberto Díaz-Peña, +4 authors, Rafael López-López.
Cancer Immunol Immunother, 2020 Oct 29; 70(5). PMID: 33113004
Review.
The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation.
Man Shang, Huijie Yang, +14 authors, Ting Wang.
Nat Commun, 2021 Mar 31; 12(1). PMID: 33782411    Free PMC article.
Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials.
Le-Tian Huang, Rui Cao, +9 authors, Jietao Ma.
BMC Cancer, 2021 Apr 19; 21(1). PMID: 33865364    Free PMC article.
An expanded universe of cancer targets.
William C Hahn, Joel S Bader, +21 authors, Cancer Target Discovery and Development Network.
Cell, 2021 Mar 06; 184(5). PMID: 33667368    Free PMC article.
Review.
The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Y Yang, H Luo, X L Zheng, H Ge.
Clin Transl Oncol, 2020 Nov 20; 23(6). PMID: 33211281
Systematic Review.
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
Hossein Borghaei, Scott Gettinger, +27 authors, Julie Brahmer.
J Clin Oncol, 2021 Jan 16; 39(7). PMID: 33449799    Free PMC article.
Deciphering molecular mechanisms of metastasis: novel insights into targets and therapeutics.
Bikashita Kalita, Mohane Selvaraj Coumar.
Cell Oncol (Dordr), 2021 Apr 30; 44(4). PMID: 33914273
Review.
Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity.
Won Suk Lee, Hannah Yang, Hong Jae Chon, Chan Kim.
Exp Mol Med, 2020 Sep 12; 52(9). PMID: 32913278    Free PMC article.
Review.
Anti-Angiogenic Therapy: Current Challenges and Future Perspectives.
Filipa Lopes-Coelho, Filipa Martins, Sofia A Pereira, Jacinta Serpa.
Int J Mol Sci, 2021 May 01; 22(7). PMID: 33916438    Free PMC article.
Review.
Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis.
Shixue Chen, Zhibo Zhang, +11 authors, Yi Hu.
Front Oncol, 2021 May 04; 11. PMID: 33937012    Free PMC article.
Systematic Review.
Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC.
Ya Chen, Zhengyu Yang, +6 authors, Baohui Han.
Front Oncol, 2021 May 04; 11. PMID: 33937084    Free PMC article.
Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma.
Maximilian J Mair, Ayseguel Ilhan-Mutlu, +8 authors, Anna S Berghoff.
Cancer Immunol Immunother, 2021 May 07; 70(12). PMID: 33956203    Free PMC article.
Inhalation delivery dramatically improves the efficacy of topotecan for the treatment of local and distant lung cancer.
Philip J Kuehl, Christin M Yingling, +6 authors, Mathewos Tessema.
Drug Deliv, 2021 Apr 17; 28(1). PMID: 33860729    Free PMC article.
Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis.
Rituparna Chakrabarti, Bhavya Kapse, Gayatri Mukherjee.
Cancer Rep (Hoboken), 2020 Jul 29; 2(4). PMID: 32721130    Free PMC article.
Review.
Physiologic colonic uptake of 18F-FDG on PET/CT is associated with clinical response and gut microbiome composition in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Lena Cvetkovic, Claudine Régis, +9 authors, Daniel Juneau.
Eur J Nucl Med Mol Imaging, 2020 Nov 01; 48(5). PMID: 33128571
A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non-small cell lung cancer.
Taisuke Isono, Naho Kagiyama, +12 authors, Noboru Takayanagi.
Thorac Cancer, 2021 Mar 13; 12(9). PMID: 33710764    Free PMC article.
Emerging principles of brain immunology and immune checkpoint blockade in brain metastases.
Jawad Fares, Ilya Ulasov, Peter Timashev, Maciej S Lesniak.
Brain, 2021 Apr 25; 144(4). PMID: 33893488    Free PMC article.
Review.
Co-Occurring Alteration of NOTCH and DDR Pathways Serves as Novel Predictor to Efficacious Immunotherapy in NSCLC.
Zhimin Zhang, Yanyan Gu, +11 authors, Chuan Chen.
Front Oncol, 2021 May 11; 11. PMID: 33968765    Free PMC article.
Recurrent spindle cell carcinoma of the lung successfully treated by chemoimmunotherapy.
Tomohiro Akaba, Yuno Shiota, +3 authors, Etsuko Tagaya.
Respirol Case Rep, 2021 May 13; 9(6). PMID: 33976886    Free PMC article.
KRAS G12C inhibition and innate immune targeting.
Tetsuo Tani, Shunsuke Kitajima, +2 authors, David A Barbie.
Expert Opin Ther Targets, 2021 Mar 12; 25(3). PMID: 33703985    Free PMC article.
Review.
Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?
Wout De Wispelaere, Daniela Annibali, +2 authors, Frédéric Amant.
Cancers (Basel), 2021 May 01; 13(9). PMID: 33922556    Free PMC article.
Review.
Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status.
Guoqiang Liu, Shuo Kang, Xinchen Wang, Fangjian Shang.
Front Oncol, 2021 May 15; 11. PMID: 33987103    Free PMC article.
Perilesional edema in brain metastases as predictive factor of response to systemic therapy in non-small cell lung cancer patients: a preliminary study.
Montse Alemany, Marta Domènech, +8 authors, Jordi Bruna.
Ann Transl Med, 2021 May 15; 9(8). PMID: 33987346    Free PMC article.
The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials.
A Galvano, V Gristina, +9 authors, V Bazan.
ESMO Open, 2021 May 04; 6(3). PMID: 33940346    Free PMC article.
Systematic Review.
KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas.
Meichen Gu, Tiankai Xu, Pengyu Chang.
Ther Adv Med Oncol, 2021 May 18; 13. PMID: 33995590    Free PMC article.
Review.
Efficacy of Combination Docetaxel and Nintedanib in Advanced Non-Small Cell Lung Cancer in Thailand: A Multicenter Study.
Krittiya Korphaisarn, Pongwut Danchaivijitr, +6 authors, Chanida Vinayanuwattikun.
Front Oncol, 2021 May 18; 11. PMID: 33996532    Free PMC article.
Tumor microenvironment disparity in multiple primary lung cancers: Impact of non-intrinsic factors, histological subtypes, and genetic aberrations.
Motohiro Izumi, Kenji Sawa, +15 authors, Tomoya Kawaguchi.
Transl Oncol, 2021 May 01; 14(7). PMID: 33930847    Free PMC article.
Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study.
Kinnosuke Matsumoto, Akihiro Tamiya, +10 authors, Tomonori Hirashima.
Transl Lung Cancer Res, 2021 May 21; 10(4). PMID: 34012781    Free PMC article.
From CheckMate 227 to CheckMate 9LA: rethinking the status of chemotherapy in the immunotherapy era-chemo-free or chemo-reform?
Haiyi Deng, Chengzhi Zhou.
Transl Lung Cancer Res, 2021 May 21; 10(4). PMID: 34012802    Free PMC article.
Combination of Immune Checkpoint Inhibitors and Anti-Angiogenic Agents in Brain Metastases From Non-Small Cell Lung Cancer.
Likui Fang, Wuchen Zhao, Bo Ye, Da Chen.
Front Oncol, 2021 May 22; 11. PMID: 34017689    Free PMC article.
Review.
[Chinese Experts Consensus on Immune Checkpoint Inhibitors 
for Non-small Cell Lung Cancer (2020 Version)].
Caicun Zhou, Jie Wang, +22 authors, Shukui Qin.
Zhongguo Fei Ai Za Zhi, 2021 Apr 26; 24(4). PMID: 33896153    Free PMC article.
Immunotherapy in non-small cell lung cancer: advancements and challenges.
Fei Zhou, Cai-Cun Zhou.
Chin Med J (Engl), 2021 Feb 18; 134(10). PMID: 33595975    Free PMC article.
Immune subgroup analysis for non-small cell lung cancer may be a good choice for evaluating therapeutic efficacy and prognosis.
Yuan Tian, Jingnan Wang, +2 authors, Yuping Sun.
Aging (Albany NY), 2021 May 12; 13(9). PMID: 33973529    Free PMC article.
Baseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment.
Jingtao Tong, Yifei Mao, +7 authors, Lu Zheng.
Cancer Manag Res, 2021 May 28; 13. PMID: 34040444    Free PMC article.
Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review.
Tao Ouyang, Yanyan Cao, +7 authors, Chuansheng Zheng.
Front Oncol, 2021 May 29; 11. PMID: 34046338    Free PMC article.
Systematic Review.
Association of Dynamic Changes in Peripheral Blood Indexes With Response to PD-1 Inhibitor-Based Combination Therapy and Survival Among Patients With Advanced Non-Small Cell Lung Cancer.
Yuzhong Chen, Shaodi Wen, +5 authors, Bo Shen.
Front Immunol, 2021 Jun 01; 12. PMID: 34054853    Free PMC article.
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study.
Vincenzo Di Noia, Ettore D'Argento, +12 authors, Emilio Bria.
Cancer Immunol Immunother, 2020 Nov 25; 70(6). PMID: 33231726    Free PMC article.
Practical Issues in the Use of Atezolizumab for Patients with Non-Small Cell Lung Cancer: Case Reports and Literature Review.
Manuel Cobo, Delvys Rodríguez-Abreu, +2 authors, Jorge G González.
Oncol Ther, 2021 Feb 15; 9(1). PMID: 33582978    Free PMC article.
Review.
Effects of Chemotherapy Agents on Circulating Leukocyte Populations: Potential Implications for the Success of CAR-T Cell Therapies.
Nga T H Truong, Tessa Gargett, Michael P Brown, Lisa M Ebert.
Cancers (Basel), 2021 Jun 03; 13(9). PMID: 34066414    Free PMC article.
Review.
Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials.
Johnathan Man, Jared Millican, +2 authors, Rina Hui.
JNCI Cancer Spectr, 2021 Jun 05; 5(3). PMID: 34084999    Free PMC article.
Systematic Review.
Optimal Therapy for Advanced Non-Small Cell Lung Cancer Without Driver Alterations.
Jose Pacheco, Erin L Schenk, Paul A Bunn.
JNCI Cancer Spectr, 2021 Jun 05; 5(3). PMID: 34085000    Free PMC article.
Development of Immunotherapy Combination Strategies in Cancer.
Timothy A Yap, Eileen E Parkes, +3 authors, Hussein A Tawbi.
Cancer Discov, 2021 Apr 04; 11(6). PMID: 33811048    Free PMC article.
Review.
ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC.
Shiqi Mao, Fei Zhou, +14 authors, Shengxiang Ren.
Cancer Immunol Immunother, 2021 Jun 08; 71(1). PMID: 34097116
Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.
Wanyuan Cui, Sanjay Popat.
Drugs, 2021 Jun 10; 81(9). PMID: 34106454
Review.
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
Kathleen N Moore, Michael Bookman, +25 authors, Sandro Pignata.
J Clin Oncol, 2021 Apr 24; 39(17). PMID: 33891472    Free PMC article.
The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen.
Nan Geng, Jingwei Su, +3 authors, Wenxia Hu.
Technol Cancer Res Treat, 2021 Jun 02; 20. PMID: 34060368    Free PMC article.
Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade.
Zia Khan, Christian Hammer, +9 authors, G Scott Chandler.
Nat Commun, 2021 Jun 09; 12(1). PMID: 34099659    Free PMC article.
Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis.
Lei Sheng, Jing Gao, +5 authors, Lian Liu.
Ther Adv Med Oncol, 2021 Jun 10; 13. PMID: 34104227    Free PMC article.
Review.
Immunotherapy in non-small cell lung cancer: Update and new insights.
Xabier Mielgo-Rubio, Eider Azkona Uribelarrea, Laura Quintanta Cortés, María Sereno Moyano.
J Clin Transl Res, 2021 Jun 10; 7(1). PMID: 34104805    Free PMC article.
Review.
Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study.
Konstantinos Rounis, Dimitrios Makrakis, +8 authors, Sofia Agelaki.
PLoS One, 2021 Jun 02; 16(6). PMID: 34061904    Free PMC article.
Assessment of the Clinical Trials Safety Profile of PD-1/PD-L1 Inhibitors Among Patients With Cancer: An Updated Systematic Review and Meta-Analysis.
Yuan Tian, Alan Huang, +4 authors, Yuping Sun.
Front Oncol, 2021 Jun 11; 11. PMID: 34109117    Free PMC article.
Systematic Review.
Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies.
Kenneth K W To, Winnie Fong, William C S Cho.
Front Oncol, 2021 Jun 12; 11. PMID: 34113560    Free PMC article.
Review.
Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors.
Dan Zhao, Haiqing Li, +11 authors, Ravi Salgia.
Cancers (Basel), 2021 Jun 03; 13(11). PMID: 34071259    Free PMC article.
Control of Tumor Progression by Angiocrine Factors.
Elisenda Alsina-Sanchis, Ronja Mülfarth, Andreas Fischer.
Cancers (Basel), 2021 Jun 03; 13(11). PMID: 34073394    Free PMC article.
Review.
Clinical Perspectives to Overcome Acquired Resistance to Anti-Programmed Death-1 and Anti-Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer.
Yong Jun Lee, Jii Bum Lee, Sang-Jun Ha, Hye Ryun Kim.
Mol Cells, 2021 May 19; 44(5). PMID: 34001680    Free PMC article.
Review.
Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management.
Qin Zhang, Liansha Tang, +2 authors, Weimin Li.
Front Immunol, 2021 Jun 15; 12. PMID: 34122422    Free PMC article.
Review.
Angiogenesis Inhibitors in Small Cell Lung Cancer.
Agnese Montanino, Anna Manzo, +12 authors, Alessandro Morabito.
Front Oncol, 2021 Jun 15; 11. PMID: 34123809    Free PMC article.
Review.
The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations.
Yongdong Feng, Guangkuo Zhu, +8 authors, Jianguo Sun.
Front Oncol, 2021 Jun 15; 11. PMID: 34123814    Free PMC article.
The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study.
Keiko Tanimura, Tadaaki Yamada, +12 authors, Koichi Takayama.
Front Oncol, 2021 Jun 15; 11. PMID: 34123822    Free PMC article.
Mechanism-based treatment of cancer with immune checkpoint inhibitor therapies.
Yara Abdou, Manu Pandey, +3 authors, Marc S Ernstoff.
Br J Clin Pharmacol, 2020 Apr 24; 86(9). PMID: 32323342    Free PMC article.
Review.
DLL1 orchestrates CD8+ T cells to induce long-term vascular normalization and tumor regression.
Naidong Zhang, Rongping Yin, +13 authors, Yuhui Huang.
Proc Natl Acad Sci U S A, 2021 May 27; 118(22). PMID: 34035167    Free PMC article.
[Review on the Combination Strategy of Anti-angiogenic Agents 
and Other Anti-tumor Agents in Advanced Non-small Cell Lung Cancer].
Ziyi Xu, Junling Li.
Zhongguo Fei Ai Za Zhi, 2021 May 27; 24(5). PMID: 34034460    Free PMC article.
Review.
Exploration of the Tumor-Suppressive Immune Microenvironment by Integrated Analysis in EGFR-Mutant Lung Adenocarcinoma.
Teng Li, Xiaocong Pang, +5 authors, Junling Li.
Front Oncol, 2021 Jun 18; 11. PMID: 34136375    Free PMC article.
Precise medicine of programmed cell death-1/programmed cell death 1 ligand 1 inhibitor immunotherapy combined radiotherapy for inoperable advanced lung cancer: A protocol for systematic review and meta-analysis.
Gang Liu, Xiaolan Lv, Yanling Ding, Yongbo Guo.
Medicine (Baltimore), 2021 Jun 16; 100(24). PMID: 34128893    Free PMC article.
Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis.
Dan-Ni Li, Wen-Qing Lu, +7 authors, Xiu-Juan Qu.
Front Immunol, 2021 Jun 22; 12. PMID: 34149702    Free PMC article.
Systematic Review.
The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index.
Ting Zhang, Xue Yang, +9 authors, Yang Xia.
Front Oncol, 2021 Jun 22; 11. PMID: 34150659    Free PMC article.
"High Tumor Burden" in Metastatic Non-Small Cell Lung Cancer: Defining the Concept.
Oliver Higuera Gómez, Amaia Moreno Paul, +5 authors, Laia Vilà.
Cancer Manag Res, 2021 Jun 25; 13. PMID: 34163241    Free PMC article.
Predictability of early changes in derived neutrophil-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Jeong Uk Lim, Hye Seon Kang, +5 authors, Sang Haak Lee.
J Thorac Dis, 2021 Jun 25; 13(5). PMID: 34164174    Free PMC article.
Immune checkpoint inhibitors combined with chemotherapy/bevacizumab therapy for patients with advanced lung cancer and heavily treated with EGFR mutation: a retrospective analysis.
Ran Hu, Zhiting Zhao, +4 authors, Jifeng Feng.
J Thorac Dis, 2021 Jun 25; 13(5). PMID: 34164187    Free PMC article.
Comprehensive analysis of blood-based biomarkers for predicting immunotherapy benefits in patients with advanced non-small cell lung cancer.
Cheol-Kyu Park, Hyung-Joo Oh, +7 authors, In-Jae Oh.
Transl Lung Cancer Res, 2021 Jun 25; 10(5). PMID: 34164263    Free PMC article.
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC.
Michael J Grant, Roy S Herbst, Sarah B Goldberg.
Nat Rev Clin Oncol, 2021 Jun 26; 18(10). PMID: 34168333
Review.
Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case Report.
Nobutaka Kataoka, Yusuke Kunimatsu, +7 authors, Takayuki Takeda.
Medicina (Kaunas), 2021 Jun 03; 57(6). PMID: 34072448    Free PMC article.
Sex-related differences in the efficacy of immune checkpoint inhibitors in malignancy: a systematic review and meta-analysis.
Li-Ting Lai, Wei-Guo Gu, +5 authors, Chun-Liang Wang.
Aging (Albany NY), 2021 Jun 05; 13(11). PMID: 34086601    Free PMC article.
Systematic Review.
Case Series of Pleomorphic Carcinoma of the Lung Treated With Immune Checkpoint Inhibitors.
Kana Hayashi, Kotaro Tokui, +12 authors, Kazuyuki Tobe.
In Vivo, 2021 Apr 30; 35(3). PMID: 33910853    Free PMC article.
The Correlation Between SPP1 and Immune Escape of EGFR Mutant Lung Adenocarcinoma Was Explored by Bioinformatics Analysis.
Yi Zheng, Shiying Hao, +6 authors, Yan Zhang.
Front Oncol, 2021 Jun 29; 11. PMID: 34178613    Free PMC article.
Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report.
Xiaomin Niu, Yingjia Sun, +4 authors, Shun Lu.
Front Oncol, 2021 Jun 29; 11. PMID: 34178624    Free PMC article.
Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report.
Alessandra Ferro, Angela Filoni, +5 authors, Laura Bonanno.
Front Med (Lausanne), 2021 Jun 29; 8. PMID: 34179028    Free PMC article.
PET/CT and the Response to Immunotherapy in Lung Cancer.
Laura Evangelista, Matteo Sepulcri, Giulia Pasello.
Curr Radiopharm, 2019 Dec 21; 13(3). PMID: 31858908    Free PMC article.
Review.
Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
E Suazo-Zepeda, M Bokern, +3 authors, G Sidorenkov.
Cancer Immunol Immunother, 2021 Jul 02; 70(11). PMID: 34195862    Free PMC article.
Systematic Review.
Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer.
Ou Yamaguchi, Hisao Imai, +16 authors, Kyoichi Kaira.
Cancer Chemother Pharmacol, 2020 Mar 21; 85(4). PMID: 32193618
The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer.
Tania Crombet Ramos, Orestes Santos Morales, +2 authors, Agustín Lage Dávila.
Front Oncol, 2021 Jul 03; 11. PMID: 34211836    Free PMC article.
Review.
FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non-small Cell Lung Cancer, A Collaborative Project Orbis Review.
Paz J Vellanki, Flora Mulkey, +16 authors, Harpreet Singh.
Clin Cancer Res, 2021 Feb 27; 27(13). PMID: 33632925    Free PMC article.
Two Complementarity Immunotherapeutics in Non-Small-Cell Lung Cancer Patients-Mechanism of Action and Future Concepts.
Kamila Wojas-Krawczyk, Paweł Krawczyk, Michał Gil, Maciej Strzemski.
Cancers (Basel), 2021 Jul 03; 13(11). PMID: 34200219    Free PMC article.
Review.
Characterization of Circulating T Cell Receptor Repertoire Provides Information about Clinical Outcome after PD-1 Blockade in Advanced Non-Small Cell Lung Cancer Patients.
Ning Dong, Andrea Moreno-Manuel, +9 authors, Eloísa Jantus-Lewintre.
Cancers (Basel), 2021 Jul 03; 13(12). PMID: 34204662    Free PMC article.
Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States.
Marion Ferreira, Thomas Secher, Nathalie Heuze-Vourc'H, Karen L Reckamp.
Pharmaceutics, 2021 Jul 03; 13(6). PMID: 34205484    Free PMC article.
Review.
Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations.
Edouard Dantoing, Nicolas Piton, +2 authors, Florian Guisier.
Int J Mol Sci, 2021 Jul 03; 22(12). PMID: 34208111    Free PMC article.
Review.
Classification of Non-Small Cell Lung Cancer's Tumor Immune Micro-Environment and Strategies to Augment Its Response to Immune Checkpoint Blockade.
Alexander Chi, Xia He, +4 authors, Jay M Lee.
Cancers (Basel), 2021 Jul 03; 13(12). PMID: 34208113    Free PMC article.
Review.
Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features.
Antonio Passaro, Silvia Novello, +11 authors, Filippo de Marinis.
Cancers (Basel), 2021 Jul 03; 13(12). PMID: 34208253    Free PMC article.
Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Fausto Petrelli, Anna Maria Morelli, +2 authors, Cinzia Solinas.
Target Oncol, 2021 Jul 06; 16(5). PMID: 34224061    Free PMC article.
Systematic Review.
Immunotherapy in Older Adults With Cancer.
Carolyn J Presley, Fabio Gomes, +2 authors, Melisa L Wong.
J Clin Oncol, 2021 May 28; 39(19). PMID: 34043444    Free PMC article.
Review.
Molecular determinants of response to PD-L1 blockade across tumor types.
Romain Banchereau, Ning Leng, +22 authors, Thomas Powles.
Nat Commun, 2021 Jun 27; 12(1). PMID: 34172722    Free PMC article.
Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies.
Karam Khaddour, Sushma Jonna, +5 authors, Yanis Boumber.
Cancers (Basel), 2021 Jul 03; 13(13). PMID: 34202748    Free PMC article.
Review.
Incidence risk of PD-1/PD-L1-related pneumonia and diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis of randomized controlled trials.
Zhi-Qiang Tong, Dong-Yuan Wu, Duo Liu, Mei Dong.
Eur J Clin Pharmacol, 2021 Feb 11; 77(8). PMID: 33564898
Systematic Review.
Microenvironmental regulation of tumour immunity and response to immunotherapy.
Mark M Kockx, Mark McCleland, Hartmut Koeppen.
J Pathol, 2021 Apr 14; 254(4). PMID: 33846997    Free PMC article.
Review.
Organoid models of the tumor microenvironment and their applications.
Tao Xia, Wen-Lin Du, Xiao-Yi Chen, You-Ni Zhang.
J Cell Mol Med, 2021 May 26;. PMID: 34033245    Free PMC article.
Review.
Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer.
Kabir A Khan, Florence Th Wu, William Cruz-Munoz, Robert S Kerbel.
EMBO Mol Med, 2021 Jun 15; 13(7). PMID: 34125494    Free PMC article.
Review.
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) version 1.1.
M Pichler, J Steyrer.
ESMO Open, 2021 Jun 28; 6(4). PMID: 34175674    Free PMC article.
Immunotherapy in the treatment of lymphoma.
Lazar S Popovic, Gorana Matovina-Brko, +5 authors, Dragana Petrovic.
World J Stem Cells, 2021 Jul 13; 13(6). PMID: 34249225    Free PMC article.
Review.
Case Report: Durvalumab-Associated Encephalitis in Extensive-Stage Small Cell Lung Carcinoma.
Yosuke Shionoya, Akito Hattori, Taro Hanada, Michihiro Fujino.
Front Oncol, 2021 Jul 13; 11. PMID: 34249743    Free PMC article.
The Effect of Asymptomatic and/or Treated Brain Metastases on Efficacy of Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis.
Sihan Li, Hongwei Zhang, +2 authors, Jun Dang.
Front Oncol, 2021 Jul 13; 11. PMID: 34249764    Free PMC article.
Systematic Review.
Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers.
Kristin L Ayers, Tommy Mullaney, +22 authors, Rong Chen.
Oncologist, 2021 Apr 09; 26(7). PMID: 33829580    Free PMC article.
Incidence and risk factors for pneumonitis among patients with lung cancer who received immune checkpoint inhibitors after palliative thoracic radiotherapy.
Satoshi Saito, Takanori Abe, +11 authors, Shingo Kato.
J Radiat Res, 2021 Jun 15; 62(4). PMID: 34121123    Free PMC article.
The histological diagnosis and molecular testing of lung cancer by surgical biopsy for intrathoracic lesions.
Toru Momozane, Kaichi Shigetsu, +2 authors, Ken Kodama.
Gen Thorac Cardiovasc Surg, 2021 Mar 27; 69(8). PMID: 33768496
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.
Martin Reck, Delvys Rodríguez-Abreu, +16 authors, Julie R Brahmer.
J Clin Oncol, 2021 Apr 20; 39(21). PMID: 33872070    Free PMC article.
Three-dimensional CRISPR screening reveals epigenetic interaction with anti-angiogenic therapy.
Michael Y He, Michael M Halford, +9 authors, Steven A Stacker.
Commun Biol, 2021 Jul 17; 4(1). PMID: 34267311    Free PMC article.
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma.
Lakshmi Nayak, Annette M Molinaro, +19 authors, David A Reardon.
Clin Cancer Res, 2020 Nov 18; 27(4). PMID: 33199490    Free PMC article.
The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy.
Bonnie L Russell, Selisha A Sooklal, +2 authors, Monde Ntwasa.
Front Oncol, 2021 Jul 17; 11. PMID: 34268109    Free PMC article.
Review.
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
Scott N Gettinger, Mary W Redman, +16 authors, Roy S Herbst.
JAMA Oncol, 2021 Jul 16; 7(9). PMID: 34264316    Free PMC article.
Nelfinavir restricts A549 cell growth by inhibiting STAT3 signaling.
Fangli He, Gang Wang, ZhengQing Xu, Zhihui Huang.
J Int Med Res, 2021 Jun 26; 49(6). PMID: 34167351    Free PMC article.
Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study.
Kenji Morimoto, Junji Uchino, +16 authors, Koichi Takayama.
Oncoimmunology, 2021 Jul 23; 10(1). PMID: 34290909    Free PMC article.
Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment.
Wuzhen Chen, Lesang Shen, +5 authors, Zhigang Chen.
Biomark Res, 2021 Jul 24; 9(1). PMID: 34294146    Free PMC article.
Review.
Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA).
Dmytro Trukhin, Elena Poddubskaya, +17 authors, STELLA Investigators.
BioDrugs, 2021 Apr 30; 35(4). PMID: 33914256    Free PMC article.
Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer.
Hiroyuki Inoue, Hirono Tsutsumi, +17 authors, Isamu Okamoto.
Transl Lung Cancer Res, 2021 Jul 24; 10(6). PMID: 34295655    Free PMC article.
International consensus on severe lung cancer-the first edition.
Chengzhi Zhou, Shiyue Li, +84 authors, Nanshan Zhong.
Transl Lung Cancer Res, 2021 Jul 24; 10(6). PMID: 34295668    Free PMC article.
Review.
Immunotherapy in oncogene addicted non-small cell lung cancer.
Luke McLean, Jose Luis Leal, Benjamin J Solomon, Thomas John.
Transl Lung Cancer Res, 2021 Jul 24; 10(6). PMID: 34295674    Free PMC article.
Review.
A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer.
Zarique Z Akanda, Paul J Neeson, +5 authors, Shankar Siva.
Transl Lung Cancer Res, 2021 Jul 24; 10(6). PMID: 34295676    Free PMC article.
Review.
Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?
Lizza E L Hendriks, Jordi Remon, Jessica Menis, Benjamin Besse.
Transl Lung Cancer Res, 2021 Jul 24; 10(6). PMID: 34295685    Free PMC article.
Review.
Exploring the immune-checkpoint inhibitors' efficacy/tolerability in special non-small cell lung cancer (NSCLC) populations: focus on steroids and autoimmune disease.
Francesco Passiglia, Valeria Cetoretta, +2 authors, Silvia Novello.
Transl Lung Cancer Res, 2021 Jul 24; 10(6). PMID: 34295686    Free PMC article.
Review.
Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis.
Giorgia Guaitoli, Marcello Tiseo, +2 authors, Francesco Facchinetti.
Transl Lung Cancer Res, 2021 Jul 24; 10(6). PMID: 34295687    Free PMC article.
Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative review.
Charles Naltet, Benjamin Besse.
Transl Lung Cancer Res, 2021 Jul 24; 10(6). PMID: 34295694    Free PMC article.
Review.
Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC).
Li-Chung Chiu, Shu-Min Lin, +3 authors, Ping-Chih Hsu.
Vaccines (Basel), 2021 Jul 03; 9(7). PMID: 34201650    Free PMC article.
Review.
The Effectiveness and Safety of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Stage III/IV: A Multicenter Study.
Jason C Hsu, Phung-Anh Nguyen, +18 authors, Christine Y Lu.
Front Oncol, 2021 Jul 27; 11. PMID: 34307141    Free PMC article.
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation.
Michele Maio, Michael Lahn, +5 authors, Siena Think Tank.
J Exp Clin Cancer Res, 2021 Jul 25; 40(1). PMID: 34301276    Free PMC article.
Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors.
Sarah J Dart, Alistair M Cook, +5 authors, Samantha E Bowyer.
Sci Rep, 2021 Jul 30; 11(1). PMID: 34321489    Free PMC article.
Genetic evidence for the causal association between programmed death-ligand 1 and lung cancer.
Zhao Yang, Rong Yu, Wei Deng, Weihu Wang.
J Cancer Res Clin Oncol, 2021 Jul 30; 147(11). PMID: 34324065
The Risk of Immune-Related Thyroid Dysfunction Induced by PD-1/PD-L1 Inhibitors in Cancer Patients: An Updated Systematic Review and Meta-Analysis.
Yuan Tian, Ran Li, +7 authors, Yuping Sun.
Front Oncol, 2021 Jul 30; 11. PMID: 34322382    Free PMC article.
Systematic Review.
The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020.
Qiaofeng Zhong, Yunxia Tao, +4 authors, Yuankai Shi.
Lancet Reg Health West Pac, 2021 Jul 31; 11. PMID: 34327360    Free PMC article.
Emerging role of circulating tumor cells in immunotherapy.
Alexey Rzhevskiy, Alina Kapitannikova, +7 authors, Majid Ebrahimi Warkiani.
Theranostics, 2021 Aug 03; 11(16). PMID: 34335980    Free PMC article.
Review.
A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma.
Cheong E Von, Ho Gwo Fuang.
Respir Med Case Rep, 2021 Aug 03; 34. PMID: 34336591    Free PMC article.
Prospective Multicenter Study of Chemotherapy-Induced Clostridium (Clostridioides) difficile Infection in Patients With Lung Cancer: North Japan Lung Cancer Study Group Trial 1204.
Yukihiro Toi, Takao Kobayashi, +4 authors, Shunichi Sugawara.
Front Oncol, 2021 Aug 03; 11. PMID: 34336670    Free PMC article.
Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy.
Houhui Shi, Kai Li, +2 authors, Xia Zhao.
Front Cell Dev Biol, 2021 Aug 03; 9. PMID: 34336860    Free PMC article.
Review.
Dramatic response to pembrolizumab with chemotherapy followed by salvage surgery in a lung cancer patient.
Shunichi Saito, Gouji Toyokawa, +4 authors, Sadanori Takeo.
Thorac Cancer, 2021 Jun 22; 12(15). PMID: 34151529    Free PMC article.
Clinical efficacy and safety of maintenance therapy for advanced non-small cell lung cancer: a retrospective real-world study.
Xiangwei Xu, Ruya Li, +4 authors, Yinqiao Chen.
World J Surg Oncol, 2021 Aug 08; 19(1). PMID: 34362384    Free PMC article.
Anti-programmed cell death ligand 1-based immunotherapy in recurrent hepatocellular carcinoma with inferior vena cava tumor thrombus and metastasis: Three case reports.
Shao-Ru Liu, Qing Yan, +5 authors, Rui Zhang.
World J Clin Cases, 2021 Aug 10; 9(21). PMID: 34368318    Free PMC article.
IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer.
Stephen P Hack, Wendy Verret, +6 authors, Andrew X Zhu.
Ther Adv Med Oncol, 2021 Aug 12; 13. PMID: 34377158    Free PMC article.
Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer.
Angel R Baroz, Isa Mambetsariev, +6 authors, Ravi Salgia.
Cureus, 2021 Aug 12; 13(7). PMID: 34377604    Free PMC article.
Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models.
Vasilios Liapis, William Tieu, +7 authors, Alexander H Staudacher.
Mol Imaging Biol, 2021 Jul 08; 23(6). PMID: 34231102    Free PMC article.
Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer.
Chia-I Shen, Heng-Sheng Chao, +5 authors, Yuh-Min Chen.
Sci Rep, 2021 Aug 11; 11(1). PMID: 34373555    Free PMC article.
Pyroptosis, a New Breakthrough in Cancer Treatment.
Dengqiang Wu, Changhong Wei, +2 authors, Sufang Zhou.
Front Oncol, 2021 Aug 13; 11. PMID: 34381721    Free PMC article.
Review.
Prolonged Complete Response of Early Stage Primary Adenocarcinoma of the Lung to Nivolumab Monotherapy.
Serhan Unlu, Michael J Grant, +2 authors, Harriet M Kluger.
Clin Oncol Case Rep, 2021 Aug 13; 4(1). PMID: 34382032    Free PMC article.
Toward personalized treatment approaches for non-small-cell lung cancer.
Meina Wang, Roy S Herbst, Chris Boshoff.
Nat Med, 2021 Aug 14; 27(8). PMID: 34385702
Review.
Current status and quality of radiomic studies for predicting immunotherapy response and outcome in patients with non-small cell lung cancer: a systematic review and meta-analysis.
Qiuying Chen, Lu Zhang, +7 authors, Shuixing Zhang.
Eur J Nucl Med Mol Imaging, 2021 Aug 18; 49(1). PMID: 34402924
Systematic Review.
Febrile neutropenia in a patient with non-small-cell lung cancer treated with atezolizumab: A case report.
Kyosuke Seguchi, Kei Nakashima, +3 authors, Yu Tanaka.
Respir Med Case Rep, 2021 Aug 18; 33. PMID: 34401279    Free PMC article.
Dramatic response to osimertinib combined with crizotinib in EGFR T790 M mutation only in blood and Met amplification only in tumor tissue expressive non-small cell lung cancer: A case report.
Dapeng Li, Qi Gui, +2 authors, Kai Chen.
Medicine (Baltimore), 2021 Aug 17; 100(30). PMID: 34397683    Free PMC article.
Maintenance treatment of combination with bevacizumab vs single agent for advanced non-squamous non-small cell lung cancer: A systematic review and meta-analysis.
Ying Kong, Liang Hong, Xiaocheng Xu, Jia Xu.
Medicine (Baltimore), 2021 Aug 17; 100(31). PMID: 34397863    Free PMC article.
Systematic Review.
Pathological Complete Response after Immune-Checkpoint Inhibitor Followed by Salvage Surgery for Clinical Stage IV Pulmonary Adenocarcinoma with Continuous Low Neutrophil-to-Lymphocyte Ratio: A Case Report.
Mitsunori Higuchi, Takahiro Kawamata, +5 authors, Hiroyuki Suzuki.
Case Rep Oncol, 2021 Aug 21; 14(2). PMID: 34413743    Free PMC article.
Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open-label phase 2 study (CLEAR).
Hibiki Udagawa, Eri Sugiyama, +17 authors, Koichi Goto.
Transl Lung Cancer Res, 2021 Aug 26; 10(7). PMID: 34430347    Free PMC article.
Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV.
Wolfgang M Brueckl, Martin Reck, +11 authors, Eckart Laack.
Transl Lung Cancer Res, 2021 Aug 26; 10(7). PMID: 34430350    Free PMC article.
Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?-a trial-level meta-analysis in PD-L1 selected subgroups.
Francesco Passiglia, Antonio Galvano, +6 authors, Viviana Bazan.
Transl Lung Cancer Res, 2021 Aug 26; 10(7). PMID: 34430351    Free PMC article.
A narrative review of primary research endpoints of neoadjuvant therapy for lung cancer: past, present and future.
Sijia Ren, Anyi Xu, +8 authors, Jianfei Shen.
Transl Lung Cancer Res, 2021 Aug 26; 10(7). PMID: 34430363    Free PMC article.
Review.
Local ablative therapies in oligometastatic NSCLC-upfront or outback?-a narrative review.
Michael C Tjong, Alexander V Louie, +3 authors, Shankar Siva.
Transl Lung Cancer Res, 2021 Aug 26; 10(7). PMID: 34430379    Free PMC article.
Review.
Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study.
Romualdo Barroso-Sousa, Tanya E Keenan, +13 authors, Sara M Tolaney.
NPJ Breast Cancer, 2021 Aug 27; 7(1). PMID: 34433812    Free PMC article.
The current issues and future perspective of artificial intelligence for developing new treatment strategy in non-small cell lung cancer: harmonization of molecular cancer biology and artificial intelligence.
Ichidai Tanaka, Taiki Furukawa, Masahiro Morise.
Cancer Cell Int, 2021 Aug 28; 21(1). PMID: 34446006    Free PMC article.
Review.
Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials.
Yang Ge, Huiyun Zhang, Nathaniel Weygant, Jiannan Yao.
Front Pharmacol, 2021 Aug 28; 12. PMID: 34447305    Free PMC article.
PD-L1 Expression in Non-Small Cell Lung Cancer: Data from a Referral Center in Spain.
Karmele Saez de Gordoa, Ingrid Lopez, +5 authors, Cristina Teixido.
Diagnostics (Basel), 2021 Aug 28; 11(8). PMID: 34441386    Free PMC article.
Predictive Role of Prior Radiotherapy and Immunotherapy-Related Adverse Effects in Advanced NSCLC Patients Receiving Anti-PD-1/L1 Therapy.
Jeong Uk Lim, Soo Han Kim, +6 authors, Chang Min Choi.
J Clin Med, 2021 Aug 28; 10(16). PMID: 34442015    Free PMC article.
Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs.
Atsuto Mouri, Kyoichi Kaira, +7 authors, Hiroshi Kagamu.
J Clin Med, 2021 Aug 28; 10(16). PMID: 34442054    Free PMC article.
Photodynamic Therapy and Hyperthermia in Combination Treatment-Neglected Forces in the Fight against Cancer.
Aleksandra Bienia, Olga Wiecheć-Cudak, Aleksandra Anna Murzyn, Martyna Krzykawska-Serda.
Pharmaceutics, 2021 Aug 29; 13(8). PMID: 34452108    Free PMC article.
Review.
Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data.
Tigran Makunts, Ila M Saunders, +7 authors, Ruben Abagyan.
Sci Rep, 2021 Sep 01; 11(1). PMID: 34462476    Free PMC article.
Combination strategies of immunotherapy in non-small cell lung cancer: facts and challenges.
Chu-Ling Li, Yong Song.
Chin Med J (Engl), 2021 Aug 04; 134(16). PMID: 34343148    Free PMC article.
The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
Chengdi Wang, Jingwei Li, +5 authors, Yalun Li.
BMC Cancer, 2021 Aug 30; 21(1). PMID: 34454455    Free PMC article.
Efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non-small cell lung cancer (NSCLC).
Ziyi Xu, Teng Li, +3 authors, Junling Li.
Thorac Cancer, 2021 Jul 17; 12(17). PMID: 34268872    Free PMC article.
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
Paul K Paik, Enriqueta Felip, +32 authors, Xiuning Le.
N Engl J Med, 2020 May 30; 383(10). PMID: 32469185    Free PMC article.
Prognostic significance of volume-based 18F-FDG PET/CT parameters and correlation with PD-L1 expression in patients with surgically resected lung adenocarcinoma.
Dalong Wang, Yingci Li, Xiaolin Chen, Ping Li.
Medicine (Baltimore), 2021 Sep 04; 100(35). PMID: 34477147    Free PMC article.
Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer.
Wei Xiong, Yunfeng Zhao, He Du, Xuejun Guo.
Front Oncol, 2021 Sep 08; 11. PMID: 34490104    Free PMC article.
Review.
Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
G Mountzios, E Samantas, +39 authors, P Christopoulos.
ESMO Open, 2021 Sep 05; 6(5). PMID: 34481329    Free PMC article.
Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study.
Kenji Morimoto, Junji Uchino, +16 authors, Koichi Takayama.
J Cancer Res Clin Oncol, 2021 Sep 13;. PMID: 34510271
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial.
Belén Sierra-Rodero, Alberto Cruz-Bermúdez, +23 authors, Mariano Provencio.
J Immunother Cancer, 2021 Aug 28; 9(8). PMID: 34446577    Free PMC article.
Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges.
Shu-Jin Li, Jia-Xian Chen, Zhi-Jun Sun.
Cancer Commun (Lond), 2021 Jun 18; 41(9). PMID: 34137513    Free PMC article.
Review.
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial.
Yuankai Shi, Kaijian Lei, +73 authors, Can Wu.
Cancer Commun (Lond), 2021 Jun 30; 41(9). PMID: 34184418    Free PMC article.
The Neutrophil-to-Lymphocyte Ratio (NLR) Predicts the Prognosis of Unresectable Intermediate and Advanced Hepatocellular Carcinoma Treated with Apatinib.
Huaqi Wang, Zhiwei Wang, +6 authors, Ti Zhang.
Cancer Manag Res, 2021 Sep 16; 13. PMID: 34522141    Free PMC article.
The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy.
David M Briere, Shuai Li, +13 authors, Peter Olson.
Mol Cancer Ther, 2021 Mar 17; 20(6). PMID: 33722854    Free PMC article.
Non-Small Cell Lung Cancer: Challenge and Improvement of Immune Drug Resistance.
Fanming Kong, Ziwei Wang, +4 authors, Yingjie Jia.
Front Oncol, 2021 Sep 18; 11. PMID: 34532293    Free PMC article.
Review.
Predicted outcomes of subdividing M1-stage metastatic lung cancer based on the prognosis and the response to local consolidative therapy.
Fang Wang, Jiani Gao, +4 authors, Chang Chen.
Ann Transl Med, 2021 Sep 18; 9(16). PMID: 34532430    Free PMC article.
Immune checkpoint inhibitor combined with anti-angiogenesis agent inhibits metastasis of advanced adenoid cystic carcinoma of the tongue base to the lung: a case report.
Ke Zhang, Hui Wang, Juemin Fang, Qing Xu.
Ann Transl Med, 2021 Sep 18; 9(16). PMID: 34532490    Free PMC article.
EGFR mutation status in non-small cell lung cancer receiving PD-1/PD-L1 inhibitors and its correlation with PD-L1 expression: a meta-analysis.
Huimin Yang, Jinxiu Zhu, +5 authors, Fei He.
Cancer Immunol Immunother, 2021 Sep 21; 71(5). PMID: 34542660
ER expression associates with poor prognosis in male lung squamous carcinoma after radical resection.
Xue Yang, Xiangfeng Jin, +2 authors, Ning An.
BMC Cancer, 2021 Sep 23; 21(1). PMID: 34548052    Free PMC article.
Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions.
Chie Morita, Tatsuya Yoshida, +11 authors, Yuichiro Ohe.
Sci Rep, 2021 Sep 23; 11(1). PMID: 34548567    Free PMC article.
Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer.
Taichi Miyawaki, Tateaki Naito, +14 authors, Toshiaki Takahashi.
Support Care Cancer, 2021 Sep 23; 30(2). PMID: 34550461
Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition.
Marcel Kemper, Georg Evers, +7 authors, Annalen Bleckmann.
Oncotarget, 2021 Sep 23; 12(19). PMID: 34548910    Free PMC article.
Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study.
Mark M Awad, Yvan Le Bruchec, +7 authors, Alexander Spira.
Front Oncol, 2021 Sep 24; 11. PMID: 34552864    Free PMC article.
The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies.
Hasan Baysal, Ines De Pauw, +5 authors, An Wouters.
Front Immunol, 2021 Sep 25; 12. PMID: 34557197    Free PMC article.
Review.
The Predictive Value of Clinical and Molecular Characteristics or Immunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
Yangyang Xu, Qin Wang, +5 authors, Yong Song.
Front Oncol, 2021 Sep 25; 11. PMID: 34557415    Free PMC article.
Systematic Review.
Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with chemo-immunotherapy or immunotherapy as first-line therapy.
Dongyup Lee, Jonghanne Park, +9 authors, Young Kwang Chae.
Heliyon, 2021 Sep 28; 7(9). PMID: 34568594    Free PMC article.
The best regimens for chemo-naïve incurable non-squamous non-small cell lung cancer with a programmed death-ligand 1, tumor proportion score 1-49%: a network meta-analysis.
Nobuhiko Fukuda, Nobuyuki Horita, +8 authors, Takeshi Kaneko.
Transl Lung Cancer Res, 2021 Sep 30; 10(8). PMID: 34584856    Free PMC article.
Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population.
Rocío Jiménez Galán, Elena Prado-Mel, +2 authors, Sandra Flores Moreno.
Biology (Basel), 2021 Sep 29; 10(9). PMID: 34571767    Free PMC article.
NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images.
Virginia Liberini, Annapaola Mariniello, +7 authors, Désirée Deandreis.
Cancers (Basel), 2021 Sep 29; 13(18). PMID: 34572771    Free PMC article.
Review.
Improving Biologics' Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures.
Christel Larbouret, Laurent Gros, André Pèlegrin, Thierry Chardès.
Cancers (Basel), 2021 Sep 29; 13(18). PMID: 34572847    Free PMC article.
Review.
From Anti-PD-1/PD-L1 to CTLA-4 and to MUC1-Is the Better Response to Treatment in Smokers of Cancer Patients Drug Specific?
Lishi Wang, Fengxia Liu, +13 authors, Jiafu Ji.
J Pers Med, 2021 Sep 29; 11(9). PMID: 34575691    Free PMC article.
Review.
Combination strategies to maximize the benefits of cancer immunotherapy.
Shaoming Zhu, Tian Zhang, +5 authors, Chong-Xian Pan.
J Hematol Oncol, 2021 Sep 29; 14(1). PMID: 34579759    Free PMC article.
Review.
Dramatic Response to Teriprilumab and Anlotinib Combination Therapy in a patient with EGFR-Mutant Lung Adenocarcinoma Who Experienced Small-Cell Transformation-Mediated Erlotinib Resistance After Failure of Chemotherapy.
Yuling Zhou, Liang Zeng, Nong Yang, Yongchang Zhang.
JTO Clin Res Rep, 2020 Feb 11; 1(2). PMID: 34589923    Free PMC article.
Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial.
James Chih-Hsin Yang, Tony S K Mok, +7 authors, Tomohide Tamura.
JTO Clin Res Rep, 2021 Oct 01; 2(3). PMID: 34590001    Free PMC article.
Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC.
Thomas A Hensing, Xiaofei Wang, +10 authors, Everett E Vokes.
JTO Clin Res Rep, 2021 Oct 01; 2(8). PMID: 34590049    Free PMC article.
Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis.
Alessandro Di Federico, Andrea De Giglio, +3 authors, Andrea Ardizzoni.
JTO Clin Res Rep, 2021 Oct 01; 2(9). PMID: 34590054    Free PMC article.
Immune checkpoints and immunotherapy in non-small cell lung cancer: Novel study progression, challenges and solutions.
Lin-Rui Ma, Jia-Xin Li, +5 authors, Pei-Yu Yan.
Oncol Lett, 2021 Oct 02; 22(5). PMID: 34594428    Free PMC article.
Review.
Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations.
Vincent Lemaire, Colby S Shemesh, Anand Rotte.
J Exp Clin Cancer Res, 2021 Oct 03; 40(1). PMID: 34598713    Free PMC article.
Review.
Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis.
Koichi Miyashita, Masato Karayama, +19 authors, Takafumi Suda.
BMC Pulm Med, 2021 Oct 04; 21(1). PMID: 34600514    Free PMC article.
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.
Alexander Drilon, Jeffrey W Clark, +18 authors, Paul K Paik.
Nat Med, 2020 Jan 15; 26(1). PMID: 31932802    Free PMC article.
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health.
Elaine Chang, Lorraine Pelosof, +15 authors, Marc R Theoret.
Oncologist, 2021 Jul 02; 26(10). PMID: 34196068    Free PMC article.
Review.
Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer.
Peter W Szlosarek, Akhila G Wimalasingham, +15 authors, Michael Sheaff.
Cancer Med, 2021 Aug 13; 10(19). PMID: 34382365    Free PMC article.
Arsenic sulfide reverses cisplatin resistance in non-small cell lung cancer in vitro and in vivo through targeting PD-L1.
Wei Tian, Yinping Sun, +4 authors, Qisen Guo.
Thorac Cancer, 2021 Sep 02; 12(19). PMID: 34469060    Free PMC article.
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.
M Reck, T-E Ciuleanu, +24 authors, T John.
ESMO Open, 2021 Oct 05; 6(5). PMID: 34607285    Free PMC article.
Cardiac Toxicity Associated with Cancer Immunotherapy and Biological Drugs.
Andrea Montisci, Maria Teresa Vietri, +3 authors, Claudio Napoli.
Cancers (Basel), 2021 Oct 14; 13(19). PMID: 34638281    Free PMC article.
Review.
The Role of Immunotherapy in the Treatment of Advanced Cervical Cancer: Current Status and Future Perspectives.
Robert J Walsh, David S P Tan.
J Clin Med, 2021 Oct 14; 10(19). PMID: 34640541    Free PMC article.
Review.
PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis.
María Rosario García Campelo, Edurne Arriola, +8 authors, Delvys Rodríguez-Abreu.
J Clin Med, 2021 Oct 14; 10(19). PMID: 34640601    Free PMC article.
Review.
First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 ≥ 50%: a systematic review and network meta-analysis.
Mingfeng He, Taihao Zheng, +5 authors, Zhenzhou Yang.
Cancer Immunol Immunother, 2021 Oct 18; 71(6). PMID: 34657171
Systematic Review.
Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Enriqueta Felip, Mauricio Burotto, +12 authors, Eleonora Restuccia.
Clin Pharmacol Drug Dev, 2021 Apr 01; 10(10). PMID: 33788415    Free PMC article.
Role of sex hormones in lung cancer.
Nathalie Fuentes, Miguel Silva Rodriguez, Patricia Silveyra.
Exp Biol Med (Maywood), 2021 Jun 04; 246(19). PMID: 34080912    Free PMC article.
Review.
Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies.
V Di Noia, A D'Aveni, +6 authors, G L Ceresoli.
ESMO Open, 2021 Oct 12; 6(6). PMID: 34634633    Free PMC article.
Review.
Direct Comparison Between the Addition of Pembrolizumab or Bevacizumab for Chemotherapy-Based First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer Lacking Driver Mutations.
Jiatao Liao, Chang Liu, +8 authors, Jialei Wang.
Front Oncol, 2021 Oct 19; 11. PMID: 34660317    Free PMC article.
Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407.
Ying Cheng, Li Zhang, +15 authors, Luis Paz-Ares.
JTO Clin Res Rep, 2021 Oct 19; 2(10). PMID: 34661177    Free PMC article.
[Peripheral Blood Inflammation Indicators as Predictive Indicators in 
Immunotherapy of Advanced Non-small Cell Lung Cancer].
Jingwei Xia, Yuzhong Chen, +2 authors, Bo Shen.
Zhongguo Fei Ai Za Zhi, 2021 Sep 16; 24(9). PMID: 34521188    Free PMC article.
Immunotherapeutic Advances for NSCLC.
Marco Massafra, Maria Ilenia Passalacqua, +6 authors, Mariacarmela Santarpia.
Biologics, 2021 Oct 23; 15. PMID: 34675481    Free PMC article.
Review.
Research Progress and Challenges in the Treatment of Central Nervous System Metastasis of Non-Small Cell Lung Cancer.
Bin Wang, Hanfei Guo, +3 authors, Gang Zhao.
Cells, 2021 Oct 24; 10(10). PMID: 34685600    Free PMC article.
Review.
Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition-overall survival modeling framework.
Phyllis Chan, Mathilde Marchand, +8 authors, René Bruno.
CPT Pharmacometrics Syst Pharmacol, 2021 Jul 17; 10(10). PMID: 34270868    Free PMC article.
Reporting quality of randomized, controlled trials evaluating immunotherapy in lung cancer.
Jun Du, Yundi Zhang, +5 authors, Zhijie Wang.
Thorac Cancer, 2021 Aug 26; 12(20). PMID: 34432361    Free PMC article.
The Abscopal Effect: A Review of Pre-Clinical and Clinical Advances.
James R Janopaul-Naylor, Yang Shen, David C Qian, Zachary S Buchwald.
Int J Mol Sci, 2021 Oct 24; 22(20). PMID: 34681719    Free PMC article.
Review.
Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer.
Tomonari Kinoshita, Hideki Terai, Tomonori Yaguchi.
Life (Basel), 2021 Oct 24; 11(10). PMID: 34685400    Free PMC article.
Review.
Atezolizumab-associated Dermatomyositis in Advanced Small-cell Lung Carcinoma.
Yoshitaka Yamaguchi, Mari Aso, Hikaru Nagasawa, Manabu Wada.
Intern Med, 2021 Mar 30; 60(18). PMID: 33776010    Free PMC article.
Successful Re-administration of Atezolizumab for a Non-small-cell Lung Cancer Patient after Cardiac Tamponade Development as a Manifestation of Pseudo-progression Induced by Combination Treatment with Atezolizumab and Cytotoxic Chemotherapy.
Koki Nakashima, Yoshiki Demura, +3 authors, Tamotsu Ishizuka.
Intern Med, 2021 Apr 06; 60(18). PMID: 33814492    Free PMC article.
Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150.
Ashley M Hopkins, Ganessan Kichenadasse, +6 authors, Michael J Sorich.
Br J Cancer, 2021 Oct 30; 126(1). PMID: 34711947    Free PMC article.
Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region.
Colby S Shemesh, Phyllis Chan, +5 authors, Benjamin Wu.
Liver Cancer, 2021 Nov 02; 10(5). PMID: 34721510    Free PMC article.
Chronic Pleuritis and Recurrent Pleural Effusion After Atezolizumab for Small Cell Lung Cancer.
Julie Lin, Bruce Fernando Sabath.
Am J Case Rep, 2021 Oct 05; 22. PMID: 34606491    Free PMC article.
Cisplatin or carboplatin for advanced non-small cell lung cancer: does it really matter?
Meghana Kesireddy, Apar Kishor Ganti.
Transl Lung Cancer Res, 2021 Nov 05; 10(9). PMID: 34733621    Free PMC article.
Immune checkpoint inhibitors for first-line treatment of advanced non-small-cell lung cancer: A systematic review and network meta-analysis.
Tzu-Rong Peng, Hung-Hong Lin, Fang-Pei Tsai, Ta-Wei Wu.
Thorac Cancer, 2021 Sep 22; 12(21). PMID: 34545685    Free PMC article.
Systematic Review.
Prognostic impact of chronological age on efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: Real-world data from 86 173 patients.
Shinkichi Takamori, Mototsugu Shimokawa, Takefumi Komiya.
Thorac Cancer, 2021 Oct 07; 12(21). PMID: 34612011    Free PMC article.
Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness.
Daniel Hirschhorn, Allison Betof Warner, +11 authors, Jedd D Wolchok.
JCI Insight, 2021 Oct 23; 6(20). PMID: 34676831    Free PMC article.
Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer.
Ashwin Somasundaram, Mark A Socinski, Liza C Villaruz.
Drugs, 2020 May 22; 80(9). PMID: 32436070    Free PMC article.
Review.
[Response of Lung Adenocarcinoma Harbouring Sensitizing EGFR Mutation
to the Fourth-line Combination Treatment of Pembrolizumab and Anlotinib].
Liling Huang, Yan Qin, +2 authors, Yuankai Shi.
Zhongguo Fei Ai Za Zhi, 2021 Oct 11; 24(10). PMID: 34628779    Free PMC article.
Immunotherapy for Stage III NSCLC: Durvalumab and Beyond.
Orla Fitzpatrick, Jarushka Naidoo.
Lung Cancer (Auckl), 2021 Nov 11; 12. PMID: 34754256    Free PMC article.
Review.
Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11-13 2019, Verona, Italy.
Matteo Bellone, Marco Bregni, +9 authors, Mario P Colombo.
Cancer Immunol Immunother, 2021 Nov 11; 71(7). PMID: 34755203    Free PMC article.
Peritumoral CD90+CD73+ cells possess immunosuppressive features in human non-small cell lung cancer.
Limei Wang, Haitang Yang, +10 authors, Sean R R Hall.
EBioMedicine, 2021 Nov 06; 73. PMID: 34740105    Free PMC article.
Bayesian Design for Identifying Cohort-Specific Optimal Dose Combinations Based on Multiple Endpoints: Application to a Phase I Trial in Non-Small Cell Lung Cancer.
Bethany Jablonski Horton, Nolan A Wages, Ryan D Gentzler.
Int J Environ Res Public Health, 2021 Nov 14; 18(21). PMID: 34769970    Free PMC article.
Do Lipid-based Nanoparticles Hold Promise for Advancing the Clinical Translation of Anticancer Alkaloids?
Jian Sheng Loh, Li Kar Stella Tan, +6 authors, Yong Sze Ong.
Cancers (Basel), 2021 Nov 14; 13(21). PMID: 34771511    Free PMC article.
Review.
The Dual Effect of the BMP9-ALK1 Pathway in Blood Vessels: An Opportunity for Cancer Therapy Improvement?
Blanca Ayuso-Íñigo, Lucía Méndez-García, Miguel Pericacho, José M Muñoz-Félix.
Cancers (Basel), 2021 Nov 14; 13(21). PMID: 34771575    Free PMC article.
Review.
Synchronous Primary Lung Adenocarcinoma and Hepatocellular Carcinoma Successfully Treated with a Combination of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel.
Takashi Egawa, Keita Masuzawa, +4 authors, Yusuke Suzuki.
Intern Med, 2021 Apr 13; 60(20). PMID: 33840693    Free PMC article.
Clinical observation of the efficacy of PD-1/PD-L1 inhibitors in the treatment of patients with advanced solid tumors.
Miao Wang, Hongchao Zhen, +4 authors, Qin Li.
Immun Inflamm Dis, 2021 Aug 19; 9(4). PMID: 34407323    Free PMC article.
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial.
Patrick A Ott, Matthew Nazzaro, +12 authors, F Stephen Hodi.
J Immunother Cancer, 2021 Nov 14; 9(11). PMID: 34772758    Free PMC article.
Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients.
Ryota Nakamura, Tadaaki Yamada, +17 authors, Koichi Takayama.
J Cancer Res Clin Oncol, 2021 Nov 27;. PMID: 34825950
Clinical Management and Outcome of Grade III Pneumonitis after Chemoradioimmunotherapy for Inoperable Stage III Non-Small Cell Lung Cancer-A Prospective Longitudinal Assessment.
Diego Kauffmann-Guerrero, Julian Taugner, +4 authors, Farkhad Manapov.
Diagnostics (Basel), 2021 Nov 28; 11(11). PMID: 34829315    Free PMC article.
Bridging Radiotherapy to Immunotherapy: The IFN-JAK-STAT Axis.
Lewis Zhichang Shi, James A Bonner.
Int J Mol Sci, 2021 Nov 28; 22(22). PMID: 34830176    Free PMC article.
Systematic Review.
Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients.
Ting Yoon Kwan, Ezharul Hoque Chowdhury.
Medicina (Kaunas), 2021 Nov 28; 57(11). PMID: 34833470    Free PMC article.
Review.
First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Results of the NEPTUN study.
Tobias Dechow, Jorge Riera-Knorrenschild, +9 authors, Karin Potthoff.
Cancer Med, 2021 Oct 21; 10(22). PMID: 34668662    Free PMC article.
Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in non-small cell lung cancer: association with clinicopathologic parameters.
Gaurav Garg, Kuruswamy Thurai Prasad, +4 authors, Amanjit Bal.
J Pathol Transl Med, 2021 Oct 06; 55(6). PMID: 34610234    Free PMC article.
[Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer].
Chuan Huang, Xue Yang.
Zhongguo Fei Ai Za Zhi, 2021 Nov 22; 24(11). PMID: 34802209    Free PMC article.
Review.
Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Alberto Bongiovanni, Flavia Foca, +12 authors, Toni Ibrahim.
Front Immunol, 2021 Dec 04; 12. PMID: 34858389    Free PMC article.
The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with Mycobacterium tuberculosis infection.
Jinpeng Shi, Jiayu Li, +13 authors, Caicun Zhou.
Transl Lung Cancer Res, 2021 Dec 04; 10(10). PMID: 34858782    Free PMC article.
Efficacy and Safety of Different Doses of Bevacizumab Combined With Pemetrexed and Platinum in First-Line Treatment of Advanced NSCLC: A Retrospective-Real World Study.
Chun-Hua Zhou, Feng Yang, +8 authors, Nong Yang.
Front Pharmacol, 2021 Dec 07; 12. PMID: 34867332    Free PMC article.
Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies.
Jessica Waibl Polania, Emily C Lerner, +2 authors, Peter E Fecci.
Front Immunol, 2021 Dec 07; 12. PMID: 34868044    Free PMC article.
Review.
Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer.
Nathaniel Wiest, Umair Majeed, +3 authors, Rami Manochakian.
Front Oncol, 2021 Dec 07; 11. PMID: 34868953    Free PMC article.
Review.
Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer.
Joao V Alessi, Biagio Ricciuti, +13 authors, Mark M Awad.
J Immunother Cancer, 2021 Nov 27; 9(11). PMID: 34824161    Free PMC article.
First-Line Pembrolizumab Mono- or Combination Therapy of Non-Small Cell Lung Cancer: Baseline Metabolic Biomarkers Predict Outcomes.
David Lang, Linda Ritzberger, +7 authors, Michael Gabriel.
Cancers (Basel), 2021 Dec 11; 13(23). PMID: 34885206    Free PMC article.
Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China.
Anwen Xiong, Jiali Wang, Caicun Zhou.
Front Oncol, 2021 Dec 14; 11. PMID: 34900707    Free PMC article.
Review.
Low Carbohydrate Diets in Cancer Therapeutics: Current Evidence.
Christopher Haskins, Justin Cohen, Rupesh Kotecha, Adeel Kaiser.
Front Nutr, 2021 Dec 14; 8. PMID: 34901101    Free PMC article.
Review.
Targeting EGFR Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates.
Catherine B Meador, Lecia V Sequist, Zofia Piotrowska.
Cancer Discov, 2021 Jul 25; 11(9). PMID: 34301786    Free PMC article.
Review.
Immunotherapy in the First-Line Setting in Wild-Type NSCLC.
Marie-Hélène Denault, Barbara Melosky.
Curr Oncol, 2021 Dec 14; 28(6). PMID: 34898579    Free PMC article.
Review.
Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies.
Ellen Cusano, Chelsea Wong, +7 authors, Doreen Ezeife.
Curr Oncol, 2021 Dec 14; 28(6). PMID: 34898590    Free PMC article.
Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights.
Catherine B Meador, Aaron N Hata.
Pharmacol Ther, 2020 Mar 11; 210. PMID: 32151666    Free PMC article.
Review.
New challenges in the combination of radiotherapy and immunotherapy in non-small cell lung cancer.
Javier Luna, Juan Zafra, +7 authors, Felipe Couñago.
World J Clin Oncol, 2021 Dec 16; 12(11). PMID: 34909394    Free PMC article.
Review.
A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors.
Amit M Oza, François Dubois, +8 authors, Nicoletta Colombo.
Oncologist, 2021 Sep 10; 26(12). PMID: 34498344    Free PMC article.
Influence of GSTP1 Polymorphism on the Clinical Outcomes of Patients With Advanced NSCLC Receiving First-Line Bevacizumab-Based Regimen: A Real-World Retrospective Study.
Fei Han, Hanji Tian, Baoli Jin, Gang Chen.
Clin Med Insights Oncol, 2021 Dec 21; 15. PMID: 34924779    Free PMC article.
Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR.
Karan Seegobin, Umair Majeed, +3 authors, Yujie Zhao.
Front Oncol, 2021 Dec 21; 11. PMID: 34926258    Free PMC article.
Review.
A cascade targeting strategy based on modified bacterial vesicles for enhancing cancer immunotherapy.
Yuewen Zhai, Yuying Ma, +8 authors, Siwen Li.
J Nanobiotechnology, 2021 Dec 22; 19(1). PMID: 34930285    Free PMC article.
Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors.
Christian U Blank, Deborah J Wong, +7 authors, Mario Sznol.
Curr Oncol, 2021 Dec 24; 28(6). PMID: 34940094    Free PMC article.
Microscale thermophoresis analysis of the molecular interaction between small nuclear ribonucleoprotein polypeptide G and the RING finger domain of RBBP6 towards anti-cancer drug discovery.
Lloyd Mabonga, Priscilla Masamba, Albertus Kotze Basson, Abidemi Paul Kappo.
Am J Transl Res, 2021 Dec 28; 13(11). PMID: 34956492    Free PMC article.
Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer.
Szu-Chun Yang, Natalia Kunst, +3 authors, Shi-Yi Wang.
Front Oncol, 2021 Dec 28; 11. PMID: 34956882    Free PMC article.
First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology.
C Gridelli, S Peters, +4 authors, F de Marinis.
ESMO Open, 2021 Dec 19; 7(1). PMID: 34922299    Free PMC article.
Review.
Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met?
Diego L Kaen, Nicolas Minatta, +3 authors, Christian Rolfo.
Adv Exp Med Biol, 2022 Jan 02; 1342. PMID: 34972964
Review.
Anti‑VEGF antibody triggers the effect of anti‑PD‑L1 antibody in PD‑L1low and immune desert‑like mouse tumors.
Nobuyuki Ishikura, Masamichi Sugimoto, +2 authors, Osamu Kondoh.
Oncol Rep, 2021 Dec 28; 47(2). PMID: 34958105    Free PMC article.
Tumor metastasis: Mechanistic insights and therapeutic interventions.
Mengmeng Liu, Jing Yang, Bushu Xu, Xing Zhang.
MedComm (2020), 2022 Jan 04; 2(4). PMID: 34977870    Free PMC article.
Review.
Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy.
Yuan Cheng, Tao Zhang, Qing Xu.
MedComm (2020), 2022 Jan 04; 2(4). PMID: 34977873    Free PMC article.
Review.
Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier.
Somayeh Vafaei, Angelina O Zekiy, +4 authors, Majid Zamani.
Cancer Cell Int, 2022 Jan 05; 22(1). PMID: 34980128    Free PMC article.
Review.
Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models.
Amaia Martinez-Usatorre, Ece Kadioglu, +10 authors, Michele De Palma.
Sci Transl Med, 2021 Aug 13; 13(606). PMID: 34380768    Free PMC article.
Patient-Derived Explants as a Precision Medicine Patient-Proximal Testing Platform Informing Cancer Management.
Abby R Templeton, Penny L Jeffery, +10 authors, Elizabeth D Williams.
Front Oncol, 2022 Jan 07; 11. PMID: 34988013    Free PMC article.
Review.
Assessment of Treatment Effects and Long-term Benefits in Immune Checkpoint Inhibitor Trials Using the Flexible Parametric Cure Model: A Systematic Review.
Thomas Filleron, Marine Bachelier, +7 authors, Jean-Pierre Delord.
JAMA Netw Open, 2021 Dec 22; 4(12). PMID: 34932105    Free PMC article.
Systematic Review.
Cost-Effectiveness Analysis of Camrelizumab Plus Chemotherapy vs. Chemotherapy Alone as the First-Line Treatment in Patients With IIIB-IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Without EGFR and ALK Alteration from a Perspective of Health - Care System in China.
Chen Zhu, Xiao-Xuan Xing, +4 authors, Hong-Mei Fang.
Front Pharmacol, 2022 Jan 11; 12. PMID: 35002693    Free PMC article.
PD-L1 Expression in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Multi-Center Retrospective Observational Study.
Xin Yang, Lili Jiang, +16 authors, Dongmei Lin.
J Cancer, 2022 Jan 11; 12(24). PMID: 35003359    Free PMC article.
Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy.
Yi Sun, Wei Chen, +20 authors, Yuwen Zhu.
Sci Transl Med, 2021 Jul 30; 13(604). PMID: 34321321    Free PMC article.
Cancer cell-expressed BTNL2 facilitates tumour immune escape via engagement with IL-17A-producing γδ T cells.
Yanyun Du, Qianwen Peng, +18 authors, Chenhui Wang.
Nat Commun, 2022 Jan 13; 13(1). PMID: 35017553    Free PMC article.
Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy-A Retrospective Bi-Centric Cohort Study.
David Lang, Anna Brauner, +7 authors, Bernd Lamprecht.
Cancers (Basel), 2022 Jan 12; 14(1). PMID: 35008255    Free PMC article.
Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives.
Ramon Andrade Bezerra De Mello, Rafael Voscaboinik, +4 authors, Georgios Antoniou.
Cancers (Basel), 2022 Jan 12; 14(1). PMID: 35008287    Free PMC article.
Review.
Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations.
Ichidai Tanaka, Masahiro Morise.
Int J Mol Sci, 2022 Jan 12; 23(1). PMID: 35008669    Free PMC article.
Review.
Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?
Christophe Maritaz, Sophie Broutin, +2 authors, Angelo Paci.
J Hematol Oncol, 2022 Jan 17; 15(1). PMID: 35033167    Free PMC article.
Review.
Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade.
Chensu Wang, Ang Cui, +11 authors, Darrell J Irvine.
Cell Rep, 2021 Nov 25; 37(8). PMID: 34818534    Free PMC article.
Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: A retrospective study.
Masaki Ishida, Kenji Morimoto, +9 authors, Koichi Takayama.
Thorac Cancer, 2021 Nov 19; 13(2). PMID: 34791812    Free PMC article.
Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non-small-cell lung cancer: A multicenter retrospective trial.
Hiromi Matsumoto, Nobuaki Kobayashi, +16 authors, Takeshi Kaneko.
Thorac Cancer, 2021 Dec 07; 13(2). PMID: 34866339    Free PMC article.
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma.
Jan Budczies, Martina Kirchner, +20 authors, Albrecht Stenzinger.
Cancer Immunol Immunother, 2021 Jun 15; 71(2). PMID: 34125345    Free PMC article.
A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab.
Kosuke Sawatari, Motohiro Izumi, +4 authors, Takashi Mamoto.
Respir Med Case Rep, 2022 Jan 22; 36. PMID: 35059287    Free PMC article.
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions.
Ming Yi, Xiaoli Zheng, +3 authors, Kongming Wu.
Mol Cancer, 2022 Jan 23; 21(1). PMID: 35062949    Free PMC article.
Review.
Safety Related to the Timing of Radiotherapy and Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer: A Single Institutional Experience.
Michael C Tjong, Malavan Ragulojan, +7 authors, Parneet K Cheema.
Curr Oncol, 2022 Jan 21; 29(1). PMID: 35049695    Free PMC article.
Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation.
Ray Sagawa, Seiji Sakata, +16 authors, Ryohei Katayama.
JCI Insight, 2021 Dec 08; 7(1). PMID: 34874919    Free PMC article.
Patient and Caregiver Preferences for First-Line Treatments of Metastatic Non-Small Cell Lung Cancer: A Discrete Choice Experiment.
Candice Yong, M Janelle Cambron-Mellott, +6 authors, Ranee Mehra.
Patient Prefer Adherence, 2022 Jan 25; 16. PMID: 35068928    Free PMC article.
Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
Carlo Genova, Chiara Dellepiane, +7 authors, Michela Croce.
Front Immunol, 2022 Jan 25; 12. PMID: 35069581    Free PMC article.
Review.
Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments.
Yuequan Shi, Xiaoyan Liu, +15 authors, Mengzhao Wang.
Transl Lung Cancer Res, 2022 Jan 25; 10(12). PMID: 35070755    Free PMC article.
Rapidly Progressive Lung Sarcomatoid Carcinoma Managed with Doxorubicin Plus Ifosfamide and Pemetrexed.
Jan Alberto Paredes Mogica, Eduardo Reyes Sanchez, +2 authors, Manuel Ernesto Magallanes Maciel.
Case Rep Oncol, 2022 Jan 28; 14(3). PMID: 35082625    Free PMC article.
Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.
Wenjing Zhang, Yujia Kong, +5 authors, Qinghua Wang.
Front Immunol, 2022 Jan 29; 12. PMID: 35087523    Free PMC article.
A short-term follow-up CT based radiomics approach to predict response to immunotherapy in advanced non-small-cell lung cancer.
Jing Gong, Xiao Bao, +5 authors, Yajia Gu.
Oncoimmunology, 2022 Feb 01; 11(1). PMID: 35096486    Free PMC article.
Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma.
Saket Jain, Eric J Chalif, Manish K Aghi.
Front Oncol, 2022 Feb 01; 11. PMID: 35096619    Free PMC article.
Review.
High expression of Stabilin-2 predicts poor prognosis in non-small-cell lung cancer.
Juanjuan Yong, Liyun Huang, +3 authors, Lin Wang.
Bioengineered, 2021 Jul 07; 12(1). PMID: 34227915    Free PMC article.
Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC.
Yang Wang, Jun Nie, +11 authors, Jian Fang.
Cancer Immunol Immunother, 2021 Jun 17; 71(2). PMID: 34131807    Free PMC article.
Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China.
Yuequan Shi, Jian Fang, +31 authors, Mengzhao Wang.
Thorac Cancer, 2021 Dec 23; 13(3). PMID: 34935288    Free PMC article.
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
Jonathan D Schoenfeld, Anita Giobbie-Hurder, +34 authors, F Stephen Hodi.
Lancet Oncol, 2022 Jan 17; 23(2). PMID: 35033226    Free PMC article.
Pretreatment Fibrinogen-Albumin Ratio (FAR) Associated with Treatment Response and Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Anti-PD-1 Therapy Plus Platinum-Based Combination Chemotherapy.
Chengliang Yuan, Meifang Huang, +3 authors, Shaozhang Zhou.
Cancer Manag Res, 2022 Feb 05; 14. PMID: 35115834    Free PMC article.
Narrative review of immune checkpoint inhibitors and radiation therapy for brain metastases.
Marina Moskalenko, Tyler P Robin.
Transl Cancer Res, 2022 Feb 05; 10(5). PMID: 35116569    Free PMC article.
Review.
First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer.
Camille Travert, Pascale Tomasini, +2 authors, Fabrice Barlesi.
Transl Cancer Res, 2019 Nov 01; 8(7). PMID: 35117007    Free PMC article.
Addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer.
Teppei Yamaguchi, Toyoaki Hida.
Transl Cancer Res, 2019 Dec 01; 8(8). PMID: 35117056    Free PMC article.
EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients.
Niki Karachaliou, Manuel Fernandez-Bruno, Jillian Wilhelmina Paulina Bracht, Rafael Rosell.
Transl Cancer Res, 2019 Jan 01; 8(Suppl 1). PMID: 35117062    Free PMC article.
Review.
Atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer?
Andrea Bianco, Susan F M Campbell.
Transl Cancer Res, 2019 Mar 01; 8(Suppl 2). PMID: 35117074    Free PMC article.
Anti-angiogenesis boosts chemo-immunotherapy in patients with EGFR mutations or baseline liver metastases: insights from IMpower150 study.
Sara Elena Rebuzzi, Francesco Facchinetti, Marcello Tiseo.
Transl Cancer Res, 2019 Dec 01; 8(Suppl 6). PMID: 35117143    Free PMC article.
Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer.
Yosuke Miura, Norimitsu Kasahara, Noriaki Sunaga.
Transl Cancer Res, 2019 Dec 01; 8(Suppl 6). PMID: 35117146    Free PMC article.
The efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic drugs in renal cell carcinomas: a systematic review and meta-analysis.
Qian He, Jiayi Li, +2 authors, Qinglan Ren.
Transl Cancer Res, 2020 Nov 01; 9(11). PMID: 35117287    Free PMC article.
Long-term survivors with immunotherapy in advanced NSCLC: is 'cure' within reach?
Sara Monteverdi, Emanuele Vita, +6 authors, Sara Pilotto.
Transl Cancer Res, 2020 Feb 01; 9(2). PMID: 35117384    Free PMC article.
In search of goldilocks: the quest to optimize combination drug strategies for the management of advanced stage non-small-cell lung cancer.
Poorva Bindal, Page Widick, Daniel B Costa, Deepa Rangachari.
Transl Cancer Res, 2020 Mar 01; 9(3). PMID: 35117478    Free PMC article.
The safety of first and subsequent lines of PD-1/PD-L1 inhibitors monotherapy in non-small cell lung cancer patients: a meta-analysis.
Yilin Yang, Peilin Pang, +3 authors, Lei Zhao.
Transl Cancer Res, 2020 May 01; 9(5). PMID: 35117689    Free PMC article.
Interrogating the interplay of angiogenesis and immunity in metastatic colorectal cancer.
Katerina Kampoli, Periklis G Foukas, +2 authors, Anna Koumarianou.
World J Methodol, 2022 Feb 05; 12(1). PMID: 35117981    Free PMC article.
Review.
Overcoming therapy resistance in EGFR-mutant lung cancer.
Antonio Passaro, Pasi A Jänne, Tony Mok, Solange Peters.
Nat Cancer, 2022 Feb 06; 2(4). PMID: 35122001
Review.
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies.
Olivier Michielin, Aly-Khan Lalani, +2 authors, Solange Peters.
J Immunother Cancer, 2022 Jan 27; 10(1). PMID: 35078922    Free PMC article.
Review.
Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study).
Takashi Seto, Kaname Nosaki, +17 authors, Kazuhiko Nakagawa.
J Immunother Cancer, 2022 Feb 03; 10(2). PMID: 35105689    Free PMC article.
First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data.
Maxime Bossageon, Aurélie Swalduz, Christos Chouaïd, Olivier Bylicki.
BioDrugs, 2022 Feb 12; 36(2). PMID: 35147894
Review.
Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers.
Alexander Drilon, Daniel S W Tan, +12 authors, Jessica J Lin.
JCO Precis Oncol, 2022 Jan 28; 6. PMID: 35085007    Free PMC article.
Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial.
Yanshuo Cao, Ming Lu, +10 authors, Lin Shen.
J Cancer Res Clin Oncol, 2022 Feb 16;. PMID: 35166929
Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy.
Gisela María Suárez, Mauricio Catalá, +15 authors, Danay Saavedra.
Front Oncol, 2022 Feb 15; 12. PMID: 35155258    Free PMC article.
Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements.
Chiara Pisano, Marco De Filippis, +2 authors, Maria Lucia Reale.
Cancers (Basel), 2022 Feb 16; 14(3). PMID: 35158987    Free PMC article.
Review.
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects.
Shengjie Tang, Chao Qin, +7 authors, Haining Zhou.
Cells, 2022 Feb 16; 11(3). PMID: 35159131    Free PMC article.
Review.
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA.
Thomas John, Hiroshi Sakai,